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"Insanity: doing the same thing over and over again and 
expecting different results. " 
A. Einstein 
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Abstract 
The aim of the project was to investigate the mechanism by which HCV evades 
therapeutic IFN treatment. This involved the development of novel testing systems 
and their application to patient samples. Initial experiments focused on flavivirus 
replicons and novel observations on effects of one of these replicons (dengue virus) 
on interferon signalling were made. The dengue replicon system was demonstrated 
to inhibit IFNa signalling by reducing the expression of STAT2, an essential 
component of the type I IFN signalling pathway. This phenomenom was then further 
examined in dengue virus infected human cells and again it was observed that the 
expression of STAT2 was reduced. The mechanism of STAT2 degradation was 
further explored and STAT2 expression was found to be restored using a 
proteasomal inhibitor. 
A second flavivirus replicon system involving BVDV was also developed as a 
reporter system, again with novel observations. The BVDV replicon system was 
shown to be sensitive to the antiviral effects of I FNa and was not shown to inhibit the 
IFNa signalling pathway. The BVDV replicon was tested as a reporter system using 
a well-known viral inhibitor of I FNa. The viral inhibitor, inhibited the antiviral action of 
IFNa on the BVDV reporter. Having developed and validated this system, the effects 
of a small number of patient derived samples were assessed and it was 
demonstrated that NS5a derived from a patient who failed to respond to IFNa 
treatment inhibited the effects of IFNa on the BVDV reporter. To increase the 
senstitivity of the assay the reporter cassette was then changed to a destabilised 
GFP for use in a FACS based assay. 
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1. INTRODUCTION 
Although the focus of this thesis is the effects of HCV derived patient proteins on the 
interferon (IFN) system, to analyse the effects, various reporter systems were 
developed. Background information for the individual reporter assays will be given in 
the relevant result chapters and here in the introduction the emphasis shall be put 
upon the interferon system, hepatitis C virus and their interactions. 
1.1.1 Interferons 
The Interferons are a large family of multifunctional secreted proteins that are 
involved in antiviral defence, cell growth regulation and immune activation (Pestka S, 
1987). They were first discovered in 1957; Isaacs and Lindenmann reported that 
chick cells infected with heat inactivated influenza virus produced a soluble factor, 
which rendered new cells resistant to infection by live influenza virus (Lindenmann et 
aI, 1957). This factor could not be sedimented by centrifugation at 100,000g for 15 
minutes, was non-dialyzable and was stable over the pH range of 1-10. They called it 
IFN as it interferes with viral replication (Isaacs et aI, 1957). 
The IFN family is separated into two types, I and II and even though there is no 
structural similarity between the two families, there is a broad overlap in the induced 
gene expression. Both families act in a functionally distinct manner; type I induce an 
antiviral state in target cells, whilst type II IFNs are predominately immunomodulatory 
(Pestka et aI, 1987). 
1.1.2 Overview of Type I Interferons 
Type I IFNs consist of alpha, which is subdivided into 13 subtypes, clustered on the 
short arm of human chromosome 9 (9p21.3) (Diaz et aI, 1993), interferon beta (~) 
and interferon omega (co) . Evolutionary the IFNa and IFN~ genes separated about 
24 
800 million years ago, the IFNw separated 700 million years later and the multi IFNa 
subtypes appeared approximately 80 million years ago (Roberts et ai, 1998). IFNa is 
produced primarily by leukocytes and IFN~ by fibroblasts, but production of type I 
IFNs is transiently induced in most nucleated cells in response to virus infection, 
dsRNA and bacterial infections. 
The IFNa subtypes are intronless genes that share about 600/0 amino acid homology 
within the coding region; they contain four conserved cysteine residues that form two 
intramolecular disulphide bonds. It is not known why there are so many different 
interferon a subtypes, whether it is dependent upon the type of viral infection or 
whether they stimulate different antiviral genes. 
1.1.3 Overview of Type II interferon 
IFNy is the only member of the type II interferon family. It has no sequence homology 
with the type I interferons, but is closely homologous to IL-10 and is found on the 
long arm of chromosome 12 in humans. I FNy plays an important role in both innate 
and adaptive immunity and antigen-specific stimulation results in it's secretion by NK 
cells and T lymphocytes. It can enhance MHC class I and " expression, activate 
macrophages resulting in increased phagocytosis, upregulate IL-2 receptor 
expression on cytotoxic T cells and promote 8 cell differentiation. 
IFNy exerts its effects by binding to the IFNy receptor, which is composed of two 
receptor chains IFNyR1 and IFNyR2 which are present on most cells. The IFNy 
receptor is associated with the Janus tyrosine kinases, Jak1 and Jak2 which become 
activated upon ligand binding and are phosphorylated leading to the dimerisation 
and nuclear translocation of STAT 1 (Signal transducers and activators of 
transcription) [reviewed in (Platanias, 2005)]. Mice with a deficiency in IFNy, the 
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receptors or STAT1 are more susceptible to microbial pathogens and some viruses . 
Also humans with mutations in the IFNy pathway are more susceptible to 
mycobacterium infections with some patients dying in early chi ldhood (Dupuis et ai, 
2001 ). 
1.1.4 Interferon a/J3 Signalling Pathway 
The type I interferon system is one of the best-studied signalling pathways; the JAK-
STAT pathways were discovered through the analysis of the mechanisms used by 
the IFNa/p. All type I IFNs bind to the same receptor on the cell surface, but with 
varying affinities, IFNa1 shows a much lower binding affinity for human membrane 
receptors than IFNa2 or a8 (Zoon et ai, 1982). The interferon receptor is composed 
of two chains; IFNAR1 and IFNAR2, both of which have been cloned (Uze et ai, 
1990) and shown to be essential for the high affinity binding and biological activity of 
the ligands (Lutfalla et ai, 1995) , IFNAR2 being the major ligand binding component 
of the complex. The intracellular domains of the receptor chains are associated with 
the tyrosine kinases, JAK1 and Tyk2. Ligand binding to IFNAR results in the 
activation of Jak1 and Tyk2, phosphorylating IFNAR1 at residue Y455, triggering a 
chain of events leading to the phosphorylation of the STATs. STATs form specific 
multimeric complexes, in this case with a member of the IRF (Interferon regulatory 
factor) family. The complex, consisting of STAT 1 , STAT2 and IRF9, called ISGF3 
trans-locates to the nucleus and activates transcription from IFN type I gene 
promoters containing the Interferon stimulated-response element (ISRE) sequence, 
a highly homologous DNA element of 14 base pairs found in all Interferon stimulated 
genes (ISGs) (Porter et ai, 1988). 
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Fig1.1 The Interferon signalling pathway. 
Type I-Binding of the type I IFN to the 
extracellular domain of the receptor chains 
causes the activation of Jakl and Tyk2 
resulting in the phosphorylation of the 
STATl-2 heterodimer forming ISGF3 with 
IRF-9. ISGF3 translocates to the nucleus and 
binds to the ISRE elements of the promoters 
in type I IFN inducible genes to activate their 
transcription . Type II-The IFNy binds to the 
receptor causing the activation of STATI via 
the Jaks. ST ATI homodimers translocate to 
the nucleus and bind to the IFNy activated 
site (GAS) promoter sequences to stimulate 
the appropriate gene transcription.(Decker et 
ai, 2005) 
A wide range of interferon inducers are known, such as natural and synthetic dsRNA, 
viral infection, intracellular bacteria, microbial products e.g. LPS and low molecular 
weight substances e.g. cyclohexamide. Although these share no structural similarity, 
recent advances have shown that they induce the type I interferon response via 
different mechanisms but that the pathways eventually converge to activate the 
same transcription factors, IRF3, NFKB and AP-1. IRF3 is a constitutively expressed 
protein found in the cytoplasm (Lin et aI, 1998), viral infection or the presence of 
dsRNA leads to it's phosphorylation by TBK1 and IKK-; and it is then rapidly 
translocated to the nucleus where it binds specifically to IFN~ IRF-E (PROI element) 
resulting in the weak activation of IFN~ (Schafer et aI, 1998). This leads to a positive 
feedback induction loop with the initially produced IFN~ inducing IRF7 expression 
(Marie et aI, 1998). IRF7 is not constitutively expressed in cells and is induced by 
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IFN signalling via the JAK-STAT pathway through the activation of ISGF3. The 
transcription of IFNa/f3 is controlled primarily through the activation of the IRFs 
! 
especially IRF3 and IRF7; IRF7 deficient mice are incapable of mounting a credible 
antiviral response (Honda et aI, 2005). 
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Fig 1.2. IFN(l/~ induction and feedback loop. 1. Virus infection stimulates a phosphorylation 
cascade, leading to the activation of at least three families of transcription factors, including NF-KB, 
AP-I and IRF3. Activation of the IFN-P promoter requires all three transcription factors. 2. IRF7 
induction phase. Secretion of early IFNP produces an autocrine response through stimulation of the 
lAK-STAT pathway by the IFN receptor system, leading to activation of the transcription factor 
complex, ISGF3. Among the genes activated by ISGF3 is IRF7, leading to accumulation of this protein 
only in response to IFN production. The continued presence of viral infection also leads to IRF7 
phosphorylation and subsequent activation. Many members of the IFN-a gene family possess promoter 
binding sites for activated IRF7 and become transcriptionally active, augmenting the IFN response. 
(Taniguchi & Takaoka, 2002) 
1.1.S.ii Toll like receptors 
Until recently it was thought that the interferon response to viral factors occurred 
when dsRNA was detected, and directly activated the transcription factor IRF3. We 
now know that there are other ways to induce the IFN. Since the discovery of the Toll 
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like receptor (TLR) family, our understanding of how the innate immunity recognises 
pathogens and mounts and effective response has grown. Toll-like receptors were 
originally discovered in Drosophilia as receptors responsible for anti-fungal immunity 
(Lemaitre et a', 1996). Since then several mammalian equivalents were identified . 
There are now 11 members of the human TLR family all of which are 
transmembrane receptors that recognise different pathogen associated molecular 
patterns (PAMPs). Each TLR has a number of potential ligands and the ability to 
form hetero- and homo- dimers, suggesting that the TLRs contain a multitude of 
potential binding sites. 
Table 1.1 Principle ligands of the human toll-like receptors(Smith et ai, 2005 ) 
Toll-like receptors Ligands 
TLR1 and 2 .------------=---~~----------------------Bacterial or spirochetal lipoproteins 
2 and 6 Bacterial lipoproteins 
2 Peptidoglycan 
3 Double stranded RNA 
4 Lipopolysaccharide 
5 Bacterial Flagellin 
7 SsRNA 
8 SsRNA 
9 CpG DNA 
10 Unknown 
1 1 Uropathogenic Bacteria (In mice) 
-----_ .. ~--- ---_.- - -----------------
Signalling pathways via TLRs originate from the conserved TIR (Toll-IL 1 receptor) 
domains via interactions with adaptor molecules such as myeloid differentiation 
factor 88 (Myd88), TIR associated protein (TIRAP), Toll receptor associated 
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molecule (TRAM) and ToII/IL-1 receptor domain-containing adaptor inducing IFN-~ 
(TRIF). Both TLR 7 and 9 have been shown to use the MyD88 adaptor molecule 
which can directly associate with IRF7, whilst TLR 3 and 4 transmit signals via TRIF 
leading to the activation of IRF3 which induces the transcription of IFN ~, which then 
activates the feedback loop to induce the transcription of the other type I IFNs. 
Although the idea of TLRs as viral sensors is an attractive mechanism, it has a few 
flaws that can only be accounted for by the presence of another viral alarm system 
such as the cytoplasmic recognition of dsRNA by RNA helicases. 
1.1.S.iii Retinoic acid inducible gene-I 
As TLRs are transmembrane proteins that exist either on the plasma membranes or 
in endosomes, they can only detect PAMPS in the extracellular space or when 
viruses enter the cells via a vesicular pathway. This does not account for all viruses; 
several RNA viruses which have been shown to be potent inducers of type I IFN 
enter the cytoplasm by fusing with the cell membrane or by directly injecting their 
nucleic acid ; they do not encounter the TLRs. MyD88-
'
-TRIF/- mice have been shown 
to be unresponsive to stimulation with all known TLR ligands, (Yamamoto et aI, 
2003). However when MyD88-
'
-TRIF/- embryo fibroblasts were infected with 
Newcastle disease virus (NOV), IFN~ was still induced to the same extent as the wild 
type cells (Kato et aI, 2005a). 
The gene that was recently identified using an expression library, responsible for this 
IFNa/~ induction in the absence of the TLR pathway was the retinoic acid inducible 
gene-I (RIG-I) (Yoneyama et aI, 2004) , the overexpression of which was also shown 
to inhibit both VSV and EMCV-induced infectivity. RIG-I is a DExD/D-box helicase 
that also contains two caspase recruitment domains (CARD). In the absence of any 
PAMPS, the RIG-I helicase domain suppresses the signalling actions of the CARD 
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domains, but the binding of the viral RNA allows the CARD domain of RIG-I to recru it 
the CARD adaptor inducing IFNf3 (Cardif) protein. The mitrochondrial bound cardif 
then recruits IKK to activate NF-KB and IRF3. The importance of RIG-I in antiviral 
defense was demonstrated with RIG-I deficient mice (Kato et aI, 2005b) ; RIG-I 
defends the host against NOV, VSV and SeV infections within the cytoplasm of 
mouse embryonic fibroblasts (MEFs) and DCs whereas the TLR antiviral defense 
recognised nucleic acids within endosomal compartments within pDCs. 
Since the discovery of RIG-I, other closely related proteins which also lead to NFKB 
and IRF3 activation and also transmit antiviral responses through the cardif adaptor 
have been found, one such example is MDA5. Similar to RIG-I, MDA5 also senses 
cytoplasmic dsRNA. Taken together with the TLR pathways, these sensors all lead 
to the stimulation of the IFNf3 gene which will then lead onto the feedback loop 
allowing an appropriate IFNa/f3 anitiviral response to occur. 
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Fig1.3 Pathways of type I IFN induction. Most negative-strand RNA viruses enter cells by 
membrane fusion, either at the plasma membrane (left) or through an endocytic process (middle), and 
release their nucleic acid into the cytoplasm. TLR3 binds extracellular dsRNA and signals through 
adaptor protein association involving the TIR domain protein TRIF, which is required for signalling to 
two protein kinase complexes, TBKI-IKKE:and IKK(l-IKK~, leading to activation oflRF3 and NF-KB. 
TLR3 is found both at the cell surface as well as on endomembranes, along with the other nucleic acid 
sensors TLR7 and TLR9, which signa] through the adaptor molecule MyD88 and the kinase IRAK. 
Whether these receptors ever 'see' viral nucleic acid components during primary infections is unknown. 
RIG-I processes viral RNPs with its helicase domain in the cytoplasm, resulting in signalling through 
its CARDs. Signal propagation presumably involves a CARD-containing adaptor protein that relays 
the signal to TBK l-IKKE kinase complexes to phosphorylate IRF3, and possibly to IKK(l-IKK~ to 
activate NF-KB as well. (Levy & Marie, 2004) 
1.1.6 Antiviral properties of Type IIFNs 
The original definition of the interferons was based upon their antiviral abilities and it 
has since been shown that this role is vital to the survival of higher vertebrates. This 
early line of defence kicks in hours to days before the immune system can react. 
Mice lacking the IFN receptors (a,f3 and y) show reduced resistance to viral infection. 
Type I IFNs activate a cascade of intracellular signalling pathways leading to 
upregulation of more than a thousand IFN-stimulated genes (ISGs) within the cell. 
The function of some of the IFNa/f3-induced proteins is well described, whereas 
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others remain poorly characterized. IN combination the upregulation of these ISGs 
confer an antiviral state, which limits the ability of the virus to infect neighbouring 
cells. The best studied genes are known to be involved in the antiviral mechanism of 
IFNa/~ action such as PKR (Protein Kinase R), MxA and 2'5'OAS (2 ' 5' Oligo 
Adenylate Synthetase). 
1.1.7 PKR System 
Several different IFNa/~ inducible proteins degrade viral RNA and inhibit protein 
synthesis, perhaps the most significant protein being PKR. PKR is a 68KDa protein 
that has a conserved domain characteristic of a serine threonine kinase and a 
domain that binds dsRNA (Meurs et aI, 1990;Meurs E, 1990). It is ubiquitously 
expressed at low levels in cells; IFN causes an increase in its expression and it is 
activated by the binding of dsRNA which is generated during the replication of RNA 
and DNA viruses. 
The PKR binds dsRNA, autophosphorylates and dimerises and is then capable of 
phosphorylating eIF-2a. PKR phosphorylates a serine residue on the alpha subunit 
of the elF-2a leading to obstruction of protein synthesis. The factor eIF-2B mediates 
the guanine nucleotide exchange step required to regenerate active eIF-2GTP from 
the inactive eIF-2GDP that is produced after each round of initiation. 
PKR also activates the NF-kB transcription factor which is required for IFN~ 
synthesis, enhances cytokine production and MHC I presentation. In virus-infected 
cells, PKR promotes cellular apoptosis through a Fas-dependent pathway, thereby 
preventing the spread of the virus to neighbouring cells. PKR also plays a role in 
modulating cell proliferation and growth; it has been implicated in the signal 
transduction pathway of IL-3, PDGF and IFNy. Although activated by a low 
33 
concentration of dsRNA, high levels have been shown to inhibit the activity of PKR. 
This has lead to different models of activation for PKR (Proud, 1995). 
1.1.8 The MxA System 
The Mx proteins were originally discovered as IFNu/j3-induced proteins that are 
capable of blocking the replication of influenza in a mouse model (Horisberger et ai, 
1983). Other members of the family were later shown to have an antiviral action 
against other RNA viruses. They are I FN-induced 70-80KOa GTPases of the 
dynamin family that have a tendency to self assemble, a relatively low affinity for 
GTP and a high rate of GTP hydrolysis. 
Another family of the large GTP-binding proteins include the human guanylate-
binding proteins (hGBP-1 and hGBP-2), human dynamin1 (hOyn1) , the yeast 
dynamin homolog VPS1 (yVPS1) and human dynamin-related protein1 (hDrp1). The 
hGBPs are induced mainly by IFNy; indeed GBP-1 is one of the most abundant 
antiviral proteins induced by IFNy and has been shown to inhibit the replication of 
both EMCV and VSV (Vesticular stomatitis virus) (Anderson et ai, 1999). 
The Mx proteins act by modifying cellular functions needed for viruses to replicate 
(Nakayama et ai, 1993;Nakayama M, 1993), thereby protecting the cells. IFNAR-/-
mice expressing the human MxA gene, survived a lethal dose of Le Crosse virus in 
comparison to mice not expressing the human MxA gene (Hefti et ai, 1999). 
In humans there are two distinct Mx GTPases; MxA and MxB, which are encoded on 
chromosome 21. Only MxA has detectable antiviral activity, shown against a wide 
spectrum of viruses (including bunya-, orthomyxo-, paramyxo-, rhabdo- , toga- , 
picorna- and hepatitis B viruses). Murine Mx1, in comparison appears to be specific 
for orthomyxoviruses, interfering with the influenza viral replication at the primary 
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transcription level. The difference in cellular localisation between the Mx proteins 
appears to give rise to their specificity; Mx1 appears to be specific for viruses that 
accumulate in the nucleus whereas, MxA accumulates in the cytoplasm of interferon 
treated cells and is partly associated with the ER where it forms tight oligomeric 
complexes (Richter et ai, 1995). 
Although the molecular mechanism of Mx action is not yet well understood, the 
GTPase activity seems to be essential for the antiviral function (Pitossi et aI, 1993). 
MxA has been shown to retain the nucleocapsid of Thogoto virus in the cytoplasm 
thereby preventing the virus from entering the nucleus and transcribing its genome, 
which can be reversed with specific MxA antibodies (Haller & Kochs , 2002). 
Conversely MxA has been show to exert it's antiviral effect against Semliki Forest 
Virus without the presence of the viral structural genes (Landis et ai, 1998) . 
1.1.9 The 2'5' OAS system 
PKR and the Mx proteins are preferentially induced by type I IFNs, other antiviral 
systems such as 2'5'OAS synthetase can be induced by both types. The 2'5'OAS 
synthetase is a family of enzymes that are activated by dsRNA to synthesize 2'-5'-
linked oligoadenylates. The number of adenosine bases varies; one form dimerises 
inactive RNaseL leading to the degradation of mRNA and another has been shown 
to bind to the bcl-2 family of proteins that has been associated with apoptosis. The 
different forms of the 2'5'OAS synthetase have different IFN and dsRNA dose 
response relationships and are active in different subcellular locations. The 2'5'OAS 
system has been shown to inhibit the replication of picornaviruses such as EMCV, 
which is thought to occur mainly in the cytoplasm (Williams & Kerr, 1978), but other 
viruses such as VSV are thought to avoid the attention of the RNaseL as their 
replication occurs in the nucleus (Chebath et ai, 1987). 
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1.1.10 The ADAR system 
Another way of inhibiting the virus by means of the type I interferon system is to 
disrupt its coding sequence. ADAR adenosine diaminase edits adenosine to inosine 
, 
which provides a mechanism to alter the functional activity of viral and cellular RNA. 
This usually occurs on viral RNA in particular negative strand RNA genomes 
resulting in mutations within the viral RNA (Bass BL, 1997). 
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Fig 1.4 Antiviral mechanisms 
of IFN action. Several 
proteins within the cells inhibit 
viral replication. PKR inhibits 
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the phosphorylation of protein 
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However, as with all things, a state of equilibrium exists, as the immune system via 
the interferon pathway fights the virus, most viruses have evolved ingenious 
strategies to interfere with the I FNa/f3 pathway. These include blocking the I FNa/f3 
induction/expression, intercepting receptor binding of IFNs through viral decoy type I 
IFN receptors, perturbation of the intracellular IFNa/f3 signalling pathway and directly 
down- regulating the level of expression of ISGs. 
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1.2.1 The viruses fight back 
Different viruses have evolved different mechanisms to evade the antiviral effects of 
IFNa/~ . Broadly, these fall into three categories, inhibition of: 1. IFNa/~ induction, 2. 
JAKSTAT pathway and 3. antiviral gene product synthesis . 80th RNA and DNA 
viruses have been shown to inhibit the function of the antiviral gene products and 
suppress IFN induction and some viruses have developed a combination of 
strategies to avoid the antiviral effect of IFNa/~ . 
Table 1.2 How different viruses evade the type I IFN response 
Mechanism Viral Proteins 
IFN induction Influenza NS1 
Ebola VP35 
Bunyavirus NS 1 
JAKISTAT Mumps V protein 
Adenovirus E1A 
Ebola VP35 
Simian Virus 5 protein 
Antiviral gene product synthesis HIVTAT 
Adenovirus VA 1 
Influenza NS1 
1.2.2 Inhibition of Interferon induction 
Viruses have developed mechanisms to avoid detection e.g. 1) negative strand RNA 
. ps'ldate both their genomic and antigenomic RNA, 2) retroviruses viruses enca 
integrate their viral genome into the host's and use the host cell machinery for their 
.' d I' t'on 3) positive strand RNA viruses replicate within transcription an rep Ica I , 
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intracellular membrane vesicles and 4) some viruses minimise the production of 
dsRNA to prevent the induction of IFNa/~. Ebola virus infection has been shown to 
block host cell responses to IFNs, inhibit induction of antiviral gene expression, and 
block I FNa/J3 production from infected cells. Expression of the Ebola virus protein 
VP35 complemented the growth of the IFN-sensitive influenza virus and also 
prevented the transcriptional activation of both the beta IFN (IFN-B) promoter and 
the IFN-stimulated ISG54 promoter (Basler et ai, 2000). VP35 was later shown to 
block IFNJ3 production by inhibiting IRF3 phosphorylation and thereby blocking its 
subsequent nuclear transportation (Basler et a', 2003). Several other viruses have 
been reported to target IRF3 activation, including the influenza virus, which uses the 
dsRNA binding ability of its NS1 protein (Talon et a', 2000) and the E3L protein of the 
vaccinia virus which uses a similar mechanism (Smith et a', 2001). 
Hepatitis A virus (HAV) is a picornavirus, with a positive-stranded RNA genome. 
Although HAV targets the liver, it is transmitted by the faecal-oral route but although 
in cultured cells it leads to a persistant, non-cytopathic infection. Within its natural 
host it does not lead to chronic disease. It has been shown that HAV infection does 
not induce IFNa in lymphocytes or IFNJ3 in fibroblasts due to the ability of the virus to 
inhibit the ds-RNA induction of interferon (Brack et a', 2002). This was later narrowed 
down to an inhibition of IRF3 phosphorylation by preventing RIG-I signalling to the 
IKK£ITBK1 kinases which activate IRF3 (Fensterl et a', 2005). 
As HAV replication occurs in association with intracellular vesicles, IFNJ3 induction 
could be stimulated via TLR3, but HAV has also been shown to inhibit this pathway. 
Although the viral protein responsible for this inhibition has yet to be found, the 
inhibition of IRF3 by HAV is a allows the virus to establish a persistent infection in 
cell cultures and evade the antiviral effects of type I IFN. 
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1.2.3 Inhibition of the STAT proteins 
The STATs are essential mediators of interferon signalling and numerous viruses 
have found ways to stop their action, e.g. several members of the Paramyxoviridae 
have been shown to inactivate the STAT proteins, mainly through the action of the V 
protein . The paramyxoviruses are a large family of enveloped, negative strand RNA 
viruses that cause a multitude of diseases. Within the family several genera exist 
such as the Rub ula virus, Respirovirus and Morbillivirus. The V protein of the 
Paramyxoviridae have been implicated in many mechanisms, including IFN 
Signalling inhibition, inhibition of dsRNA Signalling and direct interaction with STAT 
proteins. The V protein contains a highly conserved cysteine rich region which has 
been shown to be responsible for the attenuation of the antiviral effects of interferon. 
STAT1 was first found to be reduced in cells infected with the simian virus 5 (SV5) 
and this was due to the expression of the V protein, and the ability of the SV5-V 
protein to target the STAT 1 protein for polyubiquitination and proteasomal 
degradation (Oidcock et aI, 1999). The ubiquitination of STAT1 was later shown to 
require the presence of STAT2 (Parisien et aI, 2002), whilst the polyubiquitination of 
STAT3 that occurs with the Mumps virus was STAT2 independent (Ulane et aI, 
2003). 
Newly emerged paramyxoviruses e.g. Nipah and Hendra viruses also use their V 
protein to evade the IFN response through a different mechanism; they sequester 
STAT1 and STAT2 in high molecular weight cytoplasmic complexes without inducing 
their polyubiquitination (Rodriguez et aI, 2002). They can also transport activated 
STAT1 from the nucleus back to the cytoplasm. A similar mechanism is used by the 
Measles virus, which blocks IFN induced STAT 1 and STAT2 nuclear transport 
(Palosaari et aI, 2003). 
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1.2.4 Inhibition of the function of the antiviral gene products 
Several viruses have developed more than one way to evade the interferon 
response, such as the influenza virus. Influenza is a member of the orthomyxovirus 
family that has a segmented negative strand genome which encodes 10 proteins. 
With regards to IFN response the only influenza protein that appears to function as 
an IFN antagonist is the NS1 protein. The NS1 protein is an RNA-binding protein; it 
was recognised as an important antagonist of IFNa when an NS1 knockout influenza 
virus was generated, although the virus was still viable, it was highly sensitive to the 
antiviral effects of I FNa and could only replicate efficiently in cells where various 
arms of the interferon antiviral pathway are knocked out. Using micro-array studies 
the NS1 deleted viruses induced a higher expression of ISGs and NFKB in 
comparison to the wild type virus. In addition, NS1 has also been shown to directly 
interact with PKR and inhibit its kinase function. 
Another virus which has been shown to interact with the PKR system is the vaccinia 
virus. Vaccinia virus (W) is a member of the Orthopoxvirus genus; it has a large 
complex virion and a dsDNA genome that encodes approximately 200 proteins, 
several of which are specifically employed to avoid the actions of interferon. Proteins 
E3L and K3L have been shown to act intracellularly against PKR. 
The E3L gene encodes two proteins; p20 and p25 that bind cytoplasmic dsRNA 
sequestering them away from PKR, thereby causing their inactivation (Chang et ai, 
1992). The K3L protein exhibits some amino acid homology to elF2a such that K3L 
can competitively inhibit PKR phosphorylation (Beattie et ai, 1991). Deletion of either 
E3L or K3L leads to a virus with enhanced sensitivity to the antiviral effects of IFN 
(Beattie et ai, 1995). The E3L protein has also been shown to block the antiviral 
mechanisms of 2'5'OAS (Rivas et ai, 1998) and ADAR (Liu et ai, 2001) as well as 
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blocking IFN induction through IRF3 and IRF7. Yet another protein, VH1 , has been 
shown to bind and dephosphorylate STAT1 , which could be another mechanism to 
downregulate the IFN antiviral response. 
The othopoxviruses also encode IFNa/p receptor homologues to evade the antiviral 
responses of interferon (Symons et aI, 1995). The B18R gene of the Western 
Reserve strain of W encodes a protein that can function as a soluble receptor that 
binds type I IFN with high affinity despite the lack of homology to IFNAR. It can also 
bind to the surface of cells and inhibit IFN activity (Alcami et aI, 2000) . 
1.2.5 Other inhibitory methods 
Although past work has focused upon the inhibitory mechanisms that viruses use to 
perturb the interferon system, due to the large volume of research in the last few 
years into other viral sensors, evasion mechanisms have also been described 
against the TLR and the helicase systems. 
A vaccinia encoded protein (A46R) contains a TIR domain which it uses to inhibit 
TRIF mediated IRF3 phosphorylation but A46R can also binds to MyD88, TIRAP and 
TRAM thereby also interferrring with NF-KB and MAP kinase activation (Stack et aI, 
2005) . The V proteins of paramyxoviruses have been reported to specifically bind to 
and inhibit MDA5-dependent type I IFN production but to have no effect on the RIG-I 
dependent IFN signalling (Yoneyama et aI, 2005); (Childs et aI, 2007). 
However, HCV has been shown to inhibit both the RIG-I and TLR3, but due to the 
importance of IFNa treatment in patients with Hepatitis C infection , the inhibition of 
IFN by this Flaviviridae is a much researched field and is the subject of this thesis . 
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1.3.1 Flaviviridae 
HCV is a member of the Flaviviridae family which is composed of three genera; 
Flavivirus, Pestivirus and Hepacivirus of which HCV falls into the latter group. 
Table 1.3 Examples of the classification of the Flaviviridae. 
Genus Examples 
Flavivirus Yellow fever virus 
Dengue virus 
Japanese encephalitis virus 
Tick-borne encephalitis virus 
Pestivirus Bovine viral diarrhoea virus 
Classical swine fever virus 
Hepacivirus Hepatitis C Virus 
The viruses of the Flaviviridae are defined by their positive-sense single stranded 
RNA genome and a single polypeptide protein produced by translation of a single 
large open reading frame (ORF) which is subsequently cleaved by host and viral 
proteases. Both the Pestivirus and the Hepacivirus genus contain internal ribosomal 
entry sites (IRES) that provide a site of translation initiation for host ribosomes. In 
contrast, the Flavivirus genus uses ribosomal scanning to commence protein 
synthesis. 
An estimated 3% of the World's population are infected with HCV, an infection that 
can lead to cirrhosis, end-stage liver disease and hepatocellular carcinoma (HCC). 
Although the amino acid and nucleotide homology between HCV and other viruses in 
the Flaviviridae is poor, several common features have been discovered. 
1.3.2 The discovery of Hepatitis C virus 
Hepatitis C is a viral infection of the liver which was originally referred to as 'non-A, 
non-B' hepatitis until identification of the causative agent was achieved in 1989. HCV 
was discovered by cloning a fragment of viral cDNA from a chimp infected with Non-
A, Non-B hepatitis. Subsequently, the entire genome was cloned which was shown 
to be infectious when injected intrahepatically into a chimpanzee(Kolykhalov et aI, 
1997). 
HCV has always been known as a difficult virus to work with and until recently, 
research was hampered by the lack of an infectious molecular clone of HCV and the 
inability to propagate the virus in tissue culture. With the development of infectious 
clones, HCV replicon system(Lohmann et aI, 1999b) and a transgenic mouse model 
for HCV infection, the field has moved on drastically. 
1.3.3 Transmission 
HCV is a major human pathogen, chronically infecting about 170 million people 
worldwide, causing cirrhosis and hepatocellular carcinoma (HCC). Factors most 
strongly associated with HCV infection are illicit drug use and receipt of blood or 
blood products prior to an adequate screening program. In the UK, virtually every 
haemophiliac (-3,500) who received pooled factor 8 in the early 1980s became HCV 
positive (Watson et aI, 1992), but the risk of acquiring HCV from transfusions has 
since been diminished. Other risk factors include; lack or inadequately sterilised 
medical equipment, high risk sexual behaviours and social or cultural practices such 
as circumcision and tattooing. Although rare, perinatal infection can occur; 
approximatley 5% with a higher incidence seen in mothers with HIV co-infection. 
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1.3.4 Diagnosis 
The biological markers of liver disease are serum alanine aminotransferase activity 
(AL T) and aspartate aminotransferase activity (AST), both of which are normally 
found in hepatocytes but are released into the serum as a result of liver damage. 
Upon HCV infection their levels increase about ten-fold, but they are a poor guide to 
the extent of hepatic inflammation and are not specific to HCV liver damage. Liver 
biopsies, normally carried out pre-treatment are used to determine the degree of 
fibrosis and liver damage. 
Initial diagnosis of HCV is based on serological antibody tests, either enzyme 
immunoassays (EIA) or enzyme-linked immunosorbent assays (ELISA) which detect 
a mixture of antibodies directed against various HCV epitopes. The latest 
generations of tests are highly reliable and have an accuracy rate of up to 990/0. To 
detect HCV RNA, a marker of active HCV replication, a qualitative PCR is used. 
HCV RNA is detectable in the serum as early as 1-2 weeks after infection, which 
generally decreases and disappears in acute infections but in chronic infections the 
HCV RNA levels, gradually decline before reaching a plateau. For chronic HCV, 
quantitative PCR is used to monitor the efficiency of antiviral treatments and HCV 
clearance, which is usually bi-phasic; a rapid initial decline followed by a more 
prolonged response. 
1.3.5 Natural History of HCV Infection 
Acute hepatitis C infection is usually sub-clinical. After an incubation period of about 
4-20 weeks, about 20 % of patients with acute hepatitis C become jaundiced; often 
accompanied with fatigue, muscular pain, low-grade fever, nausea and vomiting . 
Around 20% of patients infected will effectively clear the virus, the majority will 
develop a persistent infection and of these a high proportion will develop chronic liver 
damage. At least 20% of patients with chronic hepatitis C develop cirrhosis, 
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characterised by regenerating nodules and a build up of fibrous tissue, a process 
that takes at least 10 to 20 years. After 20 to 40 years, a smaller percentage of 
patients with chronic disease develop hepatocellular carcinoma (HCC) . Liver failure 
from chronic hepatitis C is one of the most common reasons for liver transplants in 
the United States and hepatitis C infection is currently the cause of about half of 
cases of primary liver cancer in the developed world. 
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Fig 1.7 Natural history of Hepatitis 
C infection. Hey is a hepatotrophic 
virus which causes an acute infection 
in 20% of patients. 80-85% of 
patients develop a chronic disease 
with life threatening consequences 
such as liver failure and 
hepatocellular carcinoma. 
HCV has a positive stranded RNA genome that contains a single open reading frame 
(ORF) encoding a single polyprotein of 3011 a.a in length which is processed by host 
cell and viral proteases into 3 major structural proteins and several non-structural 
proteins, necessary for viral replication (Choo et aI, 1989;Kato et aI, 1990) 
1.3.7 The HCV virion 
Due to difficulties of replicating the virus in tissue culture, the elucidation of the 
structure of the HCV virion has been hampered. It is known that HCV is a spherical 
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enveloped virus (Feinstone et aI, 1983) of approximately 50nm in diameter (Bradley, 
1985). Potential HCV particles have been observed in human plasma, chimp liver 
and experimentally infected or transfected cell lines. 
Fig 1.8 Electron microscopy of the HCV virion. (Taken from 
www.epidemic.org/theFacts/ hepatitisClhepatitisC.html) 
1.3.8 HCV genome structure 
The HCV genome is translated as a large polyprotein which is cleaved into individual 
proteins during and following translation. The HCV proteins were identified from 
mammalian and insect cells transfected with HCV cDNA. The location of the 
cleavage sites have been identified using amino acid N-terminal sequence analysis 
of the resulting protein products. 
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Fig. 1.9 Genomic organisation of HCV. A schematic representation o~ the HCY genome a~~ its 
translation products. The boxed area corresponds to the single open readmg frame of the hepatI~Is C 
virus (Hey) genome. The stem-loop structures represent the 5' and 3' non-translated (NTR) regIons, 
including the internal ribosome-entry site (IRES). 
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The proteins have been classified into structural and non-structural. The structural 
proteins (core, E1, E2 and p7) form the nucleocapsid and the envelope of the virus 
i.e. the virion, whilst the non-structural proteins (NS2, NS3, NS4A, NS4B, NS5A and 
NS5B) encode the proteinase, helicase, RNA polymerase and co-factors necessary 
for viral replication. 
Table 1.4 Putative functions of the HeV proteins. Numbering based on the HeY-H strain. 
~=~l~coEroteins 
Protein Nucleotide Amino Acid Mol Wt. Function 
Location Location (kOa) 
5'UTR 1-341 Initiation of translation 
Core 342-857 1-191 p21 Nucleocapsid of virion 
E1 915-1490 192-383 gp31 Envelope glycoprotein 
E2 1491-2579 384-746 gp70 Envelope glycoprotein 
p7 2580-2768 384-809 p7 Viroporin - ion channel 
NS2 2769-3419 810-1026 p21 Proteinase 
NS3 3420-5312 1027-1657 p70 Proteinase & NTPase/Helicase 
NS4a 5313-5476 1658-1711 p6 NS3 Co-factor 
NS4b 5477-6257 1712-1972 p27 Replicase component 
NS5a 6258-7600 1973-2420 p58 Replicase component, ISDR 
NS5b 7601-9374 2421-3011 p68 RNA polymerase 
3'UTR 9375-9621 Replication & Packaging 
The non-structural proteins are involved in the polyprotein processing and RNA 
replication of the virus. The processing of the polyprotein requires the presence of 
two distinct proteinases, the NS2 protein and the N-terminal region of the NS3 form 
one, a zinc-dependent metalloproteinase and the N-terminal region of the NS3 
protein form the other, a serine protease. The NS2-NS3 proteinase cleaves at the 
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NS2/NS3 site and the remaining NS proteins are released by the NS3 serine 
proteinase in association with its co-factor NS4a. (Hijikata et aI, 1993). 
1.3.9 5'UTR 
The structural proteins are encoded by the N-terminal end of the polyprotein ORF but 
are preceded by a 5' untranslated region (UTR) which consists of 341 nucleotides 
(Choo et aI, 1991). Although the nucleotide sequence of HCV is highly variable as 
the viral polymerase has no proof-reading ability, the 5'UTR is a highly conserved 
hairpin structure, closely related to the 5'UTR of the pestiviruses (Bukh et aI, 1992). 
The 5'UTR contains 4 highly strucutured domains, numbered I to IV. Domains II , III 
and IV together with the first few nucleotides of the core gene make up the regulatory 
elements important for viral gene expression namely, the internal ribosomal entry site 
(IRES). The IRES allows the expression of the viral genome in a cap independent 
manner. The I RES of HCV is bound specifically by the host cell 40s ribosomal 
subunit and the eukaryotic initiation factor e1F3. These interactions allow for the 
formation of the ribosome complex that leads to the initiation of protein synthesis 
initiated in a manner distinct from the host (Lytle et aI, 2001). 
1.3.10 Core 
The core protein is an RNA-binding polypeptide that binds to the HCV genome to 
form the viral nucleocapsid. It is derived from the N-terminal 191 amino acids of the 
polyprotein and is well conserved among all isolates (Bukh et aI, 1994). The core 
protein is mostly cytoplasmic, but three possible nuclear localisation signals have 
been identified in the N-terminal region of the protein, making it possible for a 
truncated version of core to be translocated to the nucleus (Suzuki et aI, 1995) . Core 
has been shown to bind to a number of cellular proteins including apolipoprotein All , 
a cellular helicase, a heterogeneous nuclear ribonuclearprotein K and a bZIP 
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transcription factor. It can transactivate or repress a number of cellular promoters 
and interacts with c-JNK, ErK and MAPK signalling. Core has been shown to interact 
with the Iymphotoxin-~ receptor (L T~R) which is involved in the developmental 
regulation of lymphoid organs, lymph node development and apoptopic signall ing 
thereby the binding of core to L T~R could lead to HCV persistence. 
1.3.11 The Envelope proteins (E1, E2 and p7) 
The viral envelope proteins, E 1 and E2, located in the N-terminal region of the 
polyprotein, are highly glycosylated, transmembrane proteins that form stable non-
covalent heterodimers (Deleersnyder et ai, 1997). Also, E1 has been shown to 
associate through its carboxy terminus with the core protein (Lo et ai, 1995) and E2 
associates with the NS2 protein (Selby et ai, 1994). Expression of cloned HCV cDNA 
in baculovirus has indicated that an internal signal sequence, upstream of the E 1 and 
E2 proteins direct the precursor polyprotein to the endoplasmic reticulum (ER) , 
where translocation into the lumen and signal sequence cleavage takes place by 
host signal peptidases (Hijikata et ai, 1991). A high degree of variation occurs in the 
N-terminus of the E2 protein (aa 1-27), which is referred to as the hyper-variable 
region 1 (HVR-1). The HVR-1 epitopes are probably presented on the surface of the 
virion as part of the viral envelope, and contains a neutralizing epitope, which is 
susceptible to immune pressure and the selection of escape mutants. There have 
been several contradictory studies on the mutations of the HVR-1 region; it may alter 
B cell or T cell epitopes and favour viral persistence. The E2 protein contains a 
region that can compete with elF-2a for binding to PKR, thereby preventing the 
inactivation of translation by PKR (Taylor DR, 1999). This region is highly variable 
between HCV isolates and differences have also been observed between the HCV 
genotypes. 
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The p7 protein is something of an enigma. It is not necessary for RNA replication and 
therefore does not fit in with the non-structural proteins but it is not known whether it 
is a virion component either. It is a small (63 a.a) , highly hydrophobic protein which 
has similar characteristics to viroporins, proteins that form ion channels, most often 
involved in virus assembly or entry/exit . It has been shown that amantadine 
specifically inhibits the ion channel activity of the p7 protein of HCV on artificial 
membranes (Griffin et ai, 2003). Together the HCV structural proteins assemble to 
form a protective structure to surround the viral nucleic acid . (Fig 1.9) 
Fig 1.10 Model of the assembled structure of hepatitis C virus. 
(Taken from http://www.pm.orglimages) 
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1.3.12 The Non-Structural proteins. 
The non-structural proteins of HCV are involved in polyprotein processing and RNA 
replication. 
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1.3.13 NS2 
The NS2 is the first of the non-structural HCV proteins. It encodes a protein of 
approximately 21-23KDa. NS2 is a transmembrane protein downstream of p7 with 
the C-terminus located in the lumen of the ER and the N-terminus in the cytosol. The 
NS2 is a metalo-proteinase, specific for the NS2-NS3 cleavage. The active domain 
responsible for the cleavage encompasses the C terminus of NS2 as well as the N 
terminus of NS3 (Hijikata et aI, 1993). As soon as the NS2-NS3 proteinase cleavage 
occurs the activity is lost. 
1.3.14 NS3 
The NS3 protein is approximately 70KDa and has been shown to posses three 
different catalytic activities; a protease, helicase and an ATPase function . The C-
terminal domain contains the NTPase/helicase function and the N-terminal domain 
contains the serine protease activity. The amino acid sequence of the NS3 is fairly 
well conserved across the HCV genotypes and the functional motifs of NS3 are 
conserved across the Flaviviridae. 
The N-terminal contains the serine proteinase, which cleaves at the NS3/4A, 
NS4A1B, NS4B/NS5A and NS5A1B sites (Bartenschlager et aI, 1993). Cleavage at 
these positions was abolished when mutations were introduced to the predicted 
. t t Iyt· t · d HI·S1083 , Asp11 07 and Ser11 65 residues of the senne pro ease ca a IC na 
(Bartenschlager et aI, 1993), (Tomei et aI, 1993). 
Recent knocko~t experiments show that the NS3 helicase activity is essential for 
virus replication (Gu et aI, 2000). The negative-strand RNA intermediate is used as a 
template for th~ synthesis of the positive-strand progeny RNA. As the strands are 
complementary, the NS3 helicase is necessary for strand separation. 
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A role for NS3 has also been suggested in host cell transformation , which may be 
involved in hepatic cancer and liver cirrhosis associated with HCV infection 
(Sakamuro et ai, 1995). The N-terminal domain (protease) of the NS3 protein may 
have a suppressive effect on apoptosis by decreasing the amount of cellular p53 
(Fujita et ai, 1996), p53 has been found to enhance the nuclear localisation of NS3 
(Ishido et ai, 1997). 
1.3.15 NS4a 
The NS4a is a small protein of 54a.a, which forms a stable complex with the NS3 
protein and acts as an essential cofactor of the NS3 proteinase. It is essential for the 
cleavage of the NS48/NS5A site and plays an important role in the NS3-mediated 
cleavage of other sites (Tomei et ai, 1993). Stable NS3-NS4a complex formation 
requires the 22a.a. residues at the N-terminal of the NS3 protein (Failla et ai, 1995) 
and further studies have shown that the central region of NS4a is important for the 
NS4a dependent activation of NS3. 
1.3.16 NS4b 
The NS4b protein of HCV is a 27KOa protein for which no structure or function has 
yet been published, although recently it has been shown to induce a morphological 
change in the t=R membrane that might have a direct role in viral RNA replication 
(Gretton et ai, ~005). NS4b has also been implicated in the pathogenesis of HCV; 
expression of 90 genes encoding oncoproteins, tumour receptors and adhesion 
molecules wen:t affected in He La cells stably transfected with NS4b (Zheng et ai, 
2005) 
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1.3.17 NS5a 
The NS5A protein is a complex protein whose amino acid sequence can be divided 
into three domains. The first domain consists of a helix which tethers the protein to 
membranes, chelates zinc and allows the protein to form homo- and hetero-dimers 
but the function of the other two domains are so far unknown. 
As well as the three domains, the NS5A protein exists in two forms; a 
phosphorylated 56KDa (p56) and a hyperphosphorylated 58KDa (p58) form. It was 
proposed that phosphorylation took place in two phases: firstly basal-phosphorylation 
converts p49 to p56 and then hyper-phosphorylation converts p56 to p58. Conflicting 
data has been presented on the requirement of NS4A for these phosphorylation 
events, Kaneko et a/. showed that the p58 form of NS5A was enhanced by co-
expression of NS4A (Kaneko et aI, 1994b), but other groups using different strains of 
the virus could not show an association (Reed et aI, 1997). 
Although the f~nction of NS5a is so far unknown (at a good guess it is part of the 
RNA replication complex) it has been widely studied with regards to the Interferon 
sensitivity determining region (ISDR) it contains; a region of the HCV that is known to 
have a high ml.Jtation rate. This region is capable of binding to and inhibiting dsRNA 
induced PKR. The NS5a from patients infected with genotype 1 of the virus, 
specifically strains 1 a and 1 b, has been shown to bind PKR. Mutations in this region 
are thought to confer inhibition to IFN through its PKR binding ability, although this 
has only been found in patients with HCV-1 b (Enomoto N, 1995) and may depend 
upon the treatment that the patient was receiving. It also has been shown that the 
inhibition of IFN by NS5a in the lab does not correlate with patient out-come after 
IFNa treatment (Paterson et aI, 1999) as the levels of the protein expressed are so 
high that they could in no way physiologically represent the in vivo situation . 
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IFN normally acts by inducing the transcription of several antiviral genes, including 
PKR. PKR is responsible for the phosphorylation of elF-2a that blocks protein 
synthesis and therefore inhibits viral replication. Several viruses are known to 
overcome the antiviral action of PKR. NS5a is thought to target the PKR dimerisation 
required for its catalytic activity. This in turn blocks the repression of mRNA 
translation and viral replication induced by cellular exposure to IFN, thus allowing 
HCV to resist the antiviral effects of IFN. Mutations in the ISDR region make it less 
capable of binding to the PKR and disrupting its dimerisation and thus making it 
more sensitive to I FN. 
Other possible roles for NS5A include transcriptional activation, the acidic and 
proline-rich amino acids found in the C-terminus of NS5A are characteristic of 
eukaryotic transcription activators. Kato et al showed that the NS5A protein when 
fused with the GAL4 DNA-binding domain, could stimulate transcription in yeast and 
in a hepatoma cell line (Kato et aI, 1997). 
NS5A has also been found to bind to the growth factor receptor-bound protein 2 
adaptor proteins (Grb2). Grb2 is a protein that is involved in growth factor induced 
signalling by coupling the membrane receptor tyrosine kinase (RTK) to the Ras-
MAPK (mitogen-activating protein kinase). The proline rich sequences of NS5A 
resemble the $H3-binding sites found in cellular signalling molecules and NS5A 
could bind to Grb2 (via the SH3 domains of Grb2) to perturb the mitogenic signalling. 
Several mitogen activated kinases have been shown to interact with the JAKISTAT 
pathway. Therefore, NS5A inhibition of Grb2 may be another mechanism by which 
NS5A interefer~s with the interferon signalling pathway (Tan et aI, 1999). 
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1.3.18 NS5b 
NS5b is a 65KDa protein that encodes the RNA-dependent RNA polymerase (RdRp) 
of the HCV, whose amino acid sequence shows significant homology to the RdRp of 
other flaviviruses. NS5b plays a central role in HCV replication and viral diversity 
because of the lack of proof-reading activity. 
Recombinant NS5b, expressed in insect SF9 cells using baculovirus , was shown to 
have RdRp activity (Behrens et aI, 1996). Characterisation of the RdRp indicated that 
it was able to prime at the 3' end of the template RNA and to copy the 
complementary strand with a hairpin loop connecting the two strands using the 
'copy-back' mechanism. By using mutational analysis , 4a .a sequence motifs, 
designated A to 0 were identified that are crucial for the RdRp activity (Poch et aI, 
1989). 
1.3.19 The 3' Untranslated region 
The 3' UTR of the HCV genome consists of an untranslated region located 
downstream of the stop codon at the end of the ORF encoding the viral polyprotein . 
The 3' UTR consists of four sequence elements; i) a short sequence of about 40 nt 
which appears to vary considerably between genotypes, ii) a homopolymeric U tract, 
iii) a polypyrimidine stretch and iv) a novel 98 nucleotide sequence which terminates 
in a U residue (Yanagi et aI, 1999). Each of these regions has been found to be 
important for HCV RNA replication and may play a further role in HCV RNA 
translation. 
1.3.20 HCV Life cycle 
HCV is predomInantly a hepatotropic virus and therefore its life cycle must start with 
attachment and entry into a liver cell. Until the last decade, HCV research was 
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hampered by lack of infectious clones and an inability to propagate the virus in 
cultured liver cells. Introduction of the HCV replicon system (a self-replicating 
subgenomic construct) (discussed later) allowed studies of viral replication, but 
unraveling molecular details of HCV attachment and entry into hepatocytes required 
the development of additional tools. These encompass reconstituted HCV envelope 
glycoproteins, E1 and E2 (Deleersnyder et aI, 1997;Lambot et aI, 2002) , HCV 
pseudoparticles (HCVpp) in which E1 and E2 are displayed on retroviral core 
particles (Bartosch et aI, 2003a) and, more recently, HCVcc, infectious viral particles 
released in cell culture following transfection with a full-length HCV genome 
(Lindenbach et aI, 2005;Wakita et aI, 2005;Zhong et aI, 2005). These systems 
identified several cell-surface molecules which interact with HCV, including 
glycosaminoglycans (GAGs), CD81, claudin-1 and SR-BI (Helle & Dubuisson , 
2007;Cocquerel et aI, 2006;Evans et aI, 2007). These putative receptors are by 
themselves insufficient for HCV binding and cell entry; current studies focus on their 
interplay. Initial attachment via GAGs is likely, as recombinant E2 binds strongly to 
heparan sulphates (Barth H & et aI., 2003) but these have wide tissue expression 
and thus cannot confer HCV hepatotropism; additional hepatocyte-specific surface 
molecules are required. 
One vital protein is CD81, a tetraspanin with two extracellular domains: it binds 
glycoprotein E2 (Pileri et aI, 1998). Infection of Huh-7.5 hepatoma cells is inhibited by 
CD81 antibodies or by silencing CD81 gene expression. HepG2 cells which resist 
HCVpp infection become permissive if transfected to express CD81 (Zhang et ai, 
2004). However, expressing CD81 in non-hepatic cells does not allow HCVpp entry, 
suggesting a co-receptor is involved - strong experimental evidence implicates SR-
BI, though reports that CD81 has a suppressive partner EW1-2wint (Helle & 
Dubuisson, 2007) and that the tight-junction protein claudin-1 , and also claudins 6 
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and 9 (Zheng et ai, 2007) act late in the HCV entry pathway, emphasizes that the 
overall process is complex and multi-step 
SR-BI , an -82-kDa glycoprotein with a large extracellular loop and membrane-
spanning N- and C- cytoplasmic termini , is highly expressed in hepatocytes, and 
steroidogenic cells, where it facilitates bidirectional cholesterol transport. Though 
able to bind oxidized or chemically-modified low-density lipoprotein (LDL) , SR-BI is a 
physiological receptor for high-density lipoproteins (HDL) and functions to selectively 
extract cholesteryl esters (Acton et ai, 1996;Owen & Mulcahy, 2002) Intriguingly, 
SR-BI also binds apolipoprotein E (Bultel-Brienne et ai, 2002) a 34-kDa polymorphic 
constituent of various plasma lipoproteins which has multiple roles in HCV virion 
assembly and/or infectivity (Chang et ai, 2007) including effects on the persistence of 
infection (Price et ai, 2006). As with HCV-CD81 interactions, SR-BI binds the HCV 
envelope glycoprotein E2 (Scarselli et ai, 2002) and infectivity of HCVpp and HCVcc 
is stimulated by SR-BI overexpression in Huh-7.S cells or, conversely , is decreased 
by SR-BI gene silencing or by addition of anti-SR-BI antibodies (Bartosch et ai, 
2003b) Noteworthy, but still ill-understood (Bultel-Brienne et ai, 2002) is the 
association of HCV in human plasma with lipoprotein particles and, while oxidized 
LDL inhibits HCV cell entry in vitro (von et ai, 2006) HDL stimulates infectivity and 
protects HCVpp from neutralizing antibodies (Voisset et ai, 200S;Dreux & Cosset, 
2007) Thus, although the finer details of HCV cell binding and entry remain elusive, 
the HCVpp and HCVcc models verify the interplay of CD81 and SR-BI for productive 
infection and establish that HCV-SR-BI interactions are enhanced by HDL. 
After attachment to the receptor, the virus penetrates the plasma membrane via 
specific receptors and clathrin-mediated endocytosis to release their genome from 
acidified endospmes (Helle & Dubuisson, 2007). As the genome of the virus is 
positive sense, the virus tricks the cell into thinking that it is a host mRNA and 
59 I 
I 
therefore can be read by the host cell 's ribosomes. The translated polyprotein is then 
cleaved and processed before being used to create a minus strand (-) RNA template 
which in turn serves as a template for more progeny (+) strand RNA genomes. The 
positive sense RNA then interacts with the structural proteins and is encapsidated. 
Immunostaining and electron microscopy have shown that E 1 and E2, the envelope 
proteins, are predominantly located in the endoplasmic reticulum (ER) (Dubuisson J 
et ai, 1994), suggesting that HCV buds from the ER and are released from the cells 
via the exocytosis pathway. 
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HCV isolates fall into three major catagories; genotypes, subtypes and quasispecies, 
depending on tpe degree of sequence divergence. Six major HCV genotypes and 
several more subtypes have been identified on the basis of nucleotide sequence 
60 I 
I 
similarity (Simmonds, 1999). The distribution of HCV genotype varies geographically; 
in the UK it is estimated that the majority of HCV infections are either genotype 1 or 
3, overall in Europe the majority of infections are genotype 1, genotypes 4 and 5 are 
principally found in Africa and genotype 6 is primarily distributed in Asia I with 
genotype 3 predominant in India and Pakistan (http://hcv.lanl.gov/components/hcv-
db/new geography/geography.comp). 
Table 1.5 Hey genotypes and distribution 
Genotype 
1 
2 
3 
4 
5 
6 
Distribution 
----- -.-
Northern Europe, North America, Japan 
Similar to genotype 1 
Endemic in South East Asia 
Middle East, Egypt and Central Africa 
South Africa 
Distributed in Asia 
The genotypes vary in their response to I nterferon alpha treatment; infection with 
HCV-1 b associated with the lowest interferon response rate and higher chronicity 
rate whereas genotypes 2 and 3 are associated with a more favourable I FN 
response and genotypes 4, 5, and 6 are intermediate (www.nice.org.uk). Genotype 1 
is more prevalent in patients with cirrhosis, suggesting that it causes a more 
progressive disease. The genotype of HCV may determine the patient's ability to 
eliminate the di~ease . 
1.3.22 HCV Q~asispecies 
Not only do different genotypes and subtypes of HCV exist, but due to the lack of 
proof-reading ability of its RNA-dependent RNA polymerase, HCV exists as a 
population of different but closely related genomes known as quasispecies; multiple 
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clones with different nucleotide sequences have been isolated from a single patient 
(Martell et ai, 1992). Different methods have been used to study HCV Quasispecies : 
sequencing of cloned RT -PCR products, single-stranded conformation polymorphism 
(SSCP), temperature-gradient gel electrophoresis (TIGE) and gel-shift analysis 
(GSA). These techniques have shown that quasispecies populations differ in genetic 
complexity (number of variants) and genetic divergence (the genetic distance 
between variants). Although mutations are introduced randomly during viral 
replication, due to constraints upon the nucleotide and/or protein sequence, the 
changes vary across the genome with certain areas more prone to changes. Some 
mutations become 'fixed ' within the HCV genome whilst others are lost. The rate of 
fixation describf3s the number of substitutions per genomic site per year which can 
be used to compare mutation rates of different viruses, different genes within the 
same virus or the mutation rates of single residues. One region of the HCV genome 
has marked diversity among different isolates. The hypervariable region 1 (HVR 1) is 
situated in the amino terminus of the envelope protein E2. There has been a 
correlation between highly divergent HVR1 region and chronicity; patients who 
developed a chronic infection had a significantly higher HVR 1 genetiC divergence 
after 8-11 weeks post infection, compared to patients who eliminated the virus during 
the acute phase (Farci et ai, 2000). 
One of the drivIng forces for the evolution of the HVR quasispecies is thought to be 
the anti-HVR1 antibodies specific for each quasispecies. In chimps, antibodies to the 
HVR 1 are known to be protective and when variants within the HVR 1 arise, the 
antibodies are no longer protective and therefore the quasispecies become capable 
of escaping ne~tralisation (Farci et ai, 1992). 
The effect of the HCV quasispecies has been studied by several groups and it 
appears that a higher diversity in the HVR 1 before the start of treatment is related to 
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patients who do not respond to IFN (Kanazawa et aI, 1994). Before treatment a 
mixture of diverse quasispecies co-exists. During treatment the more-resistant 
quasispecies are selected and become predominant, whi le other quasispecies 
disappear. Although the heterogeneity of the HVR 1 is important in viral evasion of 
antibody-mediated immune reponses, no direct role in the evasion of the IFNa 
treatment has been discovered. In fact, HCV quasispecies with identical HVR1 
amino acid sequences have been shown to respond differently to IFN therapy 
(Enomoto & Sato, 1995) 
1.3.23 HeV replicon 
Our understanding of the hepatitis C virus was greatly improved with the 
development of a selectable subgenomic replicon (Bartenschlager et aI, 
2003;Lohmann et aI, 1999a). Replicons are subgenomic, self-replicating RNA 
molecules that contain all the nucleotide sequences required for RNA replication , 
transcription , and translation, but are not themselves infectious. The structural genes 
were deleted and replaced by a selectable marker (neomycin phosphotransferase, 
conferring G41 B-resistance) and a second IRES-element was introduced to allow 
translation of the HCV nonstructural region. This allowed the generation of human 
hepatoma cell lines expressing the self-replicating HCV RNAs and proteins. 
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Fig 1.12 Schematic 
representation of the 
method used to establish 
HCV-replicon containing 
cell lines. The subgenomic 
RNA are transfected into 
Huh7 cells. The cells 
containing replicating HCV 
replicons develop resistance 
to G418 and will therefore 
form colonies. (Taken from 
http: //www.med.uni-
heidelberg.de/hyg/ hyg5/EN! 
HCV.HTM) 
The original HCV replicon could only replicate at a low level but replication was 
enhanced up to 10,000 fold through the acquiring of cell culture adaptive mutations 
(Krieger et aI, 4001 ;Lohmann et aI, 2003). Mutations tended to be clustered but not 
exclusive in the NS5A area, and although mutations in the NS4, NS5A and NS5B all 
enhanced replication of the replicon they were incompatible with each other. 
Whereas mutations in the NS3 region, only slightly enhanced replication on their 
own, in combination with other mutations they further enhanced the replication 
(Bartenschlager et aI, 2004). Although the original replicon was derived from a 1 b 
genotype other$ have since followed and there are now HCV replicons for genotypes 
1aand2a. 
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Although the replicon system advanced our knowledge of HCV, it still has it 
limitations. These were overcome recently by the development by three separate 
groups of a MCV infection system in vitro (Wakita et aI, 2005); (Zhong et aI, 
2005;Lindenbach et aI, 2005). 
Using the JFH-1, a genotype 2a HCV isolate obtained from a patient with fulminant 
hepatitis, Wakita et a/. showed that the JFH-1 isolate, replicated and secreted viral 
particles after transduction into Huh7 cells of transcribed RNA. When transfected into 
the Huh7.5 cell line, which are highly permissive for HCV RNA replication, the viral 
titres were increased. The secreted virus was infectious and this could be neutralized 
by C081-specific antibodies and by immunoglobulins from chronically infected 
individuals. Lindenbach et a/. used a full length genotype 2a subgenomic replicon, 
which was found to replicate efficiently within cell culture and more importantly it did 
so without adaptive mutations which are thought to be detrimental to the production 
of infectious particles in culture. By constructing a chimeric replicon they developed a 
system that allows for efficient replication of HCV. The virus was neutralised by an 
E2-specific human monoclonal antibody which showed that E2 was essential for viral 
entry. They also showed that the secreted virus could be blocked by blocking CD81 . 
1.3.24 Current Treatment 
Treatment so far is based on the antiviral action of interferon alpha in combination 
with ribavirin, which clears the virus in around 30-40%) of the patients. Ribavirin was 
one of the first antiviral drugs to be discovered. It is a synthetic guanosine analogue 
with broad spectrum activity against DNA and RNA viruses. It has been suggested 
that ribavarin monotherapy inhibits cellular DNA synthesis and promotes a CD4+ 
Th1 immune reponse (Hu et aI, 2001), but recently Dixit et a/ suggested, based on 
mathematical modelling of viral kinetics in treated patients that ribavirin in the 
presence of pegylated IFNu, caused the produced virions to be less infectious, 
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thereby potentially reducing the number of hepatocytes that could be infected (Dixit 
et ai, 2004). However other mathematical models have shown that ribavirin is a 
mutagenic agent that causes fatal errors in the replication of HCV producing non-
viable virions (Crotty et ai, 2000) . 
Another innovation in HCV therapy is the pegylation of the interferon protein. The 
pegylation of IFNa (a polyethelene glycol group is covalently attached to the IFNa 
molecule by a chemical process) increases the half life of the protein by several days 
(Glue et ai, 2000) and increases the percentage of patients that clear the virus to 
approximately 55%. Moreover, in view of its slow clearance, it allows treatment to be 
reduced to weekly administration. 
1.3.25 Clinical studies 
Studies of hepatitis C viral kinetics have been used to evaluate different treatment 
regimes and are used to monitor response to therapy. On the basis of these kinetic 
studies HCV patient treatment-response categories have been defined. A sustained 
virological response (SVR) requires HCV RNA to be undetectable in serum 24 weeks 
after the end of therapy. McHutchinson et al demonstrated that 98% of patients with 
SVR were HCV RNA negative having completely cleared the infection 
(McHutchinson et ai, 2002). 
Combination therapy results in an overall 50-600/0 response rate in all patients, 
increasing to 80% response rate with genotypes 2 and 3. Two weeks into 
combination therapy the response rate is tested by quantitative PCR, patients who 
do not exhibitin~ a greater than 2 log drop in viral load are unlikely to clear the virus 
with continued therapy and are considered non-responders (NR) , but there are also 
sub-categories of patients for whom treatment fail. Those who experience a 
significant decrease in HCV RNA during treatment can be defined as "partial 
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responders" and "responder-relapsers" become HCV RNA negative during therapy 
but relapse after the end of treatment (Fried et aI, 2002 ). 
Treatment outcome Definition 
Non-responder (NR) ._- .- . - ... ----;-;-------:--::=--------------No significant reduction in HCV RNA (> 1 
log) at any stage of treatment 
Complete-responder (CR) HCV RNA negative during treatment and 
have no HCV RNA in serum 6 months 
after the end of treatment. 
Partial responder Significant decrease of HCV RNA during 
treatment 
Responder -relapsers HCV RNA negative during treatment but 
relapse after the end of treatment 
~~--~~--------------------------------------------.-. --Table 1.6 Definitipns of patient response to IFN treatment. 
In a study by Zeuzem et ai, sustained virological response after monotherapy with 
pegylated IFNa2a was 39%) in comparison to 19%) SVR with standard IFNa2a 
(Zeuzem et aI, 2001) . Clinical trials have shown that IFNa and ribavirin combination 
treatment significantly increases the rate of SVR both in untreated and previously 
treated but relapsed patients and the rate was increased further when ribavirin was 
used in combination with pegylated IFNa2a. SVR was achieved in 56% of patients 
treated with the combination pegylated I FNa2a and ribavirin therapy compared with 
ribavirin combil1ed with standard IFN (45%) and 30% with peglFNa2a alone (Fried et 
aI, 2002). How~ver, this treatment regime has a high relapse rate associated with 
genotypes 2 anp 3 (24%) and 54% of patients with genotype 1. The current standard 
therapy uses a combination of pegylated IFN and ribavirin , but the duration and 
response to therapy are genotype specific: Genotype 1 patients require 48 weeks of 
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combination th~rapy for 50% successful viral elimination, while genotype 2 and 3 
patients require 24 weeks of combination therapy for 80-90% viral elimination 
(Hayashi & Takehara , 2006) . 
1.3.23 Resis~nce to Treatment 
Frequent viral load measurements and mathematical modelling determine viral 
kinetics in chronic HCV (Zeuzem et aI, 2001). Studies of chronic HCV patients during 
IFNa treatment reveal a biphasic decline in HCV RNA levels after the first IFNa 
treatment. The initial phase of viral decline is rapid , approximately a 0.5 -2 log fall in 
HCV RNA levels within 48 hours which has been shown to be dose dependent i.e. 
the rate of viral decline is inversely proportional to the dose of IFNa, where the IFNa 
slows down virus production and/or viral release. If the IFNa treatment was 100% 
effective then viral replication would stop completely and HCV RNA would be 
undetectable within a matter of days, but this first phase of viral decline is followed by 
a slower second phase decline which is highly variable among patients. The second, 
slower phase appears to reflect the gradual clearance of the virally infected cells by 
the patient's immune system at the same time as the inhibition of HCV replication 
(Neumann et aI, 1998;Zeuzem et aI, 2001). During chronic HCV infection, HCV 
replication kinetics are at a steady state; virus production and de novo infection of 
the cells are counter-balanced by virion degradation and death of infected cells. The 
production-clearance rate of viral particles during this steady state is 1012/day, where 
viral particles have a half life of approx. 3 hours (Neumann et aI, 1998). The standard 
I FNa dosage r~gime of 3 million units 3 times a week was not sufficient to maintain 
such viral kinetics, but the addition of ribavirin and pegylated I FN helps maintain the 
viral clearance kinetic. 
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Fig 1.13 HeV vi ral 
kinetics after IFNa 
treatment. 
Resistance to treatment is not only dependent on the type of therapy. Virological 
factors and the patient's immune response may also make a difference. Patient 
chartacteristics known to be associated with poor response to IFN treatment include 
older age, male gender and African or Hispanic ethnic background. A compounding 
factor was non-compliance due to the numerous side effects associated with IFN 
treatment such as depression, diarrhoea, nausea, fatigue and flu-like symptoms 
which can be severe. 
It appears that the response to treatment may be a balancing act between viral 
replication and patient immune response. In the case of a strong replicating virus, the 
immune response may be irrelevant, but conversely in the case of a weal replicating 
virus a strong immune response may be sufficient to clear the disease. 
1.3.23 Future Treatments 
Due to the limitations of the current therapy, not only in response rates, but also cost 
and side effects, several new avenues such as siRNA, novel interferons and 
therapeutic vaccines are currently being researched, a few of which have reached 
first stage clinical trials. Improvements in the interferon area comes through novel 
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interferons such as IFNw, prolonging the half life of IFNu further with molecules such 
as albumin and using other nucleoside analogues to promote the induction of IFNu. 
RNA interference (RNAi) is a process of silencing gene expression with small RNA 
duplexes specifically knocking down a gene message and subsequent protein level 
by targeting them for cleavage by ribonucleases. Several siRNA (silencer RNA) for 
HCV have been developed; a HCV-specific siRNA has been shown to inhibit levels 
of a fusion NS5B-luciferase reporter transcript when the siRNA and the target were 
co-transfected into mice (McCaffrey et aI, 2002). A recent publication used RNAi to 
inhibit ongoing HCV replication in an HCV replicon system with siRNA targeting the 
NS3 and NS5 regions of the HCV genome being most effective (Kapadia et aI, 
2003). 
Although earlier reports into development of an oral HCV serine protease inhibitor, 
BILN 2061 (Boehringer Ingelheim, Germany) were encouraging , patients infected 
with genotype 1, receiving a two-day course of treatment with BILN 2061 , 
experienced a rapid drop in their HCV viral loads of 2 to 3 logs (100-1 ,000 fold 
decreases) (Hinrichsen et aI, 2004), but patients infected with either genotype 2 or 3 
did not experience the same drop in their viral load (Reiser et aI, 2005) and recently 
due to adverse side-effects, plans to develop the drug have been put on hold. 
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Table 1.7 A sample of prospective Hey targeted therapeutics. 
Compound Company Clinical Target Mechanism of Action 
Name Phase 
BILN 2061 Boehringer- 11* NS3-4A Pro Serine protease inhibitor 
Ingelheim 
VX-950 Vertex Ib NS3-4A Pro Serine protease reversible covalent 
inhibitor 
NM283 Novartis II NS5B pol Nucleoside analogue 
JTK-103 Japan Tobacco II NS5B pol Non-nucleoside allosteric inhibitor 
HCV-796 ViroPharma la NS5B pol Non-nucleoside allosteric inhibitor 
*Development halted due to cardiotoxicity in monkeys ~,-
1.4.1 HCV Inhibition of the Interferon Pathway. 
Evading the antiviral response triggered by IFNa is crucial to the success of any 
virus. Several recent studies have clarified that HCV RNA is a potent trigger of IFN 
induction, leading to an antiviral state. Therefore HCV must have evolved several 
mechanisms to evade the IFN system and establish a persistant infection. 
Unravelling the mechanisms by which HCV evades the antiviral systems may lead to 
a greater understanding of the antiviral pathways and the development of better 
drugs to counteract ability of the virus to avoid elimination. 
After HCV infection, the host response is initiated in the hepatocytes, leading to the 
expression of s~veral ISGs, conferring an antiviral state within the cell. The dsRNA of 
the virus is det~cted extracellularly by TLR3 leading to the activation of the protein 
kinases TBK1 and IKK£ and intracellularly by RIG-I, which binds to cardif, once again 
leading to the activation of TBK1 and IKK£. These kinases phosphorylate the 
transcription factor IRF3 which forms homodimers that translocate to the nucleus to 
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induce the expression of IFNp. The activation of IKK£ leads to the degradation of IKB 
releasing NF-K8, which translocates to the nucleus and functions with IRF3 again in 
inducing the expression of IFNp. This is then released to activate the JAKISTAT 
pathway, resulting in the expression of ISGs. The amount of IFN produced and the 
expression of ISGs can predict the disease outcome. During the acute phase of 
disease, the in{ected hepatocytes continuously produce IFN and express ISGs, but 
by the chronic phase, the viral proteins by-pass the innate immune system and the 
antiviral actions of I FN thereby turning the tide in favour of viral replication. 
1.4.2 Inhibition by the Core protein 
HCV core protein has been shown to evade the IFN response by inducing the 
expression of SOCS3 (Suppressor of cytokine signalling 3), which is known to inhibit 
the JAK-STAT pathway (Bode et aI, 2003). SOCS3 can inhibit the activity of Jak1 
and Tyk2 as well as directly inhibiting the assembly of ISGF3 which is required for 
the expression of ISGs. However, mice expressing HCV proteins suggest that 
SOCS3 only plays a minor role in repressing the JAK STAT signalling. STAT1 
phosphorylation still occurred in these mice, but the ability of STAT1 to bind DNA 
was impaired. A form of STAT1 (hypomethylated), which has been found in the liver 
of chronic HCV patients, has been shown to associate with the Protein inhibitor of 
activated STAT protein (PIAS) blocking the ability of the phosphorylated ST AT1 to 
bind to the DNA sequence. The Protein phosphatase 2a (PP2A) in turn has been 
shown to produce hypomethylated STAT1 (Duong et aI, 2004). Taken together the 
PP2A and PIAS proteins could contribute towards the inhibition of IFN signalling. 
More recent studies, have shown that the first 23 amino acids of the core protein 
reduce the phpsphorylation of STAT 1 and inhibit the IFN signalling pathway. 
Conversely the C-terminal of STAT 1 , specifically the SH2 domain which is required 
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to form STAT1/2 homodimers, was required for the interaction between STAT1 and 
the core protein (Lin et aI, 2006) 
1.4.3 Inhibition by NS5A 
HCV has developed several mechanisms to evade the antiviral response of 
interferon. The early focus of research was on the NS5a protein which contains the 
controversial Interferon sensitive determining region (ISDR) (discussed previously) 
and has also b~en shown to directly interact and inhibit PKR. 
1.4.4 The Interferon sensitivity determining region. 
The full-length sequence of NS5a from patients that responded and who failed to 
respond to treatment were compared (Enomoto N, 1995). Patients who responded to 
treatment were found to be infected with genotype 1 b isolates with recurring 
mutations within a 40a.a. region in the carboxyl half of the NS5a protein. This region 
was subsequently termed the ISDR. Further research disputed these findings. Within 
the European ~nd North American HCV isolates there is no correlation between the 
ISDR and response to treatment. (Paterson M, 1999). Several reasons have been 
postulated for the discrepancy between the European and Japanese ISDR studies. 
These include, IFN treatment regimes, treatment response rates, mutation 
frequencies, population genetics and the definition of treatment response. However, 
a recent meta .. analysis and long-term follow up provided overall support for the 
association be~een the ISDR and treatment outcome (Pascu et aI, 2004). 
1.4.5 NS5A Clnd PKR 
As previously qiscussed, several viruses inhibit the antiviral response by targeting 
PKR. The NS5A protein of HCV has been shown to interact with the catalytic domain 
of PKR, disrupting PKR dimerisation and PKR-mediated elF2a phosphorylation . The 
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ability of NSSa to bind PKR, is dependent upon the ISDR and a further 26 a.a 
downstream. By introducing specific mutations within the ISDR, identical to those in 
IFN-responsive HCV strains, the ability of NSSa to bind to PKR and inhibit its 
functions was abolished (Gale, Jr. et ai, 1998) . 
However, the use of cell lines inducibly expressing NSSA to determine its mediated 
inhibition of PKR in HCV resistance has led to conflicting results. In support of the 
role of NSSA as an inhibitor of PKR, diminished phosphorylation of PKR and elF2a 
in the presence of NSSA have been documented in human cells lines (Wang et aI, 
2003). 
E2 has been shown to inhibit the kinase activity of PKR, blocking the downstream 
signalling. The E2 protein contains a sequence identical to the auto-phosphorylation 
site of PKR and the phosphorylation site of elF-2a (Taylor et aI, 1999). 
A strong body of evidence is accumulating suggesting that the NSSA proteins, while 
capable of inhibiting PKR, may not influence the sustained response to I FN 
treatment (Paterson M, 1999) (Squadrito et aI, 2002). Paterson et al cloned the 
NSSA gene from patients showing a clear non-response (NR) and complete 
response (CR) to treatment. These were expressed in HT1080 cells (human 
fibroblasts) unqer the control of an inducible promoter and using an antiviral assay 
their effect on IFNa mediated inhibition of EMCV measured. The NSSA-CR clone 
was found to be more inhibitory of the antiviral actions of IFNa than the NSSA-NR 
clone. 
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1.4.6 NS5A and IL-8 
A further association between NS5A and the interferon response was discovered 
through a link with IL-S. In 2001, Polyak et a/ showed that NS5A could induce the 
expression of IL-S, (consistent with the finding that high levels of IL-S are found in 
chronically infected HCV patients (Polyak et aI, 2001 a) and furthermore showed that 
the IL-S inhibited the IFN induced antiviral response (Polyak et aI, 2001 b) . 
1.4.7 Inhibition of IFN induction by NS3/NS4A 
Foy et al showed by using siRNA technology in Huh? cells that silencing RIG-I, but 
not TRIF abolished signalling to the IFN~ promoter induced by Sendai virus. Further 
experiments showed that expression of RIG-I was suppressed with increasing 
amounts of NS3/4a, which inhibited the N-terminal region of RIG-I. Treatment of cells 
with an active site inhibitor of the NS3/4A protease relieved this suppression and 
restored intracellular antiviral defenses. 
Four different groups then identified a CARD containing protein that links the viral 
sensors RIG-I and Mda5 via CARD-CARD interactions to the activation of IRF3 and 
NFKB. This protein was variously called IPS1, MAVS, VISA and Cardif. 
IFN~ promoter stimulator 1 (lPS1) was identified by Kawai et a/ using cDNA libraries 
and they showed that over-expression of the protein activated IFNu, IFN~ and NFKB 
promoters to elicit an antiviral response that inhibited VSV replication. They also 
demonstrated that IPS 1 associated with the CARD region of RIG-I and mda5 but 
could interact with FADD in a CARD independent manner (Kawai et aI, 2005). 
Using a bioinformatics search for proteins with CARD similar to RIG-I , Seth et a/ also 
identified the same protein and called it MAVS (Mitochondrial antiviral signalling) and 
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also showed that it activated NFKB and IRF3 and that the protein was localised to the 
mitrochondrial membrane (Seth & et ai , 2005). 
Further evidence of this proteins function as an adaptor was demonstrated by Xu et 
ai, who named the protein VISA (virus-induced signalling adaptor) (Xu et aI, 2005) . 
The adaptor protein was then shown to play an important role in the way that HCV 
disrupts RIG-I signalling to IRF3 and NFKB. Meylan et al showed that the HCV 
NS3/4a protease cleaves the Cardif protein during HCV infection in vitro at Cys-508, 
resulting in the dislocation of the N-terminal fraction of the protein from the 
mitochondria and disrupting the induction of IFNI3 (Meylan & et ai, 2005). 
Table 1.8 
Summary of the roles the Hey proteins play in inhibiting the IFN response (Qureshi , 2007) 
HCV Protein Role in IFN evasion 
NS3/4a Attenuate signalling from RIG-I and TRIF 
Core Upregulate SOCS3 expression , inhibits STAT1 activation 
NS5a Upregulate IL-8 
NS5a and E2 Inhibit PKR activity 
HCV proteins Disruption of STAT1 and signalling via PP2A 
HCV proteins Removes ISG56 block 
1.5 Summary 
The inhibition Qf the interferon system by HCV is crucial to its success; this thesis 
investigates diff~rent systems that could potentially be used to study the interactions 
between various HCV derived proteins and the interferon system with the aim of 
targeting therapy more effectively. A full understanding of the interplay between HCV 
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and the IFN system will enable rational design of new antiviral drugs. Present in vitro 
systems rely on either a single genotype replicon or the newly developed JFH 1 cells. 
Present animal models of HCV infection are flawed . Although the chimpanzes are 
infectable with HCV they do not go on to develop liver disease. An alternative 
method involves the use of the UPA-SCID mouse which exhibits abnormal liver 
development. These mice can be transplanted with human hepatocytes which are 
infectable with HCV. However, due to the differences between murine and human 
immune systems and specifically for this thesis, the IFN system, the UPA-SCID 
mouse is a poor model. Development of further models based on patient derived 
material will allow a broader spectrum of testing across genotypes. 
Most viruses have now been discovered to encode specific IFN antagonists . By 
identifying the viral inhibitors, novel anti-viral drugs can be developed to block their 
activity. These novel drugs could prevent the viral antagonists from blocking the I FN 
signalling pathway and/or IFN response, thereby restoring the natural IFN response , 
enabling the patient to clear the infection or significantly improve the success of IFN 
therapy. The aim of this thesis is to investigate the potential of cell based replicon 
systems to act as a reporter assay and identify the individual proteins capable of 
inhibiting the IFN antiviral system. 
As HCV is a member of the Flaviviridae, other members of the same family have 
been utilised to study the inhibitory effects of HCV. Although a dengue replicon was 
developed it was deemed inappropriate as a reporter system, but the effects of the 
dengue replicon on the interferon antiviral system have been studied in further detail 
to provide more insight into the mechanisms of dengue infection (chapter 4) 
The other Flav;virius replicon system tested in this thesis was the Bovine vira l 
Diarrhea virus (8VDV). This has previously been shown to be sensitive to type I IFN , 
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with which our studies concurred. The inhibitory effects of patient derived HCV 
proteins were tested in the BVDV reporter system (chapter 5) and further analysis 
carried out by reporter assays for both MxA and 6-16 (chapter 6). The advantages 
and disadvantages of each system will be further discussed in the relavent chapters. 
In summary, the biological effects of patient derived HCV proteins were investigated 
as well as their impact on the antiviral effects of interferon. 
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2. METHODS 
Background 
To evaluate p~tative IFN inhibitors we developed different assay systems. Two 
approaches were taken to address this problem. One looked directly at interferon 
signalling in the cells using an interferon sensitive promoter construct coupled to a 
reporter gene. The other directly models interferon inhibition of virus by expression of a 
viral replicon containing a reporter gene. In these systems the effects of viral inhibitors that 
modify the effects of IFN can be assessed. 
Cells treated with IFN will see a decrease in the RNA replication of the reporter 
whilst the IFNa/J3 antagonist will lessen/prevent the decrease in RNA replication of 
the reporter. The assay has been used to give a comprehensive analysis of HCV 
proteins from patients undergoing IFN +/- ribavirin treatment, showing a response or 
resistance to therapy as well as those who have relapsed and those who have gone 
on to develop HCC. 
IFN 
+/-
Putative Viral Inhibitor 
TranSient expression 
ANALYSIS TO :rv.IEASURE ruE CHANGE IN REPORTER ACTIVITY 
Fig 2.1 SchematiF diagram showing how the rep.orter system wou.ld work .. A put~tive IFN 
. h'b' 'tr 'ently transfected into cells expressIng the reporter wIth and wIthout Interferon In I Itor IS ansI 
treatment and the reduction in the reporter assessed, 
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2.1 Materia,s 
2.1.1 E. coli strains and Genotypes 
Competent E. coli cells were purchased: 
TOP10F' One Shot 
(I nvitrogen) 
JM109(DE3) 
(Promega) 
DHSa 
2.1.2 E.coli growth media 
SOC broth 
Luria Bertani Broth (LB) 
LB agar (LBA) 
F' The mcrA ~(mrr-sdRMS-
mcrBC) <D801acUM1S ~lacX74 deoR recA1 
araD139 ~(ara-leu)7697 galU galK rpsL endA 1 
nupG 
endA1 recA1 gyrA96 thi hsdR17 (rK- , mK+) 
relA 1 A(DE3) supE44 ~(lac-proAB) [F' traD36 proAS 
laqlQ Z~M1S] 
F-<D80IacZ~M 1S~(lacZYA-argF) U 169 deoR recA 1 
EndA1 hsdR17(rk-, mk+) phoA supE44 A- thi-1 gyrA96 
relA1 
2%(w/v) tryptone, O.S%(w/v) yeast extract, 20mM 
glucose, 10mM NaCI, 2.SmM MgCI2 , 10mM MgS04 
1%(w/v) tryptone, O.S%(w/v) yeast extract, O.S%(w/v) 
NaCI 
LB, 1.So/0(w/v) agar-agar 
2.1.3 Tissue Culture Reagents 
All tissue culture reagents were purchased from Invitrogen/Life Technologies: 
DMEM (Dulbecco's Modified Eagle Medium), FBS (Foetal Bovine Serum), RPMI 
(Roswell Park Memorial Institute), PBS (Phospho Buffer Saline) , 10XTE (Trypsin-
EDTA), PIS (Penicillin Streptomycin), L-Glutamine 
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2.1.4 Molecular Weight Markers 
100bp DNA ladder (Promega, Inc.): 100, 200, 300, 400, 500, 600, 700, BOO , 900 , 
1000, 1500bp fragments. 
1 Kb ladder (Promega, Inc.): 250, 253, 500, 750, 1000, 1500, 2000, 2500, 3000, 
4000,5000,6000, BOOO, 10000bp fragments 
2.1.5 Buffers and Solutions 
Molecular Biology Reagents 
EDT A solution 
TAE Buffer 
TBE Buffer 
Sodium Acetate 
Agarose Loading Dye 
X-Gal 
0.5M EDTA [pH B.O] (1 L): add 1B6.1 9 EDTA-2H20 to 
BOOml distilled water. Add 20g NaOH pellets to 
approx. pH B.O. Allow to dissolve and pH accurately to 
B.O. Add water to 1 L and autoclave to sterilize. 
SOX TAE stock (1 L): add 242g Tris base (Trizma) , 
57.1 ml glacial acetic acid and 100ml O.SM EDTA [pH 
B.O]. Make up to 1 L with water. 
SX TBE stock (1 L): add 54g Tris base (trizma), 27.Sml 
boric acid and 20ml O.SM EDTA [pHB.O]. Make up to 
1 L with water. 
3M NaAc [pH 5.2] (100ml) : dissolve 40.Bg NaAc-3H20 
in BOml distilled water. Adjust pH to 5.2 with glacial 
acetic acid. Make up to 100ml and autoclave to 
sterilize. 
0.250/o(w/v) bromophenol blue, 0.25%(w/v) xylene 
cyanol FF in 40O/o(w/v) sucrose solution. 
20mg/ml solution (10ml): dissolve 200mg X-Gal in 
10ml dimethylformamide (DMF). Store in light proof 
container at -20°C. 
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10XMOPS Buffer 
SSC Buffer 
SSC Wash Buffer 1 
SSC Wash Buffer 2 
SSC Wash Buffer 3 
1 M disodium hydrogen 
orthophosphate 
Anhydrous (1 L) 
1 M sodium dihydrogen 
orthophosphate 
1-hydrate (1 L) 
1 M Sodium phQsphate 
buffer (1 L) 
Northern Blot 
hybridization byffer 
O.2M MOPS, O.OSM sodium acetate, 0.01M EOTA, [pH 
S.S-7.0] (1L): add 41.B69 MOPS, 4.102g sodium 
acetate, 3.72g EOTA in BOOml of OEPC-water and mix 
to dissolve. Make up to 1000ml with OEPC-water 
Adjust pH with NaOH and store at room temperature 
protected from light. 
20X SSC (1 L): add 17Sg NaCI and 9Sg Tri-sodium 
citrate in 700ml of water. Make up to 1 L with water and 
stir until dissolved. 
2X SSC + 1% (w/v) SOS (1 L): add 100ml of 20X SSC 
and 1 9 SOS in 900ml of water. Stir until dissolved. 
0.2X SSC + 1% (w/v) SOS (1 L) : add 10ml of 20X SSC 
and 1 9 of SOS in 990ml of water. Stir until dissolved. 
2X SSC (1 L): add 100ml SSC in 900ml of water. 
Add 141.96g of disodium hydrogen 
orthophosphate anhydrous in 1 L OEPC-water. 
Add 69g of sodium dihydrogen 
orthophosphate 1-hydrate in 1 L OEPC-water. 
Mix 666ml of disodium with 333ml of sodium 
dihydrogen and adjust pH to 7.2. Autoclave. 
0.2M sodium phosphate buffer [pH 7.21 1 mM 
EOTA [pH B.O], 1% (w/v) BSA, 7% (w/v) SOS, 4So/0 (v/v) 
formamide (SOml): add Bml from 1 M sodium 
phosphate buffer [pH 7.2], O.4ml from 0.1 M EOTA [pH 
B.O] , O.4g BSA in a double baked container and stir 
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PBS 
10 x TBS 
until dissolved. Then add 2.8g SOS and 18.2ml 
formamide. 
137mM NaCI, 2.7mM KCI , 4.3mM Na2HP04-7H20 , 
1.4mM KH2P04. The final pH should be 7.1. 
12.11 9 TRIS [100mM], 87.66g NaCI [1500mM] make 
up to 1 L with ddH20 
2.1.6 Protein Analysis Reagents 
Whole cell lysis buffer 2ml HEPES KOH [1 M], 5mls NaCI [1 M], 2mls 
NP40, 0.5g Na Deoxycholate, 0.2g SOS, 1 ml 
Orthovanadate [100mM], 1 ml EGTA [100mM], 
10mls NaF [100mM], make up to 100mls with 
ddH20 
SOS-PAGE sample buffer 397JJI ddH20, 63JJI Tris-CI (1 M, pH6.8) , 400JJI 
SOS (10°/0), 100JJI glycerol, 0.5JJI BPB. 
SOS-PAGE gel running buffer 3g Tris base, 14.5g Glycine, 1 9 SOS, make up 
to 1 L with ddH20 
Western Transfer buffer 
Blocking Solution I 
Blocking Solution II 
2.1.7 Miscellaneous 
OEPC-treated water 
Methyl violet Stain 
IPTG (100mM stock) 
2.9g Tris, 1.46g Glycine, 100ml Methanol, 
make up to 500ml with ddH20 
PBS with 5°1o milk 
TBS with 5% PVP and 0.5°/0 FBS 
Add 1 ml OEPC to 1 L water. Leave overnight at 37°C 
and autoclave to sterilize. 
2°/0(v/v) formaldeyhyde and 0.25°/0(w/v) methyl violet. 
Dissolve 0.238g IPTG in 10ml of distilled water and 
filter sterilize. Store at -20°C. 
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Ampicillin (1 OOmg/ml) 
PBS-Tween 
TBS tween 
Dissolve 1 9 ampicillin in 10ml of distilled water and 
filter sterilize. Store at -20°C. 
5% Tween added to 137mM NaCI , 2.7mM KCI , 4.3mM 
Na2HP04-7H20, 1.4mM KH2P04. 
2% Tween added to 10mM TRIS and 150mM NaCI 
2.1.8 Encep~alomyocarditis Virus 
A laboratory stock of EMCV (108 pfu/ml) was generously provided by Ms D.Watling 
(Imperial Cancer Research Fund, London, UK). 
2.1.9 Interferpns 
The IFNa used in the majority of experiments was Roferon2a (9million units/ml) 
obtained from Roche. The IFNa subtypes were a kind gift from Norman Finter. The 
subtypes were HPLC purified from a mixture commercially licensed as Wellferon 
which was obtained from Sendai infected human Iymphoblastoid cells. The mixture 
contains a-1, -2, -8, -10, -14, -17 and -21 with IFNa-4 and -7 as minor components . 
2.1.10 Oligonucleotides 
Oligonucleotides were synthesized by Sigma-Genosys. The primers were dissolved 
to 100f.lM in distilled water and stored at -20°C. 
Table 2.1 Miscellaneous peR primers 
Primer 
SP6 
T7 
GATTTAGGTGACACTATAG 
TTAATACGACTCACTAT 
-_.---------- ---
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Table 2.2 Primers for PCR amplification of constitutive genes 
Primers 
- G=-A-=--=P=-=D- H- (-fo-r-) ---.. -.- ." ... -
GAPDH (rev) 
RPL 13A (for) 
RPL 13A (rev) 
Sequence (5' to 3' ) 
- ---._ .... . _- - -----:----=-:---=-=-=--=----------
ACAGTCCATGCCATCACTGCC 
GCCTGCTTCACCACCTTCTTG 
CCTGGAGGAGAAGAGGAAAGAGA 
TTGAGGACCTCTGTGTATTTGTCAA 
Table 2.3 Primers for peR amplification of Interferon stimulated genes 
Primers Sequence (5' to 3') 
-----_ . .. __ . _ ._---_.- ------ ._---------- ----
MxA (for) AACAACCTGTGCAGCCAGTA 
MxA (rev) AAGGGCAACTCCTGAGAGTG 
IRF7 (for) GAGCCCTTACCTCCCCTGTTAT 
IRF7 (rev) CCACTGCAGCCCCTCATAG 
250AS (for) ACAGGCAGAAGAGGACTGGA 
250AS (rev) GCCAGGAGTCAGGAGACTTG 
PKR (for) TCTCTGGCGGTCTTCAGAA T 
PKR (rev) ACTCCCTGCTTCTGACGGTA 
Table 2.4 Primers for PCR amplification of Dengue 
Primers Sequence (5' to 3') 
---- ----_ .. -_._----_._---------------=-=---=-==--CTGAAGTGTGGCAGTGGGATT Dengue NS 1 (for) 
Dengue NS 1 (rev) 
Dengue probe* 
Rep T7 forward 
Rep Rv 
CTTCAAAGCTAGCTTCAGCTATCCA 
CACAGACAACGTGCACACATGGACAGA 
GGCGGCCGCTAATACGACTCACTAT 
AGAACCTGTTGATTCAACAGCACCAT 
*The Dengue probe is labelled with FAM and quenched with Tamra 
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Table 2.5 Primers for peR amplification of the BVDV replicon 
Primers Sequence (5' to 3' ) 
-;p~dU::G~NIi_BDiR:;-.-;-1 ----G~C:::-:T::::-:G::::-:G::::-:A-=-G=-C=-=T=-=C=-=I--I-I -G-AG-G-A-- --- -_ ._. - . 
pdGN-BR.2 GGCCA TGCAACTTGTGACCCA T AGAG 
pdGN-BR.3 GTCACAAGTTGCATGGCCCAGTCCAAGC 
pdGN-BR.4 GCA TGTTT AAACCCACA TTGA TCCT AGCAGAAGC 
pdGN-BR.4 Hpal 
T79-BVDV 
T715-BVDV 
3'UTR BVDV 
GCATGGTTAAACCCACATTGATCCTAGCAGAAGC 
ATGAATTCGTTAATACGACTCACT 
GTATCGATGAATTCGTTAATACGACTCACT 
GGGGGCTGTTAGAGGTCTTCCC 
Table 2.6 Primers for PCR amplification of HCV 3b 
Primers 
3b 3'UTR 
3b 5'UTR 
3b Core (for) 
3b Core (rev) 
3b E1 (for) 
3b E1 (rev) 
3b E2/NS 1 (for) 
3b E2/NS 1 (rev) 
3b NS2 (for) 
3b NS2 (rev) 
3b NS3 (for) 
3b NS3 (rev) 
3b NS4 (for) 
3b NS4 (rev) 
Sequence (5' to 3') 
ACAGGGTTGGGGTGTTAACCTAC 
TCTTCACGCGGAAAGCGTCTAG 
CTCGAGACCATGAGCACACTTC 
GAATTCATCTGGACGCGGGGCAAGTCAAGC 
CTCGAGACCATGCTGGAGTACAGGAATGCGTC 
GAATTCACGCGTCCACTCCTGAAAACATGATTAG 
CTCGAGACCATGACAACACACACCACTGGTGGC 
GAATTCATGCGTCCGCCAGAAGGAGG 
CTCGAGACCATGCGCGTGTGTGTGGCCCTC 
GAATTCACAACCGCGCCGAAACGGGC 
CTCGAGACCATGGGCCGCGAGTTGTTGCTGGG 
GAATTCACGTGGTGACTTCCAAGTCAGCTGACATG 
CTCGAGACCATGAGCGCCTGGGTGCGGTTG 
GAATTCAGCAGGGACTAGGATAGTCCTCGTTG 
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3b NS5 (for) 
3b NS5 (rev) 
CTCGAGACCATGAACGGTGACTGGTTACATG 
GAATTCATCACCGAGCAGGTAGGAGGAAAATGCC 
- -~-.------ --_ .. ,.-,,- -
Table 2.7 Primers for nested peR amplification of NS5a* 
Primers 
1363 
1364 
1365 
1366 
Sequence (5' to 3' ) 
CAGTGGATGAACCGGCTGATA 
ATGTCCGGTTCCTGGCTAAGGGA 
ACTAAGACATTGAGCAGCA 
TGTGGTGACGTAGCAACGAGTTGCT 
*These primers were also adapted for the PCR amplification of NS5a from different 
genotypes. All primers contained suitable restriction enzymes for cloning . 
2.1.11 Vectors 
The pGEM-T Easy vector system (Promega) was used to subclone PCR fragments . 
pGEM-T easy <;;ontains 3'-T overhangs at the insertion site providing a compatible 
overhang for peR products generated by certain thermostable polymerases. These 
polymerases o~en add a single deoxyadenosine, in a template-independent fashion , 
to the 3' -ends of the amplified fragments. 
The plRES2DsRed2 vector (Clontech) was used to express the HCV Non-structural 
genes in mammalian cells. It is a bi-cistronic expression vector containing the 
cytomegaloviru~ (CMV) promoter and the I RES of the EMCV permitting both gene of 
interest and the Dsred2, a red fluorescent protein (RFP) , derived from non-
bioluminescent reef coral (class Anthozoa) to be translated from a single mRNA. 
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2.2 Methods 
Most methods were conducted I'n accordance 'th WI standard procedures for 
Molecular Biology. For further references see: 
1. Sambrook, J. Molecular Cloning-laboratory manuals E.F. Fritsch, and T. 
Maniatis-3rd edition; Cold Spring Harbor Laboratory Press 
2. Current Protocols in Molecular Biology by Frederick M. Ausubel; John Wiley 
and Sons. 
2.3 Agaros~ gel electrophoresis 
Electrophoresis through agarose or polyacrylamide is a common method of 
separating and purifying fragments of DNA or RNA. The gels are stained with the 
fluorescent intercalating dye ethidium bromide and DNA bands in the gel can be 
visualized under ultraviolet light. This method can detect as little as 1 to 10ng of 
DNA. 
The electrophoretic mobility of a DNA/RNA fragment is inversely proportional to the 
log10 of the number of base pairs in that fragment. By comparison to known 
molecular weight standards, the length of the DNA fragments can be ascertained. 
However, superhelical circular, nicked circular and linear forms of DNA of the same 
molecular weight migrate through agarose gels at different rates. Therefore any 
molecular weight standards used must be in the same form as the sample DNA. 
To form a DNA agarose gel, 19 of agarose was dissolved in 100mls of 1xTAE 
buffer. When it had cooled to a temperature of around 55°C (termed 'hand hor), 1 JlI 
of 10mg/ml Ethldium Bromide (Sigma) was added, the molten agarose was poured 
into the gel fraflle and allowed to set before adding enough 1 xTAE buffer to cover 
the gel. 
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Prior to loading, 21J.1 of loading dye was added to the DNA sample and carefully 
pi petted into the wells . The gel was run at a 5V/cm until the bromophenol blue front 
had migrated at a sufficient distance. Gels were then visualized using a UV trans-
illuminator and then photographed if required. 
2.4 RNA extraction 
2.4.1 Caution about RNases 
When working with RNA samples it is necessary to take certain precautions to avoid 
RNAse contamination. RNAses are ubiquitous molecules in the laboratory 
environment a"d very insensitive to normal sterilization techniques, such as 
autoclaving. 
A) Care should be taken to avoid contact with any dirty surfaces, pipettes, 
pipette tips, glassware. Gloves should be worn at all times and changed regularly. 
Sterile disposable plastic-ware should be preferably used and all solution should be 
treated with DEPC or purchased RNAse free. 
B) The RNA gel tank and forming chamber should be washed thoroughly with 
detergent and water and left to dry after washing with ethanol. It should then be 
soaked in 3% hydrogen peroxide solution, which will inactivate any RNAses and 
washed with Dl;PC-water before pouring the formaldeyhyde gel solution. 
C) All reagents should be kept on ice to reduce the activity of RNAses present. 
However, with the application of a little care, carefully autoclaved pipette tips , clean 
surfaces washed with 70% ethanol, RNAse contamination can be minimized. 
2.4.2 RNA isolation from mammalian cells and biopsies 
(The procedur~ was scaled according to the amount of RNA required for 
subsequent steps) 
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The cells were plated in 6-well plates and treated with the appropriate stimulus. The 
medium was removed and 1 ml Trizol (Invitrogen) was added and left for 5 minutes 
to allow for complete dissolution of all cellular components. This system employs a 
formulation of guanidinium thiocyanate and urea in conjunction with a phenol 
solution. The Trizol solution was mixed and placed in a 1.5ml eppendorf. 200~1 of 
chloroform were added and the mixture was shaken vigorously for 15sec and 
incubated at room temperature for 3 minutes. The organic and aqueous phases 
were separated by centrifugation at 12,000g for 15 minutes at 4°C. The aqueous 
phase (top layer) was then transferred to a new microcentrifuge tube and the RNA 
was precipitated by the addition of an equal volume of isopropanol. The mixture was 
incubated at room temperature for 10 minutes and then centrifuged at 12,000g for 
10 minutes at 4°C. The RNA pellet was washed with 70% ethanol and resuspended 
in an appropriate amount of DEPC-treated water and stored at -80°C until further 
use. 
2.4.3 Extraction of HCV RNA from serum 
HCV RNA was extracted from patient serum using the QIAamp Viral RNA mini kit 
(Qiagen). This system uses the selective binding properties of a silica gel based 
membrane. 140J.l1 of the sample is lysed in buffer AVL with carrier RNA under highly 
denaturing conpitions to inactivate RNases to ensure isolation of intact viral RNA 
before adding 560J.l1 EtOH to provide optimum binding to the membrane. The 
membrane is then washed in two steps using firstly buffer AW1, then AW2 to 
remove contaminants. The RNA is eluted in 60J.l1 of buffer AVE and stored at -80°C 
until further use. 
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2.4.4 Visuali$ing the RNA 
The integrity of the RNA preparation was assessed by gel electrophoresis. To form 
an RNA agaro$e gel, 1 g of agarose, 7Sml of DEPC-water and 10ml of 10XMOPS 
solution was poured into a 2S0ml conical flask and dissolved. At the same time, 
17.Sml of formaldeyhyde was poured in a SOml flask and heated to SO°C for 1S 
minutes. The agarose solution was then allowed to cool to around 50°C in a 
waterbath and the formaldeyhyde added slowly in a ventilated hood to protect the 
investigator from the intoxicated fumes of the formaldeyhyde solution. 2/-l1 (stock 
SOJ.lg/ml) of ethidium bromide was then also added. When all the components were 
dissolved, the solution was poured into a forming chamber, the comb added 
carefully and left to cool at 4°C. Prior to loading, 6/-l1 of RNA-formaldeyhyde loading 
dye (Ambion, Inc.) was added to 20/-l1 of RNA sample and then incubated at 6SoC for 
10 minutes. Immediately after the samples were immersed in ice for S minutes and 
loaded carefully into the wells. 
2.5 Synthe,is of eDNA from RNA 
2.5.1 DNasel treatment 
DNasel is an enzyme that degrades both double and single stranded DNA 
endonucleolytically, producing 3' -OH oligonucleotides without damaging the RNA 
prior to RT -PCRs, especially necessary in cases where the primers are not intron 
spanning. In the presence of Mg2+, DNasel attacks each strand of DNA 
independently ~nd the sites of cleavage are distributed in a statistically random 
fashion. To 3J.l9 of the total RNA, 3units of RQ1 RNase-free DNasel (Promega) 
were added and 1/-l1 of 10xbuffer (400mM Tris-HCI (pHS.O), 100mM MgS04, 10mM 
CaCI2) and made up to 10ul with DEPC treated H20 . The mixture was incubated at 
37°C for 30 rllinutes, before stopping the reaction with 1/-l1 RQ1 DNase Stop 
Solution [20mM EGTA (pHS.O)] and heat inactivating at 65°C for 10 minutes. 
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2.5.2 Reverse Transcriptase 
The discovery and cloning of reverse transcriptases (RT; RNA-Dependent DNA 
polymerases) from retroviruses has altered the central dogma of molecular biology 
(DNA~RNA~protein). For the retroviruses, this enzyme catalyses the synthesis of 
proviral DNA from the RNA genome contained within the virion . For the molecular 
biologist, the enzyme is used to generate cDNA from RNA. The most commonly 
used are those from Avian Myeloblastosis (AMV) and Moloney Murine Leukaemia 
Virus (MMLV), MMLV is preferred for longer mRNA templates as its RNase H 
activity is weaker than the AMV RT enzyme. Like any other DNA polymerase, RT 
requires a primer for first strand synthesis, either oligo-dT (Promega) or random 
decamers (Promega) depending on the original mRNA template. 
2J.lg of the DNasel-treated RNA and 1 J.lg of the first strand synthesis primer in a total 
volume of 10J.l1 H20 were incubated at 70°C for 5 minutes to melt secondary 
structure within the template. The tube was then immediately cooled on ice to 
prevent the secondary structure from reforming. The following components were 
added in order. 
Table 2.8 Reverse Transcription reaction components (Promega) 
Components Amount 
MMLV 5x Reaction Buffer 
dNTPs (10mM each) 
RNasin Ribonuclease Inhibitor 25 units 
MMLV RT 200 units 
Nuclease-Free H20 to final volume 
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The reaction was mixed and incubated for 60 minutes at 37°C. Once completed , the 
mixture was heated to 72°C for 10 minutes and returned to ice or stored at -20°C for 
future use. 
2.6 Polymerase chain reaction (peR) 
The invention of PCR and its subsequent evolution and refinement as a research 
tool has had a profound effect upon the way molecular biology has progressed in 
the last decade. This technique relies upon the specificity of two primers for their 
substrate. Following an initial denaturation step, the temperature is lowered to allow 
for the pnmers to anneal to the target sequence, followed by an 
amplification/elongation step. This is repeated for many cycles (25-30 rounds) . It is 
therefore theoretically possible to significantly amplify a single molecule within a 
mixture. 
The major advance in PCR technology came with the introduction of thermostable 
polymerases, purified from thermophilic bacteria such as Thermus aquaticus, that 
remain stable qt high temperatures. More recent advances include the introduction 
of polymerase with 3'-5' proofreading activity. Additionally, thermal cyclers with 
short ramping 1imes have minimized any manual interference in the amplification 
process and have increased performance. More recent advances in PCR have been 
the development of the real-time, quantitative PCR, which allows the researcher to 
follow the experiment in real-time and accurately quantify the gene of interest. 
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2.6.1 Primer design 
There are certain simple rules that should be followed when designing primers: 
A) The primer sequences should not be complementary to each other. The 
formation of primer dimers will adversely affect the quantity of the desired product. 
B) The primers should roughly have similar annealing temperatures, which 
depend on the length and G/C content of the primers. There are different ways of 
calculating the melting temperature of the primers but an accurate determination is 
generally not necessary. 
C) The primer can usually be designed with a short stretch of unrelated bases 
at the 5'-end, which allows for the insertion of a short sequence, restriction site or 
altered nucleotipe into the template sequence. 
D) In general, a length of 15-20 bases is suitable for a pnmer. However, if 
mutations are to be introduced then longer primers might be designed, which will 
tolerate the mismatches better and allow for stabilization of the annealing process. 
The mismatch region should be flanked by regions of good primer-template match, 
unless they are located at the 5'-end of the primer. Usually, in the case of mutational 
PCR, the mismatches are designed in the middle of a lengthy primer. 
E) As a general rule, the 3'-end base(s) (especially the last one) should have a 
high G/C content, which will stabilize the amplification process. 
To aid with the primer design several web based programs were used 
e.g. Primer3 http://frodo.wi.mit.edu/cgi-bin/primer3/primer3 WWW.Cgl. 
Exon Primer http://ihg.gsf.de/ihg/ExonPrimer.html, 
2.6.2 Standard peR reaction conditions 
The PCR reactIon is usually performed in 25, 50 or 100/-11 volumes. The reaction 
buffer is provided as an optimised 10X solution. The reaction mixture is 
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Supplemented VVith an excess of reaction substrates: dNTPs (an equimolar mixture 
of dATP, dCTP, dGTP and dTIP to an overall concentration of 200J.lM), template 
DNA, primers (O.2J.lg/50J.lI) and 1.5mM MgCI2 . 
Reaction tubes are then placed in the thermal cycler and the DNA denatured at 
95°C for 5 minutes. The DNA is then amplified by 30 cycles of 50secs at 580C 
(annealing temperature), followed by 50secs at 72°C (polymerisation) and 50secs at 
94°C for denaturation. At the end of the amplification cycles, an additional 
polymerisation step is added for 7 minutes to "tidy-up" the incomplete ends of the 
product. Usually, 5J.l1 of the PCR product is run on an agarose gel to determine 
product formation . The rest can be stored at -20°C. 
2.6.3 PCR contamination 
PCR contamination is a very common phenomenon in areas where researchers are 
working with DNA high-copy number tasks, such as PCR. To ensure that such 
contamination is avoided, separate areas were designated for setting up the PCR 
reaction, which could be UV irradiated, along with separate micro-pipettes, reagents, 
equipment and laboratory coats and sterilized pipette tips. 
To prevent accidental contamination, negative PCR controls were typically included. 
Should these give positive results, then the experiment and current batch of reagent 
aliquots were discarded. 
2.6.4 Hi-Fidelity PCR 
One of the acc~pted trade-ofts of thermostable DNA polymerases, is the high error 
rate. The Phusion high fidelity DNA polymerase has good proof reading ability and 
the ability to amplify long fragment lengths. Phusion 's error rate is 50-fold lower than 
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that of Thermus aquaticus (Taq), and 6-fold lower than that of Pyrococcus furiosus 
(Pfu). The Phu$ion polymerase possesses processivity 10-fold greater than Pfu and 
Taq . 
2.6.5 Amplifi~ation of HCV genes from patient serum 
When a PCR is running under optimum conditions, the concentration of DNA 
product approximately doubles at every cycle. As the concentration of HCV RNA in 
serum isolated from infected patients is very Iowan additional step using nested 
primers was employed. 
50111 PCR reactions were carried out using Phusion HF PCR buffer (Finnzyme) , 
100pmoles of primers (see table 2.5 and 2.6) , 1.5mM MgCb and 1 unit of Phusion 
high fidelity DNA polymerase (Finnzyme). 200fl.1 thin-walled reaction tubes were 
used in a PTC 100 thermocycler (MJ Instruments). The reactions were heated to 
94°C for 2 min pefore 40 cycles of: 94°C for 30secs (denaturation) , 53°C(dependent 
on primer) for 30 secs ( primer-template annealing) and 72°C for 1 min 30 secs 
(polymerisation) . This was followed by 72°C for 2 min and then held at 4°C until 
analysed on a 1 % agarose gel. 
2.6.6 Site-Directed mutagenesis and gene assembly by PCR 
Site-directed mutagenesis allows the introduction of specific mutations in specific 
genes, in specific locations within the gene, something not possible by chemical or 
enzymatic means. 
PCR primers were design that contained mismatches to the target sequences. 
During each round of amplification, the modified nucleotide became incorporated 
into the target s~quence and after sufficient rounds it became the dominant species. 
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The generated peR products were smaller than the full size template, which allowed 
for gel purification of the amplified mutant sequences. It is of course necessary at 
the end of the gene assembly process to sequence the spliced product to check 
whether the correct mutation has been introduced. 
2.7 Making DNA 
For maintenance, storage, manipulation and replication of nucleotide sequences, 
genes of interest are frequently transferred to bacterial plasmids. These double-
stranded closed circular DNA molecules behave as accessory genetic units that 
replicate independently of the bacterial chromosome. By transferring a nucleotide 
sequence to a plasmid (cloning), transforming a laboratory strain of E. coli with the 
recombinant plasmid, the replicating bacteria can be used to reproduce multiple 
copies of the genes of interest. 
2.7.1 Transfer vectors (pGEM-T Easy) 
The commercially available pGEM-T Easy Vector System (Promega) was used 
during this study. The vectors are commercially prepared by cutting vector pGEM-
5Zf( +) with EcoRV and adding a 3' terminal thymidine to both ends. These 3' 
terminal overhangs at the insertion site improve the ligation efficiency of a peR 
product into the plasmid not only by preventing the vector from re-circularising 
during the ligation but also by taking advantage of the template independent activity 
of some thermo-stable polymerases to add a single deoxyadenosine to the 3' ends 
of the amplified fragments. 
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Fig 2.2 Transfer plasmid pGEM-T Easy, Obtained from Promega. 
2.7.2 Extraction and purification of plasmid DNA 
Plasm ids are generally prepared from bacterial cultures grown is the presence of a 
selective agent such as an antibiotic. Isolation of plasmid DNA involved three steps: 
A) Growth of the bacterial culture 
B) Harvesting and lysis of the bacteria 
C) Purification of the plasmid DNA 
2.7.3 Growth of the bacterial culture 
The plasm ids were purified from cultures grown In liquid medium, containing the 
appropriate antibiotics that have been inoculated from a single bacterial colony 
picked from a freshly streaked selective agar plate. Antibiotic selection was applied 
at all stages of growth to maintain selective pressure at all times. Overnight cultures 
were grown for no more than 12-16 hours to prevent ampicillin depletion (hydrolysis) 
in the culture by the ~-Iactamase , encoded by the plasmid-linked bla gene. 
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2.7.4 Alkalin~ lysis (qiaprep miniprep system) 
This method uses alkaline conditions to lyse the bacterial cells, followed by binding 
of plasmid DNA to an anion-exchange column under appropriate low salt and pH 
conditions. RNA, proteins and other contaminants are removed by a medium-salt 
wash. The plasmid DNA was eluted in a high-salt buffer. 
The bacterial pellet was resuspended in 250!J.1 of cold Buffer P1 and vortexed 
vigorously until no cell clumps were visible. 250!J.1 of Buffer P2 was added and the 
tube gently inv~rted 4-6 times until the solution became clear. Chromosomal DNA 
was precipitated by the addition of 350!J.1 of Buffer N3, which also neutralised the 
lysate and adjusted it to high-salt binding conditions necessary for the adsorption of 
the DNA to the QIAprep column. The mixture was incubated on ice for 10 minutes 
before centrifugation at top speed for 10min at 4°C. The supernatant was applied to 
the column and centrifuged for 30 sec at room temperature. The column was 
washed with O.5ml of Buffer PB which inactivates any endonucleases present 
(essential when working with endA+ strains such as the JM series, HB101 and its 
derivatives) and ensures that the plasmid DNA is not degraded, followed by a wash 
with 0.75ml of Buffer PE. The flowthrough was discarded and the column was 
centrifuged again for an additional 1 min to remove residual wash buffer before 
eluting with 50!J.1 PE. The eluted plasmid DNA was stored at -20°C. 
2.7.5 Large scale DNA preparation 
The Qiagen Plasmid Midi kit was used for large-scale DNA preparations, uSing 
100ml overnight E. coli cultures. The method is otherwise a scaled up version of the 
MiniPrep protocol with an additional endotoxin removal step. 
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2.8 Purifying DNA 
2.8.1 Recovery and purification of DNA 
Several times during the course of experiments it became necessary to purify the 
DNA fragments obtained by certain applications, such as PCR or restriction 
digestion, from other contaminants present (primers, dNTPs, undigested plasmid 
DNA, and enzymes). 
The QIAquick system (Qiagen) was chosen to perform that task because of certain 
advantages it presented, namely, convenience and reliability. The QIAquick system 
combines the ease of spin-column technology with the selective binding properties 
of silica-gel membrane. DNA adsorbs to the silica-membrane in the presence of high 
salt while contqminants pass through the column. Impurities are efficiently washed 
away, and the pure DNA is finally eluted with Tris buffer or water. 
2.8.2 Ethanol/Isopropanol precipitation of DNA 
Precipitation of DNA (or RNA) during a molecular biological procedure is often 
required to concentrate or purify the sample. This can be accomplished within the 
limits of a microfuge tube. Due to the restricted volume of the eppendorf tube, the 
maximum volume that can be practically precipitated using this procedure is 500Jll. 
1/10 volumes Qf 3M sodium acetate (pH 4.8) is added, followed by 2.5 volumes of 
cold ethanol or 1 volume of cold isopropanol, The solution was vortexed thoroughly 
and placed in the -80°C freezer for 30 minutes. The tube is then spun at 12,000g for 
15 minutes at 4°C. The supernatant is aspirated and the pellet dried in a vacuum 
dessicator. A cQ-precipitant was often added to the nucleic acid solution to improve 
visualization of 1he pellet, usually GlycoBlue (Ambion). 
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2.9 Cloning 
2.9.1 Restriction endonuclease digestion of DNA 
Type II restriction endonucleases cleave unprotected DNA at well-characterized , 
pre-determined recognition sequences. The typical recognition sequence is an exact 
palindrome of 4, 5, 6, 7 or 8 base pairs with an axis of rotational symmetry. 
Cleavage of d$DNA by a restriction enzyme can generate a number of different 
ends. Usually, these ends have 5'-phosphate and 3'-hydroxyl ends although 
exceptions are known. Such a cut may yield either 'blunt ends' (both ends having 
the same length) or a single stranded 3' or 5' overhang, dependent on the enzyme. 
Usually, a DNA concentration of 5~g/10~1 was digested in a volume of 50~1. To this , 
5~1 of 10X reaction buffer was added, plus enzyme to a concentration of 2 units/Ilg 
DNA (typically 1-2~1) . One unit of enzyme is generally sufficient to digest 11lg of 
DNA in an hour. The reagents were mixed and incubated at 37°C for an hour, or 
longer if complete digestion was required. 
2.9.2 Dephosphorylation of linearized DNA fragments 
During a ligation reaction the 5' end phospho-group and the 3' hydroxyl-group 
become the sul;>strate for the T 4 DNA ligase resulting in a phosphodiester bond. By 
removing the 5' end phosphate from the DNA vector using the calf intestinal alkaline 
phosphotase (ClAP), it is unable to self-ligate. 
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Table 2.9 Components of a Dephosphorylation reaction 
Time 
10X Alkaline Phosphatase Reaction Buffer 
DNA 
Enzyme 
H20 
Temperature 
2.9.3 Ligation of DNA fragments 
O.Sh (5' overhangs) 
1 h (blunt ends) 
4 JlI 
1pmol ends 
1 Unit 
Up to 40 JlI 
37°C (5' overhangs) 
50°C (blunt ends) 
The reaction that allows for the insertion of the desired gene into a vector is 
catalyzed by T 4 DNA ligase and involves the A TP-dependent formation of a 
phosphodiester bond between the 3' hydroxyl end of a double-stranded DNA 
fragment and the 5' phosphate end of the same or another DNA fragment. The 
ligation reaction can take place between fragments that possess complementary 
cohesive ends or blunt ends to produce circular recombinant molecules. 
The following reaction conditions are for ligation of DNA fragments with 
complementary cohesive ends. During the capture cloning of PCR products where 
pGEM-T Easy transfer vectors were used a molar ratio of 3: 1 (insert:vector) was 
recommended. 
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Table 2.10 Components of a Ligation Reaction 
Time (h) 1/24 
5X Ligase Reaction Buffer (JlI) 4 
Insert:Vector Ratio (molar) 3:1 
I nsert Ends (fmol) 3-30 
Vector Ends (fmol) 9-90 
Total DNA 0.01-0.1 
Ligase (Units) 0.1 
Temperature (OC) 23-26/14 
Final Reaction volume (~I) 20 
All the components were added into an autoclaved 0.5-ml eppendorf tube and 
centrifuged briefly to bring all the contents to the bottom of the tube. 
2.9.4 Transformation of competent E. coli cells with recombinant DNA 
The competent cells were thawed and kept on ice until needed. The cells were 
gently mixed and 1-50ng of ligated DNA or 0.1 ng of supercoiled plasmid DNA was 
added to the cells and the tube swirled gently. The cells were incubated on ice for 
30min. Each transformation reaction was heat-pulsed at 42°C for 20-60 seconds 
depending on the type of cells (30 seconds for TOP1 OF' , 45 seconds for other cell 
types) . Immedi13tely after the heat pulse the reactions were incubated on ice for 2 
minutes. 950JlI of preheated SOC solution was added to the cells and the reactions 
incubated at 37°C for 1 hour with vigorous shaking (225rpm). An appropriate 
amount of the transformation reaction (1 00-200~1) was plated onto an LB agar plate 
supplemented with the appropriate antibiotic. 
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2.9.5 
2.9.5.i 
Identification of colonies that contain recombinant plasm ids 
a.-Complementation (BluelWhite screening) 
The pGEM-T Easy vector, along with many of the vectors in current use, carries a 
short segment of DNA that contains the coding information for the first 146 amino 
acids of the ~ .. galactosidase gene (lacZ). Situated within this coding region is a 
multiple cloning site that does not disrupt the reading frame of the a-peptide coding 
region of ~-gaIClctosidase but results in the harmless addition of a few aminoacids in 
the amino fragment of the enzyme. The plasmid is inserted into a host cell that 
encodes the carboxy fragments of enzyme but not the amino fragment that is 
plasmid encoded. Neither fragment is active by itself, but in cells that have acquired 
the plasmid vector the two fragments can associate to form enzymatically active 
protein. This type of association is called a-complementation. The fully functional a-
peptide can catalyze the cleavage of X-gal (5-bromo-4-chloro-indonyl-b-D-
galactoside) substrate and produce a characteristic blue colour. In contrast, insertion 
of a DNA fragment into the multiple cloning site almost always disrupts the coding 
reading frame and results in the production of an amino fragment unable for a-
complementation. Therefore, bacterial clones that contain an insert produce white-
coloured colonies thus allowing recombinant clones to be directly identified by colour 
screening on indicator Luria-Bertani agar plates containing IPTG and X-gal. The 
agar plates also contain the antibiotic ampicillin to select against clones that do not 
contain any plasmid. 
The procedure for testing bacterial clones for a-complementation was as follows: 
To a pre-made LB agar plate supplemented with 100J.lg/ml of ampicillin , 40J.l1 of a 
20mg/ml stock of X-gal and 6J.l1 of a 100mM stock of IPTG (isopropylthio-b-D-
galactoside) was added. The solution was spread over the entire surface of the plate 
using sterile technique before incubatating at 37°C for 1 hour in order for the solution 
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to be absorbed. The plate is inoculated with the transformed bacteria , dried quickly 
and then placed inverted overnight in the 37°C incubator. The next day the colonies 
have fully developed. Colonies that do not contain the insert are blue, whilst those 
that do are coloured white. Sometimes, colonies that contain the plasmid are 
coloured blue because the insert has been cloned in-frame with the ~-galactosidase 
amino fragment resulting in the production of a protein able for a -complementation. 
The JM series of cells (eg. JM109) carry the amino fragment of ~-galactosidase on 
an F' episome. Strains containing an F' episome should always be maintained on 
minimal medium plates (M9) supplemented with thiamine-HC!, This selects for the 
presence of the F' episome which carries a nutritional requirement for growth 
(proline biosynthesis) and decreases the number of false positives. 
2.9.S.ii Antibiotic selection 
Several of the plasmid vectors used in this study carried the bla reading frame that 
encoded for p ... lactamase, an enzyme that degrades the antibiotic ampicillin. By 
using ampicillin sensitive host strains (competent cells for the transformations 
reactions) we can select for transformants that have successfully acquired the 
plasmid that confers ampicillin resistance. This type of selection is only able to 
detect clones that have incorporated the antibiotic resistance conferring plasmid and 
cannot discriminate between insert and non-insert carrying clones. However, this 
does not diminish in the least the importance of this selection method. In fact, while 
a-complementqtion selection can be used with pGEM-T Easy vectors (contains the 
amino fragment of p-galactosidase). 
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2.9.S.iii PCR screening 
E. coli colonies expected to contain insert (white) were screened by PCR 
amplification across the pGEM-T MCS using the SP6 and T7 primers (table 2.1) . A 
small amount of each colony was added to 25f.l1 standard PCR reaction (see 2.6.2) . 
PCR products were examined by electrophopresis in 1 % agarose TAE gel and 
visualised by UV irradiation. 
2.9.6 DNA s,quencing 
An ABI Prism 377 Dye Terminator Cycle Sequencing Kit was used with Ampl iTaq 
DNA Polymerase FS Ready Reaction mix (Applied Biosystems, CA, USA). The 
AmpliT Aq DNA Polymerase FS enzyme was designed specifically for use with 
fluorescent labelled dye terminators and has no 5'-3' nuclease activity. The 'Ready 
Reaction mix' contains all the reagents necessary for DNA sequencing (except DNA 
and primers). This system uses dlTP instead of dGTP to minimize band 
compressions. 20f.l1 reactions were setup, containing 6f.l1 of Ready Reaction mix, 
approximately O.5f.lg of DNA and 3-5 pmoles of primer. Once thermocycling was 
complete, the reaction products were ethanol precipitated and resuspended in 5f.l1 of 
formamide dextran blue dye. 2f.l1 sequencing reactions were loaded per lane of the 
gel. (In later experiments the DNA sequencing was done courtesy of the Genome 
centre, Bart's ~nd the London, Charter House Square, London). DNA sequence 
data was analysed using BioEdit and the sequence checked using the BLAST 
program http://www.ncbi.nlm.nih.gov/BLAST/. 
2.10 Real-Time PCR 
Real-time PCR is an extraordinarily powerful technique, which relies on two 
important discQveries: the finding that the Taq polymerase possesses 5 '~3'­
exonuclease activity and the construction of dual-labelled oligonucleotide probes, 
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which emit a fluorescence signal only on cleavage, based on the fluorescent 
resonance energy transfer (FRET). Unless otherwise mentioned, all real-time PCR 
reactions were carried out on the Rotor-Gene, Corbett Research (Mortlake, Sydney, 
Australia). 
2.10.1 SYBR green 
SYBR green is a DNA-binding dye that incorporates into dsDNA, it is undetectable 
in its free form but once bound to dsDNA it starts to emit fluorescence. The 
excitation and emission maxima of SYBR green I are 494nm and 521 nm 
respectively and the fluorescent signal increases proportionally with increasing 
amount of amplicon generated with each cycle and therefore can be used in the 
q~antification of DNA. However, as SYBR green binds to any dsDNA, detecting not 
only the specific target, but also non-specific PCR products and primer-dimers, a 
method of eliminating unspecific products is needed: 
2.10.2 Melting curve analysis 
Fig 2.3 Mechanism of SYBR green 
action. Unbound SYBR green does not 
emit fluorescence. As soon as the SYBR 
green binds to dsDNA target fluorescence 
occurs. 
The melting tEtmperature (Tm) of a DNA double helix depends on its base 
composition (%GC, and its length, especially if it is very short). All PCR products for 
a particular primer pair should have the same melting temperature unless there is 
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contamination, mis-priming or primer-dimer artifact; therefore by checking the Tm 
we can confirm the specificity of the PCR reaction as SYBR green does not 
distinguish between one DNA species and another. After the cycling has been 
completed, the temperature is raised by 1°C/sec and the change in fluorescence is 
measured. At the melting point, the two strands of DNA will separate and the 
fluorescence will rapidly decrease. The software plots the rate of change of the 
fluorescence with temperature against the temperature resulting in the Tm of the 
product. 
dF 'd 
o 
'11 reshold ___ ..----__ ---r-__ ---r ___ r-__ 
180 18~ ISO 19~ :c , .. c t . 
Other considerations for using SYBR green 
Fig 2.4 Melting curve analysis. 
The change in fluorescence with 
temperature indicates whether the 
PCR product is identical. Pure 
homogenous PCR products 
produce a single, sharply defined 
melting curve with a narrow peak. 
In contrast, primer-dimers melt at 
a relatively low temperatures. 
A) Ideally, the length of the PCR product is 100-1S0bp 
B) The Tm of the primers should be between SO-60°C 
2.10.3 SYBR areen Real time peR set up 
The real time PCRs were set up using a CAS 1200 Robotics system, Corbett 
Research (Mortlake, Sydney, Australia) using QuantiTect SYBR green 2x Mix 
containing, Hot start Taq DNA polymerase, SYBR green I, ROX, dNTPs, buffer 
(Tris.CI , KCI, (~H4hS04' SmM MgCb) (Qiagen) and 1 J.lM final concentration of each 
primer (Sigma-Genosys), made up to 2SJ.l1 with nuclease-free H20. 
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2.10.4 Real time SYBR green PCR conditions 
The PCR using Qiagen SYBR green I must start with an initial incubation of 15 
minutes at 95°C to activate the HotStart Taq DNA polymerase. 
Table 2.11 Cycling conditions for SYBR green 
Step Time Temperature Ramp Additional 
comments 
Initial 15 min --.---~- .~--95°C 20°C/sec 
activation step 
Denaturation 15 sec 94°C 20°C/sec 
Annealing 20-30 sec 50-60°C 20°C/sec 
Extension 10-30 sec 72°C 20°C/sec Aquire data to 
appropriate 
channel 
-~-"" .-~""'" .-.-~ .. -.....,.~-~--.,,"--", ,-, .. - _ ··, .-, '-'-_c _____ --' .. 
2.10.5 Taqman probes 
In Taqman assays the Taq polymerase enzyme cleaves an internal labelled 
nonextendable probe during the extension phase of the PCR. Three 
oligonucleotides are used; a forward and reverse primer and a probe. The probe is 
dual-labelled, vvith a reporter dye e.g. FAM (6-carboxyfluorescein), covalently 
attached at the 5' end and a quencher dye e.g TAMRA (6-
carboxytetramethylrhodamine), bound to the 3' end by a linker. As long as the probe 
is intact (during annealing), the fluorescence energy is quenched by the proximity 
between the fluprophore and quencher. During the extension phase of the PCR the 
probe is cleaveQ by the 5'~3' enzymatic activity of the Taq polymerase, thereby the 
109 
quencher and the fluorophore are separated allowing fluorescence emission from 
the reporter dye. 
F 
•• 
2.10.6 Dengue real-time PCR 
• 
F ig 2.5 Schemat ic diagra m showing 
how taqrnan p robes detect peR 
products. After denaturation the primers 
and probe anneal to the target. 
Fluorescence doesn't occur because of 
the proximity between flurophore (F) and 
quencher (Q). The probe is cleaved 
during extension by the 5' to 3' 
enzymatic activity of Taq, separating the 
fluorophore and quencher allowing 
fluorescence from the reporter dye. 
The quantitative dengue taqman PCR was carried out with Qiagen hot start taq and 
set up using the CAS 1200 robotics system (Corbett Research). The PCR reaction 
was set up to be 251J1 containing : 
Table 2.12 Dengue taqman PCR components 
Components Amount 
Water Up to 251J1 
10xBuffer (containing 15mM Mg2+) 2.51J1 
Mg2+ (25mM) 0.751J1 
Forward Primer (10mM) 0.751J1 
Reverse Primer (1 OmM) 0.751J1 
Probe (5mM) 11J1 
dNTPs (1OIJM) 21J1 
Taq 0.21J1 
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The PCR reaction was carried out on the Rotorgene (Corbett Research) using the 
conditions below. 
Table 2.13 Cycling conditions for dengue taqman PCR 
Step Time Temperature Ramp Additional 
comments 
Initial 15 min 95°C 20°C/sec 
activation step 
Denaturation 15 sec 94°C 20°C/sec 
Annealing 20-30 sec 60°C 20°C/sec 
Extension 10-30 sec 72°C 20°C/sec Aquire data to 
FAM channel 
----- - , - ... 
---:".-. 
2.10.7 Generation of Standard curves 
Standard curves can be used for both absolute and relative quantification. In order 
to generate a standard curve, at least 5 different concentrations of the standard 
should be measured, and the unknown target should fall within the range tested. For 
absolute quantification of DNA, the copy number or concentration of the nucleic 
acids used as standards must be known . 
Table 2.14 Molar conversions for nucleic acid templates 
Nucleic Size pmol/ug 
Acid/Genomic DNA 
1Kb DNA 1000bp 1.52 
Homo sapiens 3.3 x 109bp in haploid 4.7 x 107 
gene 
III 
Molecules/ug 
9.1x1011 
2.8 x 105 (for single 
copy gene) 
Using genomic DNA, a standard curve was generated from 30ng down to 3pg in a 
ten fold dilution set up using the CAS-1200 from Rotorgene. After completing the 
cycling reactions, the data was displayed as change in fluorescence against cycles. 
Norm. Fluoro . 
0.6 
0.5 
0.4 
0.3 
0.2 
0 .1 
.Threshold _____________ ~__..;;;:::::.:..._~:::.:::.__==~---c=---
5 10 15 25 30 35 
Fig 2.6 Example of a peR run used to set up a standard curve. A ten-fold dilution of human 
genomic DNA was used as a template. 
From Fig 2.6, a standard curve was extrapolated by using a best fit line from the log-
linear region of each curve. A standard curve of the CT (cycle threshold) against the 
concentrations was plotted. 
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Fig 2.7 Standard curve plot data obtained from fig 2.6. 
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10AQ3 10AQ4 
2.10.8 Constitutively expressed genes 
To correct for experimental variation in individual RTs and PCRs the experiment can 
be normalised to a constitutively expressed gene. Normalisation to housekeeping 
genes is not always straight forward. It is important to find one that is expressed at a 
constant level among different tissues and is not influenced by the experimental 
treatment. The most common housekeeping genes in use at the moment are ~-
Actin, which encodes a cytoskeleton protein and is expressed among almost all cell 
types and GAPpH, an abundant glycolytic enzyme, present in most cells . 
2.10.9 Data Analysis 
After the run was completed, the threshold cycle (CT) value (cycle at which a 
significant increase with an exponential growth of PCR product was first detected) 
was manually set. The Ct value is inversely proportional to the amount of product 
present. The threshold should be placed above any baseline activity and within the 
exponential increase phase (which looks linear in the log transformation). 
The Ct of the gene of interest was normalised to the housekeeping gene, either 
using the ratio or the algorithm; 
R I 
. . 2(Ct GAPDH - Ct Gene of interest) 
e atlve expresslon= 
The experiment was discarded, if 
1. The ne~ative (no template) controls were positive 
2. The no RT enzyme controls were positive, indicating the presence of 
genomiq DNA contamination. 
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3. There was a difference of 3 or more cycles in the housekeeping gene, wh ich 
indicates that the expression of the normaliser is either up or down-regulated 
and therefore cannot be used. 
2.11 Macro-,rrays 
Radiolabelled ODNA was generated from 20 /-1g total RNA by reverse transcription 
with Superscript II (Gibco) in the presence of 32p-dCTP. Residual RNA was 
hydrolysed by alkaline treatment at 70°C for 20 min and the cDNA was purified 
using G-50 columns (Amersham Pharmacia). Before hybridisation to the 
macroarrays the labelled cDNA was mixed with 50 /-1g COT-DNA (Gibco) and 10 /-1g 
Poly-A DNA (Sigma, St. Louis, USA), denatured at 95°C for 5 minutes and 
hybridised for 1 h to minimise non-specific binding. Preparation of the macroarrays 
(representing 150 known ISGs), hybridisation of the radioactive cDNAs and 
scanning and analysis of the macroarrays were carried out as described previously 
(Schlaak et ai, JBC, 2002). 
(This work was carried out at the Department of Gastroenterology, University of 
Essen, Germany by Dr. Schlaak). 
2.12 In vitro transcription 
This was carried out using Ambion T7 MegaScript, which is designed for the large 
scale production of RNA. For in vitro transcriptions DNA with a promoter site is 
required as a t~mplate. This can be either linearised plasmid DNA or PCR products 
that contain an RNA polymerase promoter. A PCR primer was designed to 
incorporate the T7 promoter included in the BVDV plasmid to match with the 3' UTR 
at the opposite end to use as a template. To obtain enough template, 25 PCR 
reactions were performed and pooled together before being purified using a Qiagen 
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PCR purification kit. The following reaction components are for the In vi tro 
transcription, which are assembled on ice under RNA working conditions. 
Table 2.15 Components for an in vitro transcription 
Components Amount 
Nuclease-free water To 50~1 
ATP solution 5~1 
CTP solution 5~1 
GTP solution 5~1 
UTP solution 5~1 
1 Ox Reaction Buffer 5~1 
2.5~g linear template DNA 2 . 5~g 
2~1 Enzyme mix 5~1 
The reaction was mixed thoroughly and incubated at 37°C for 15 minutes and then 
at 37°C overnight. The DNA template was removed by DNase I treatment and the 
RNA recovered by Lithium chloride (LiCI) precipitation (ppt). 1 ~I of DNasel was 
added to the reaction mixture and incubated at 37°C for 15 min, the reaction was 
stopped and the RNA ppt by adding 30~1 Nuclease-free water and 30~1 LiCI ppt 
solution. The mixture was left at -20°C for 30 min before centrifugation at 4°C to 
recover the RNA pellet which was washed with 70% Ethanol and re-suspended in 
DEPC treated water and measured by UV spectrophotometer. 
For dengue replicon RNA, the template was again prepared from a pooled PCR 
reaction using RepT7 and Rep Rv primers (see table 2.4) . This reaction also 
involved the adpition of a cap analog (5/J.1) and dropping the amount of GTP to 1/J.1 
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for the first 15minutes before adding a further 1111 of GTP and incubating the 
reaction at 37°C for a further 2 hours. 
2.13 ELISA 
Dengue NS1 ELISA 
A 96 well plate was coated overnight at 4°C with SOIlI of coating buffer containing 
Rabbit aNS 1 (1: 1S00) before being washed with PBS Tween 20 (all washes are 
carried out 3-4 times). 1S01l1 of 1 % gelatin in PBS with Azide was placed in the wells 
and left for 1 hour at room temperature to block. The contents of the plate were then 
emptied and washed again with PBS Tween 20. The samples were serially diluted in 
PBS Tween 20 + 0.2S% gelatin, and together with a standard curve of Dengue NS1 
(100-Sng/ml), left to incubate for 1 hour at 37°C before being washed with PBS-
Tween 20. 100JlI of 1 H7.4 diluted to 1/1000 in PBS Tween gelatin was added to the 
plate and incubated for 1 hour at 37°C before being washed with PBS Tween 20. 
100lli of 1/1000 dilution of goat anti mouse IgG/Peroxidase conjugate was added to 
each well and again incubated for 1 hour at 37°C. The plate was then washed three 
times with final wash solution and 100lli of TMB substrate solution were added for 
15 minutes at room temperature in the dark. The incubation was stopped with 100111 
of 1 M H2S04 and the plate mixed with swirling for 1S seconds. The absorbance at 
450nm was measured in a microplate reader within S minutes after the addition of 
the stop solution. 
2.14.i 50S-Polyacrylamide gel electrophoresis 
The BIO-RAO minigel format was used for routine acrylamide gel electrophoresis. 
The plates wer~ cleaned with water and ethanol before use and assembled. The 
use of SOS in the gel and in the loading buffer produces protein denaturation and 
coats the proteins with a negative charge. Thus the proteins will migrate through the 
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gel on the b~sis of size rather than charge or shape when subjected to 
electrophoresis. Prior to electrophoresis the sample (bacterial pellet or precipitated 
protein) were re-suspended in 100J..l1 of loading dye and boiled for 10 minutes to 
denature the proteins. The sample was then centrifuged briefly and loaded on the 
gel. 
2.14.ii Sample preparation for STAT2 Westerns 
Due to difficulties in achieving consistent results for STAT2 immunoblotting an 
alternative sample preparation method was devised. 
The cell pellet was centrifuged and washed twice in PBS before adding 100J..l1 of 
whole cell lysis buffer (WCL) containing 10J..l1 Sigma protease inhibitor cocktail and 
10J..l1 PMSF [100mM] and left to incubate on ice for 10 min. The lysate was 
centrifuged at 14,OOOrpm at 4°C for 15 min and the nucleic acid pellet removed. The 
lysate can be stored at -20°C at this stage. To 20J..l1 of the lysate, 2.5J..l1 OTT [1 M] and 
7.5J..l1 gel loading buffer (Invitrogen) was added before heating to 70°C for 10 min. 
The sampre was then centrifuged briefly and loaded onto the gel. 
2.15 Western blotting 
The protein samples were separated by SOS-PAGE and the stacking gel removed . 
The running gel was soaked in protein transfer buffer for 10 minutes for equilibration 
to prevent any distortions within the gel during the transfer process. A sheet of 
Hybond PVDF membrane (Amersham) was cut to size and activated in methanol 
and then washed briefly in transfer buffer. The electroblotting cassette was 
assembled and the transfer process was carried out at 25V for an hour. Fo"owing 
transfer, the membrane was removed and rinsed briefly In PBS. Non-specific 
binding sites were blocked by immersing the membrane In 5% (w/v) blocking 
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reagent in PBS overnight. The membrane was rinsed five times with washing buffer 
for 10 minutes each time, then incubated with an appropriate dilution of the primary 
antibody in blocking solution for an hour at 4°C. The washing steps were then 
repeated as earlier, then incubated for 1 hour with an appropriate dilution of 
secondary antibody in blocking solution and washed again. The ECl reagents 
supplied with the Amersham Hybond ECl western blotting kit were mixed and the 
membrane immersed in them. After 5 minutes incubation the membrane was 
wrapped in clingfilm and exposed to a sheet of autoradiography film for 30secs-5 
minutes before being developed. 
2.16 Cell m~intenance 
The following cell lines were used in this thesis. Unless otherwise stated culture 
mediums were supplemented with 100/0 fetal bovine serum. 
A549 cells 
HT 1 080 cells 
2FTGH cells 
Huh7 
K562 
K562~CPAC2A 
K562~CPAC2A cured 
ThP1 
ThP111CPAC2A 
Huh7/LN-BR 
HL 116 
OMEM 
OMEM 
OMEM + 200mg/ml hygromycin B 
OM EM 
RPM I 
RPMI + 3ng/ml Puromycin 
RPMI 
RPMI 
RPMI + 3ng/ml Puromycin 
OMEM + 250IJg/ml G418 
OM EM 
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Cell lines were maintained using standard tissue culture techniques. Frozen stocks 
of cells were stored in liquid nitrogen. Cells were trypsin ised, pelleted and 
resuspended in 90% FCS, 1 0% DMSO at a final concentration of 1-1 OX 106 cells/ml. 
Then they were dispensed as 1 ml aliquots into cryovials (Costar). The cells were 
initially frozen at -ao°c for 24 hours and then transferred to liquid nitrogen. Cell 
recovered from liquid nitrogen were initially thawed by agitation in a 37°C waterbath . 
The cell aliquot was then washed by centrifugation , resuspended in fresh medium 
and placed in a T25 flask. No drug selection was added in the first 48 hours after 
thawing, to permit the cells to recover. 
2.17 Transfection 
A variety of strategies are available for the delivery of genes into eukaryotic cells . 
They fall into three categories; 
1. Biochemical 
2. Physical 
3. Viral-mediated. 
The experimental conditions necessary to transfect cultured cell lines with DNA vary 
from one cell line to the next. Whether the cells are being transfected for transient or 
stable expression, the fraction of cells transfected is always low and therefore it is 
desirable to oplimise the transfection conditions for each individual cell line using a 
positive control, An ideal method to transfer genes into the cells of interest depends 
upon. 
1. High efficiency of transfer 
2. Low toxicity 
3. Reprodycibility 
4. Suitability for in vivo and in vitro applications. 
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2.17.1 Liposome mediated (DNA) 
Cells were transfected with Fugene6 transfection reagent (Roche) using a scaled 
down version of the protocol supplied. The cells (generally Huh?) were grown 
overnight in 12 well plates in supplemented DMEM up to 80% confluency. The 
Fugene 6 was added to DMEM to make up to 100lJI and left at room temperature for 
5 minutes before adding 0.5lJg of DNA. This was incubated for a minimum of 15 
minutes again ~t room temperature. The mixture was then added drop-wise to the 
cells and left for 24-48 hours, depending upon the experiment. 
2.17.2 TransMessenger (RNA) 
Cells were grown on coverslips in 24 well plates overnight in supplemented DMEM 
up to 30% confluent. On the day of the transfection 4111 Enhancer R was added to 
Buffer EC-R and mixed gently before adding 21lg of RNA to a final volume of 100ul 
and mixed by gentle vortexing for 10 seconds before incubating at room 
temperature for 5 minutes. 8111 of TransMessenger Transfection reagent was added 
to the mix and gently vortexed for 10 seconds before allowing the transfection-
complex to be formed at room temperature for 10 minutes. In the meantime the cells 
were washed twice with sterile PBS. 100111 of DMEM without serum was added to 
the Transfection mix and added dropwise onto the cells on the coverslip and left for 
48 hours before visual ising using the fluorescent microscope. 
2.17.3 Electroporation 
Electroporation is the use of a trans-membrane electric field to induce pores in the 
cell membrane thereby allowing molecules to pass from one side to the other. 
Electroporation is affected by three major factors. 
1. Cell to cell variability causes some cells to be more sensitive to electroporation 
than others. 
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2. For pores to be formed the pulse amplitude and duration had to be above the 
lower limit threshold . 
3. The number of pores and the effective pore diameter increases with the product 
of amplitude and diameter. 
Cells that were approximately 90% confluent were trypsinised and washed twice in 
electroporation buffer before adding 1 x1 06 cells/100ul to 1 mm cuvettes. The cells 
were then pulsed using an Advance Pulse Agile Electroporation system (model 
PA4000) (CytoPulse Sciences, Inc.) at an electric field of 1600V/cm, pulse width of 
0.2milli-seconds, twice with O.SSsecond intervals between pulses. The cells were 
then pulsed again at 400V/cm with a pulse width of 0.8milli-seconds four times with 
a 0.12Ssecond interval between pulses. The cells were then transferred to a 6 well 
plate containing coverslips and left for 48 hours in DMEM containing 10% serum 
before visualising using a fluorescent microscope. 
2.17.4 Curing of the dengue replicon cells 
KS62 cells th~t were stably expressing ~CprME-PAC2A were removed from 
puromycin selection and passaged continuously in RPMI containing 10% FBS and 
SOOlJg/ml glycirrhizic acid. At intervals, cells were checked for replicon expression 
by indirect immunofluorescence for dengue NS1 . Once the cell line appeared to be 
cured of the replicon , it was subsequently grown in RPMI containing 10% FBS. The 
continued absence of replicon in this cell line was checked by indirect 
immunofluoresGence for dengue NS1 and RT-PCR for dengue RNA. 
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2.18 X-GAL staining 
2.18.1 Adherent Cells in Monolayer Tissue Culture 
This technique was used to visualise the ~alactosidase gene product from the 
lacZ gene of pSFV3-LacZ (Invitrogen) when expressed in mammalian cells following 
transfection. 
The culture medium was removed from the 6-well plates and the cells were fixed by 
the addition of 5% paraformaldehyde (PFA) for 10 minutes in the dark. The PFA was 
then removed and the cells were washed 4 times with PBS. The cells were then 
covered with freshly prepared X-Gal staining solution (1 mg/ml X-Gal , 4mM 
potassium ferricyanide, 4mM potassium ferrocyanide and 2mM magnesium 
chloride) . These were incubated at 37°C until satisfactory staining had been 
achieved (usually between 2hours-18hours). Stained cells were stored at 4°C after 
replacing the X-Gal staining solution with cold PBS prior to photography. 
2.18.2 Adherent Cells, 96 well format. 
As a transient transfection control, a ~-Gal plasmid was transfected at 20 times less 
the concentration of the reporter plasmid. The cells were lysed in 100jJi of the 
passive lysis buffer (PLB) supplied with the luciferase kit (Promega, UK) and left 
shaking at room temperature for 15 minutes before transferring 30jJi to a separate 
plate. 20Jjl Reporter Buffer and 50jJi Assay buffer were then added before 
incubating at 37°C until a faint yellow colour developed (usually between 3-6hours) . 
The reaction was stopped with sodium carbonate and the plate read at 415nm. 
2.19 Luciferase Assays 
The appropriat~ cells were seeded at 1 x1 03/well in a 96-well Microlite plate 
(Thermolife Sciences, UK) in 100J..l1 of growth medium containing 10% FCS and 
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stimulated and/or transfected as necessary. After a further 24 hours, the cells were 
washed twice with PBS before being lysed in 1 OO~I passive lysis buffer (PLB) 
supplied with the luciferase assay kit (Promega) . 25~1 of luciferase assay reagent 
was added to 20~1 of the lysed cells and the luciferase expression was read using a 
microplate luminometer (EG & G Berthold). 
2.20 FACS 
For each test, 0.25 - 0.5 x 106 cells were pelleted and resuspended in 50/-11 of a 
previously determined concentration of antibody diluted in RPMI holding medium 
containing 0.01 010 NaN3 and incubated on ice for 30 minutes. Where necessary, the 
cells were washed and a second layer of FITC or PE conjugated goat anti-mouse 
IgG2 (Fab'h w~s added for 30 minutes on ice. The cells were then washed and 
resuspended to 1-2 x 106 cells/ml for analysis on a FACScan flow cytometer using 
Cell Quest software (Becton Dickinson). 
2.21 Fluorescence microscopy 
Cells were grown overnight on sterilised coverslips in their appropriate medium 
before washing twice with PBS. These were then briefly washed in ddH20 to get rid 
of any PBS crystals and then fixed in 50:50 acetone/methanol at -20°C for 1 min or 
fixed in 40/0 par~formaldehyde in PBS at room temperature for 30 minutes. The cells 
were then washed twice in PBS, 10 minutes each time before being allowed to air 
dry. The cells Gontaining the red or green fluorescent proteins were then mounted 
cell-side down on a slide containing mounting solution, the excess being carefully 
removed befor, sealing the coverslip and being visualised under the fluorescent 
microscope. 
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2.21.1 Dengue IF 
For the NS 1 immunofluorescence the cells were grown as above on sterile 
coverslips and fixed in 50:50 acetone/methanol for 2 minutes. The cells were then 
washed briefly in ddH20 before being transferred to an empty 24-well plate and 
incubated with the primary antibody diluted 1 :200 in PBS/0.1 % BSA at room 
teperature for 45 minutes. The coverslips were washed 3 times with PBS/0.1 %BSA 
before incubating them with goat anti-mouse F(ab')2-FITC conjugate (Jackson 
Immunochemicals) diluted 1: 1 00 in PBS/0.1 %BSA at room temperature for 45 
minutes. The coverslips were washed 3 times with PBS, drained and inverted onto a 
drop of fluorescent mounting medium on a glass microscope slide. The edges of the 
coverslip were sealed with nail varnish and the cells viewed immediately using a 
fluorescent microscope. The Hoescht normalisation antibody was diluted 1 :250 in 
PBS/0.1 % BSA for 5 min at room temperature. 
2.22 Growing EMCV 
EMCV is a member of the cardiovirus genus of the family Picornaviridae. It is a 
positive-sense RNA virus and causes diseases such as type I diabetes, encephalitis 
and myocarditis in mice. EMCV has been widely used for studies on the molecular 
mechanisms of virus replication and for quantifying the antiviral activity of type I 
interferons. 
To grow a stoQk of the virus a permissible cell line such as A549 was used. The 
cells were 70% confluent before washing with PBS and replacing with DMEM 
containing 2%) serum and 1/-11 of EMCV stock (M.O.I 5) for 1 hour. The medium was 
then replaced with supplemented DMEM and the cells left in the incubator until there 
were no visibl~ signs of cell growth. The cell debris was then removed by 
centrifugation at 200g for 7 minutes and the supernatant containing the EMCV was 
aliquoted into cryovials and stored at -80°C until required. 
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2.22.1 Plaque Assay - to quantify the amount of EMCV 
1 x1 0
6 
A549 cells were plated out in a 6 well plate and left overnight in a 370C 
incubator. When confluent (usually after 18 hours) the medium was replaced with a 
10-fold dilution of EMCV in duplicate and left to adsorb for 1 hour in the 37 ='C 
incubator. After an hour the virus is replaced with 2.5mls of CarboxyMethylCellulose 
(CMC)/DMEM and left overnight. The CMC limits the spread of the viruses thereby 
making the plaques easier to count. The following day the CMC/OMEM is removed 
and the wells stained with methyl violet for 20 minutes before washing with PBS and 
counting the plaques 
If the dilution of 0.01 /-ll virus per ml produces 100 plaques, then this corresponds to 
1 pfu//-li of diluted virus. For an antiviral assay 0.5pfu/cell is required . If 100 cells are 
plated, we assume that they double overnight to 200 cells, therefore 100 pfu of 
EMCV will be required. 
2.22.2 Antiviral assay 
The standard antiviral assay used here is based on two facts. First, EMCV virus is 
sensitive to the antiviral effects of interferon and second, that the cell lines used 
allow EMCV replication. 
The assay is carried out in a 96-well format. Cells were plated at a density of 1 X 104 
cells per well in a flat-bottomed 96-well plate. After 24 hours the medium is removed 
and a titration qf interferon is added to the cells. After another 24 hours, the medium 
is removed and the cells are incubated with an EMC virus solution of 0.5pfu/cell (in 
DMEM containing 2% serum). After 1 hour the medium is removed and replaced 
with DMEM cOfltaining 10% serum. Approximately 16-24 hours later, cell viability is 
determined by staining with methyl violet and the absorbance is measured at 570nm 
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In a plate reader. Assays were usually performed in duplicate and data were 
normalized, plotted and a dose-response curve fitted using GraphPad Prism 
(GraphPad Software, Inc., CA, USA). The EC50 (concentration that interferon is 500/0 
effective) was calculated using this software. 
2.22.3 Trans-r~scue Assay 
This assay was modified from the above antiviral assay to accommodate the fact 
that the K562 cells are non-adherent. The same principle applies; 2x106 non-
adherent cells are treated overnight with varying doses of IFNa2a. The next day 
1 x1 06 cells are counted and 0.5pfu/cell EMCV added in OMEM containing 20/0 
serum for 1 hour at 37°C before being centrifuged and grown in 6well plates in 
OMEM containing 10% serum. After 18 hours the cells are again centrifuged at 
6000rpm for 2 minutes and the supernatants collected. The supernatants are then 
added as a two-fold dilution onto an A549 monolayer in a 96 well format for 1 hour 
before being replaced with OMEM containing 10% serum and again left overnight. 
The following day, cell viability is determined by staining with methyl violet and 
reading the absorbance at 570nm in a plate reader. The 00 is then plotted against 
the dilution of the EMCV. 
2.23 Bioinformatics 
Bioedit, WinMDI, Autoassembler, VectorNTI, pORAW32, GraphPad Prism. 
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3. Results: Amplifying, Cloning and Expressing HCV fragments 
Although the main emphasis of the thesis is the actual construction and testing of a 
reporter system for an interferon inhibitor, various HCV proteins were obtained from 
patients to test and compare their inhibitory effect on the interferon system with 
treatment outcome. 
In order to determine the inhibitory effects of the HCV proteins on the cellular 
response to IFNu, the HCV genes were cloned for expression. HCV samples were 
obtained from both liver and serum samples from patients with different genotypes. 
Their treatment outcome was retrospectively used to compare to the results 
obtained with the reporter system. 
Several studies have concentrated on various genes in HCV e.g. NS5a and core as 
being instrumental in inhibiting the interferon response. These genes were amplified 
and were then transfected into the reporter assay and their affect on the IFN system 
determined. 
3.1 Experimental Outline 
The genes encoding different HCV proteins were cloned for expression. Two NS5a 
constructs was generated and a pair of previously cloned NS5a constructs was 
obtained. The NS5a ORFs were subcloned into an expression vector for transient 
expression in vitro. 
3.1.1 Cloning and expressing the HCV genes 
The HCV gene$ were originally cloned into the pGEM-T vector system prior to sub-
cloning into the plRES2DsRed2 expression system. 
127 
3.1.2 Patient Details 
Serum samples and liver biopsies were obtained from (with informed consent, ethics 
approval No. P1-04-039) HCV infected patients attending the hepatology clin ic at 
the Royal London Hospital, Whitechapel , London, UK. The patients selected were 
newly diagnosed and being assessed for Pegylated Interferon alpha-2a (Pegasys) 
and Ribavirin (Copegus) treatment. All patients were diagnosed by detecting IgG 
antibodies to HCV and all were viraemic (HCV RNA detected using the Roche 
Amplicor assay, detection levels of HCV RNA as low as 50IU/ml) , performed by the 
Virology Department, Bart's and the Royal London). Patients were excluded if they 
had evidence of co-infections with HIV or HBV. 
Table 3.1 Details of patient samples used for the amplification of the He V genes. 
Patient 10 Serum or Blood HCV Genotype 
#001 Serum 3b 
#002 Liver 1 
#003 Liver 1 
#004 Liver 3b 
#005 Liver 3a 
#006 Liver 1a 
#007 Liver 3 
#008 Liver 3a 
#009 Serum 3b 
#010 Serum 3b 
#011 Serum 3b 
#012 Serum 3b 
#013 Serum 3b 
#014 Liver 1 
128 
#015 Liver 3 
#016 Liver 1 
#017 Liver 1 
3.1.3 Designing PCR primers for the amplification of individual HCV genes 
Using pDRAW32, primer3 and BLAST, initial PCR primers were designed to amplify 
the various structural and non-structural genes of HCV containing overhanging 
sequence for the appropriate restriction site (Xhol and EcoRI) , Kozac sequence and 
a translation initiation codon - ATG (see list of primers, table 2.3). Most eukaryotic 
mRNAs contain a short recognition sequence that facilitates the initial binding of 
mRNA to the small subunit of the ribosome. The consensus sequence for initiation 
of translation in vertebrates; the minimum Kozak sequence is: ACCATGG. 
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Fig 3.1 HeV genptype 3b, showing primers designed using the pDRA W32 program. The various 
colours show the pyrcentage GC in 22bp blocks in the genome, red being 31 % to blue 90%. 
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The majority of patients included in the study were infected with either genotype 1 or 
3b and therefore primer design was based on these sequences. 
3.1.4 Optimisation of cDNA Reaction Conditions 
The first strand synthesis is an important step for the amplification of a gene and 
should be optimised to obtain the best possible results . First strand synthesis can be 
primed using a variety of primers, e.g . random hexamers, oligo dTs or sequence 
specific primers. Random primers and oliogo dTs are used to create a pool of 
cDNAs but sequence specific primers have been shown to generate the highest 
yield of the specific product. In this case, random hexamers and sequence specific 
primers were w~ed before deciding on a 50:50 mixture, due to the lack of a polyA tail 
in the HCV genome. The choice of reverse transcriptase enzyme is now vast. For 
this purpose the RT enzyme must be sensitive enough to use on low RNA yields, 
produce a long length accurate transcript (up to -5Kb), cope with GC rich regions 
and be able to work at temperature up to 60°C (higher temperatures produce more 
faithful cDNA especially if the template is GC rich). Although several RT enzymes 
were tested, the Phusion AMV RT enzyme was selected as it fulfilled all the above 
criteria. 
3.1.S PCR problems 
Due to the low level of HCV in some patient serum/liver samples additional methods 
were used to amplify the required genes. 
3.1.6 NSSa N~sted PCR 
Although several attempts were made to amplify the full length NS5 gene with 
different first strand synthesis methods, different PCR enzymes and conditions, 
none were successful; it was decided to concentrate on the NS5a region which has 
been extensively studied in relation to the ISDR. Primers 1364-1366 (previously 
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designed by U. Kumar at St Mary's Hospital Medical School, London, UK) were 
used in a nested peR reaction to obtain the NS5a peR product. 
3.2 PCR Amplification 
3.2.1 PCR Amplification of the NS5a gene 
Although nested primers improved the peR efficiency, different peR primers were 
designed, depending upon the genotype and various combinations were found to be 
successful for each patient. For genotype 1 samples, the original nested primers 
worked well, but in other cases, the primers had to be re-designed to incorporate the 
changes. Using the HeV alignment website (http://hcv.lanl.gov/contentlhcv-
db/GET ALIGNMENTS/alignments.html) and BioEdit, primers were re-designed to 
be specific for the 3b genotype. 
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Fig 3.2 peR amplification of full length NS5a 
from patient samples. Nested primers 
specifically designed for genotype 1 incorporating 
the sticky ends, kozac sequence and the ATG. 1 % 
agarose TAE gel. Predicted peR product = 
1426bp. Marker lane = 1 Kb ladder (promega). 
peR amplification was attempted from all samples, but using the original nested 
peR primers, tile best products were obtained with samples #002 and #003 (Fig. 
3.2). Samples #006, #007 and #008 were also successfully amplified using these 
primers althougj1 at a much lower yield. Amplification of other samples , known to be 
genotype 3b was attempted using the genotype specific primers. 
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u Fig 3.3 peR amplificatio n of NS5a Q) E 
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product = 1426bp. Marker lane = 
I Kb ladder (Promega). 
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peR products were obtained from samples #001 and #009. Although the first strand 
synthesis step was carried out with a mixture of random hexamers and the NS5 
reverse primer, sample #001 was also primed with the specific primer alone and 
gave a greater yield than the mix; this did not correspond to any increase in product 
for other samples. 
Table 3.2 Success of amplification of the NS5a HCY gene by nested PCR 
Sample 10 Primer set 
#001 3b 1364-1366 
#002 1364-1366 
#003 1364-1366 
#004 Failed 
#005 Failed 
#006 1364-1366 
#007 1364-1366 
#008 1364-1366 
#009 38 1364-1366 
#010 Failed 
#011 Failed 
#012 Failed 
#013 Failed 
---_._ ...__ . 
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3.2.2 peR amplification of NS3 
Attempts to amplify the full length NS3 gene from serum and liver biopsies were 
more successful than the full length NS5 gene and it wasn't necessary to use nested 
peR. Amplification was attempted from all the samples but the success rate was 
limited to samples #001 and #009. 
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Fig 3.4 PCR amplification of the NS3 gene. Sample #001 
was amplified using primers incorporating sticky ends, the 
kozac sequence and ATG. 1% agarose TAE gel. Predicted 
PCR product = 1972bp. Marker lane = 1 Kb ladder 
(Promega). 
As the amplification of NS5a and NS3 were successful with sample #001 , it was 
decided to concentrate on amplifying the rest of the genes from this patient. So far 
peR products have also been obtained for the NS4 gene from this sample. 
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~ 964bp Fig 3.5 PCR amplification of the NS4 gene. Sample #001 was 
amplified using primers incorporating sticky ends, the kozac sequence 
and ATG. 1 % agarose TAE gel. Predicted PCR product = 964bp. 
Marker lane = 1 Kb ladder (Promega). 
The peR products obtained were used in subsequent cloning steps. 
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3.3 Cloning the HCV genes 
All HCV primers used in this thesis were designed with Xhol and EcoRI sites for 
insertion into p,RES2-DsRed2 vector, but were sub-cloned into pGEM-T for ease of 
transfer between different expression systems and also as a fa il-safe mechanism. 
The pIRES2-DsRed2 vector is a bi-cistronic vector containing an EMCV IRES 
between the multiple cloning site and the red fluorescent protein thereby allowing 
both the gene of interest and the DSRed2 gene to be translated from a single 
bicistronic RNA. The RFP allows the transfected cells to be detected by either 
fluorescent microscopy or FACS which will be convenient in later assays. 
As the pfu enzymes do not allow the addition of an A-tail for cloning into a pGEM-T 
transfer vector, an A-tail was added to all peR products using Qiagen taq and dATP 
[1 mM] at 70°C for 15min before they were purified using Qiagen peR purification kit. 
The modified PCR products were then ligating into the pGEM-T vector. This 
additional step overcame some problems with PCR yield and allowed the peR 
fragment to be sequenced using SP6 and T7 primers (see table 2.1) 
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Fig 3.6 Gel electrophoresis of doub~e digest~d pG EM-T samples con.taining the NS5a peR 
products. Purified plasmid DNA was digested with XhoI and Ec.oRI to obtam the NS5a pe R product 
with sticky ends (1.5Kb). The inset gel shows a further separatlO~ of the bands to ens~re that there 
was no cross contamination whilst cleaning up the NS5a band, circled bands were excised, cleaned 
and used for subsequent cloning steps. 
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After the digested fragment was obtained and cleaned from the pGEM-T vector It 
was ligated into the desired pIRES2-DsRed2 vector overnight and grown up In 
DH5a cells. The resulting colonies were tested for the presence of the NS5a gene 
again by double digestion using Xhol and EcoRI . Positive colonies were grown up 
further and the plasmid DNA isolated using a Qiagen endo free midi-kit to ensure 
high quality DNA was obtained for transfections and further experiments. 
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Fig 3.7 Gel electrophoresis of the NSSa gene double digested from the expression vector 
pIRES2-DsRed2. Colonies from samples #002 and #003 were screened for the presence of the HeV 
gene by a "quick, crude" mini-prep. Positive colonies were then grown up further and purified using 
and endo-free kit. The above double digestion shows the presence of the NS5a gene and the difference 
in the quality of the DNA. 
Several different genotypes and quasispecies of the HCV genes exist. Although 
samples #002 and #003 were reported to be derived from patients infected with 
HCV genotype 1, a difference in their NS5a gene was seen by restriction digest with 
#002 having either an extra EcoRI or Xhol restriction site. Although the junction 
across the plasmid and PCR product was sequenced to ensure that the NS5a PCR 
products were in frame and therefore would express their proteins, full-length 
sequencing of the NS5a genes was not completed. 
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3.4 Expres$ion of the NS5a in vitro 
Expression of the NS5a from the pIRES2-DsRed2 constructs was tested using 
Western blotting and antibodies specific for the NS5a protein. The individual 
constructs were transfected into Huh7 cells using Fugene6 and left for 24-48hours 
before detection. The protein of the expected size for phosphorylated NS5a (56-
58KDa) (Kaneko et aI, 1994a) was detected using an anti-NS5a rabbit serum. 
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Fig 3.8 Detection and expression of NS5A protein derived from patient samples. Huh7 cells were 
transfected using Fugene6 with pIRES2-DsRed2-NS5A or mock transfected for 24 hours. Cells were 
lysed and loaded onto a Tris-Glycine 10% polyacrylamide pre-cast gel. Prestained protein standards 
were used. Pooled rabbit anti-NS5A serum was used in a Western Blot to detect NS5A protein. 
3.5 ExpressinQ and detecting the RFP 
To confirm that the pIRES2-DsRed2 plasmid would function as part of a reporter 
assay in a FAQS based system, BHK cells were transfected with 2J.lg of the vector 
using Fugene6 at a ratio of 3:2 and analysed by flow cytometry at 24hrs. 
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Fig 3.9 BH K cells transfected with pIRES2DsRed2. BHK cells were plated and left overnight to 
achieve - 70-80% contluency before being transfected with pIRES2-DsRed2 using Fugene6 and 
analysed by flow cytometry A. Mock Transfection and B. pIRES2-DsRed2. 
For the designed reporter assay the experiment needs to be conducted in a suitable, 
IFN sensitive cell line such as Huh7 or HepG2, both liver cell lines as HCV is a 
hepatotropic virus. Huh7 cells were plated out and left to grow until -70-800/0 
confluent before transfecting at a ratio of 3:2 with Fugene6. The cells were left for 
24hrs then analysed by flow cytometry. 
Although -45% transfection rate was seen with BHK cells, this could not be 
achieved using Huh7 cells where the transfection efficiency was normally 50/0 . The 
protocol was modified to optimise the transfection, varying the ratios, increasing the 
time between transfection and FACS analysis up to 72hrs and changing to another 
liver cell line but to no avail. The highest transfection efficiency achieved with the 
liver cell lines was only 8%. 
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Transfection Cell Type Reagent: DNA Amount DNA Length of Reagent (~g) Transfection 
(hrs) Fugene6 BHK 3:1 2 48 
Fugene6 BHK 3:2 2 48 
Fugene6 BHK 6:1 2 48 
Fugene6 HeLa S3 3:1 2 24 
Fugene6 HeLa S3 3:1 2 24 
Fugene6 Huh? 3:2 2 24 
Fugene6 Huh? 3:2 2 24 
Fugene6 Huh? 3:2 4 24 
Fugene6 Huh? 3:2 4 48 
Fugene6 Huh? 3:2 2 48 
Fugene6 Huh? 3:2 2 ?2 
Fugene6 HepG2 3:2 4 24 
Fugene6 HepG2 3:2 4 48 
Fugene6 HepG2 3:2 2 48 
Table 3.3 Methods, conditions and cells tested to optimise the pIRES2-DsRed2 transfection. 
To ensure that the problem did not lie with the FACS analysis, i.e. that the cells 
were transfected but in the liver cell lines the red fluorescence was too weak to 
differentiate from background, Huh? cells were co-transfected at a ration of 1: 1 with 
a GFP containing plasmid. 
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Fig 3.10: Fluorescence microscopy to demonstrate the different transfection efficiencies using 
GFP and RFP plasm ids. HepG2 cells were transfected using Fugene6 and left overnight before 
being visualised under the fluorescent microscope. Left hand panels show the cells under light 
microscopy, the GFP transfected cells and the overlay between them . The right hand panels show the 
cells under light microscopy, the RFP transfected cells and the overlay between them. 
Whilst transfection of approximately 5% of cells was observed in cells transfected 
with the RFP-expressing vector, a 10-fold greater percentage was demonstrated in 
the cells tran$fected with GFP-expressing plasmid. This experiment clearly 
demonstrated that it was not the transfection method which was at fault , but a 
problem inherent with the piRES vector. Furthermore, having achieved high 
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transfection levels in BHK cells, as evidenced by RFP expression detected by flow 
cytometry, the problem appeared specific to the human cell lines being used. It is 
important to note that when using fluorescence microscopy, a significant proportion 
of the cells transfected with the RFP-expressing vector appeared to fluoresce at 
very low levels. Whilst it was impossible to conclusively determine whether this was 
merely background fluorescence, if it was not, a plausible explanation for the 
observed phenomena could be that RFP expression was very low and consequently 
not picked up when analysing the flow cytometry data. 
Although the vector chosen did not appear to be suitable for FACS analysis there 
are several other RFP vectors available as well as other colours which could be 
detected in a dual assay with our green fluorescent reporter. Work is ongoing in the 
lab to address these transfection and FACS issues. To address whether the reporter 
system would be effective, two previously characterised NS5a clones have been 
used. 
3.6 Previous Patient-Derived Clones (NS5a-CR and NS5a-NR) 
The native NS5a clones, termed NS5a-CR (complete responder) and NS5a-NR 
(non-responder) were derived from serum of patients whose IFN-treatment outcome 
was known. NS5a-CR was cloned from pre-treatment serum from a patient who 
showed a complete and sustained response to IFN-treatment. NS5a-NR was 
generated from serum taking during treatment from a patient who showed no 
response to IFN-treatment (Paterson M, 1999). These NS5a PCR products were 
previously cloned into the pHook expression vector from Invitrogen and in this thesis 
were used as an initial test of the reporter system as they represent an extreme in 
the IFN-respon$e phenotypes and therefore would give maximal differences in the 
reporter assay. 
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4. RESULTS 
Developing and testing a Dengue replicon to use as the reporter system. 
Dengue was chosen as a prospective reporter system due to it's phylogenetic 
relationship to HCV and the effect of type I interferon on early dengue viral 
replication. We aimed to generate an IFN sensitive dengue replicon and assess the 
effects of different HCV proteins on its sensitivity to I FN. 
4.1.1 INTRODUCTION 
Dengue virus is a mosquito-borne flavivirus that most commonly causes a mild 
acute febrile illness (dengue fever) and less frequently causes a severe life-
threatening illness characterised by disordered haemostasis and increased vascular 
permeability (dengue hemorrhagic fever/dengue shock syndrome; DHF/DSS) . 
Dengue's nam~ comes from the Swahili Ki denga pepo, which refers to the sudden 
onset of cramps and illness caused by evil spirits. The name was used later by 
English speakers to describe an epidemic in the Spanish West Indies in 1827. 
Dengue has since been known by several pseudonyms including ; breakbone fever, 
dandy fever, denguero, bouquet fever, giraffe fever, polka fever, or the 5-day or 7-
day fever. 
The clinical symptoms of dengue are mentioned as early as 992 AD in a Chinese 
encyclopaedia (Gubler, 1998) but the first detailed description was the 1780 
outbreak in Philadelphia by Benjamin Rush (Rush, 1789). Although Rush observed 
that the outbreak was ongoing in an unusually warm summer with an uncommonly 
large population of mosquitoes, he failed to link the disease with the insect. It wasn 't 
until the early 20th century after the mosquito was identified as the vector for yellow 
fever and malaria that it was established that dengue was also a mosquito-borne 
disease. 
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The primary vector of the dengue virus is the Aedes aegypti mosquito; a small highly 
domesticated black and white tropical insect that prefers to feed on humans and 
typically lays it's eggs in artificial containers, such as tyres containing water. As a 
consequence, dengue is an urban-dwelling acquired disease. 
Fig 4.1 Aedes aegypti taking a blood 
meal from a human (taken from 
http://www.cbwinfo.comIBiologicaV 
Vectors/ Aedes.html) 
Dengue infection does not have a direct pathogenic effect on the mosquito. After 
ingestion of a blood meal, there is infection of the epithelial cells lining the mid-gut. 
The virus then moves into the haemocle and infects the salivary gland, where it can 
be secreted again to cause infection in humans. Although several attempts have 
been made to eradicate or control the World's mosquito population, especially in the 
1950s, it has proven difficult to use insecticide on a large scale and mosquito levels 
have surged back to pre-elimination attempts. This is one of the factors implicated 
as being responsible for the increased incidence of dengue fever in the world, the 
others being the introduction of new viral strains and the increase airplane travel. 
In recent years, the geographic range of dengue in tropical and subtropical regions 
of the world has extended and DHF/DSS is occurring in new areas of the world and 
with increased incidence (Jacobs, 2000;Guzman & Kouri, 2003). Currently, there are 
an estimated 50 million cases of dengue each year and 500,000 cases of DHF 
requiring hospitalisation (2002). 
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World Distribution of Dengue - 2000 
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4.1.2 STRUCTURE AND GENOME 
Fig 4.2 World distribution 
of dengue virus and thei r 
mosquito vector, Aedes 
aegypti, in 2000 (taken from 
http://www.cdc.gov/ncidodldv 
bidldengue/map-distribution-
2000.htm) 
The dengue virus comprises a 10Kb single stranded positive sense RNA, wrapped 
in an icosahedral nucleocapsid, within a lipid envelope. The genome consists of a 5' 
cap (m7G5ppp'A) , three structural proteins (capsid (C) , prM, the precursor to the 
membrane (M) protein and the envelope (E) protein and seven non-structural 
proteins but lacking a 3' polyadenylation tail. The genome is translated as a large 
polyprotein that is cleaved co- and post-translationally by cellular proteases and a 
virally encoded serine protease. 
4.1.3 STRUCTURAL PROTEINS 
The Capsid (C) protein 
The C protein is a highly basic -11 Kd protein (25% lysine and argentine residues) 
that forms a riQonucleoprotein complex with packaged genomic RNA. The nascent 
C protein contains a hydrophobic domain that acts as a signal sequence for the 
translocation of prM into the lumen of the ER. Mature protein is generated by a viral 
serine protease upstream of this hydrophobic domain .(Stadler et aI, 1997) 
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The prM protein 
The prM protein is cleaved by the host protease, furin (Stadler et aI, 1997), located 
in the golgi to form the structural protein M (8Kd) and the N terminal Pr segment 
which is secreted into the extracellular medium where antibodies against it are 
thought to provide immunity. Although the cleavage of prM does not impair viral 
release it is required to provide a highly infectious virus. 
Envelope prot~in 
The envelope (E) protein consists of 494 amino acids in three antigenic domains. 
Domain I is the central structural domain, containing the N-terminus. This is flanked 
by domain II which contains a fusion peptide at its distal end and domain III , an 
immunoglobulin-like domain that is thought to contain the putative receptor binding 
site. The E protein is important in viral entry into host cells (Chen et aI, 1996) as well 
as being the major target of the humoral immune response. It contains two 
glycosylation sites at Asn-63 and Asn-153 located in domains I and II respectively 
and is anchored to the ER membrane. E protein homodimers disassociate at low pH 
and each monomer re-associates with two adjacent E proteins to form a trimer that 
extends outward from the virion surface exposing the hydrophobic fusogenic 
domains. Initial attachment is thought to be due to basic glycoaminoglycan (GAG)-
binding motifs on the C-terminus of E protein, that bind the heparin sulphates of the 
GAG family. The dengue virus structure has recently been determined and its 
surface is unusually smooth with the E protein organising itself to form a protective 
shell around thEt virus. 
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4.1 .4 NON-STRUCTURAL PROTEINS 
NS1 protein 
Fig 4.3 The dengue vi rus - the first flavi\ irus 
structure to be detennined. The virus surface is 
unusually smooth and its membrane is completely 
enclosed by a protein shell. This computer 
illustration shows how the major protein, called 
"E" for envelope protein, organizes itself to fonn a 
protective shell around the virus. The protein is 
colour-coded blue, green and yellow to show the 
three specific domains of the protein. (Purdue 
University computer illustration)(Zhang el ai, 
2003) 
The NS 1 glycoprotein, which is approx 46Kd exists as a cell-associated, cell-surface 
or a secreted form. NS1 is translocated into the ER lumen and released from the C-
terminus of the E protein and is cleaved from NS2A nearly immediately after 
synthesis by an unidentified host protease. NS 1 is slowly secreted from mammalian 
cells, where three NS1 dimers come together into a soluble hexameric form , but is 
not secreted from mosquito cells. Dengue NS 1 is expressed on the surface of 
infected cells and the secreted form of NS 1 elicits strong humoral immune 
responses, and immunisation with purified or recombinant NS1 can be protective. 
NS2A and NS28 proteins 
NS2A and NS28 are relatively small proteins (22 and 14Kd respectively) . They are 
cleaved from each other by a serine protease. NS2a is required for the correct 
proteolytic clea\(age of the C terminus of NS 1 and NS28 is a membrane associated 
protein that forms a complex with NS3, it acts therefore as a cofactor for the serine 
protease function of NS3. 
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NS3 protein 
NS3 is a large (70Kd) cytoplasmic protein that associates with the membrane 
through it's interaction with NS2B. It contains several enzymatic activities that 
implicate this protein in polyprotein processing and RNA replication . The N-terminal 
residues along with NS2b form the serine protease function which mediates 
cleavages at the NS2a/NS2b, NS2b/NS3, NS3/NS4a and NS4b/NS5 junctions as 
well as cleavages that generate the C-termini of the mature core protein. The C-
terminal residues of NS3 share significant homology with other RNA helicases 
containing the motif Asp-Glu-Ala, unwinding the RNA in preparation for RNA 
replication. 
NS4A and NS4B proteins 
Both the NS4 proteins are small hydrophobic proteins that are membrane 
associated. Although no definitive role has been given to these proteins, NS4a and 
NS4b appear to be co-localised in the site of viral RNA replication. 
NS5 protein 
NS5 is a large, highly conserved protein which functions as the RNA dependent 
RNA polymera~e (RdRP) of the virus. It includes the motif Gly-Asp-Asp (GO~) 
common to all RdRPs. 
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Cytoplasm 
• Site of signal peptidase cleavage 
A Site of NS2BINS3 cleavage 
lumen of ER 
- Internal site of NS2B/NS3 cleavage essential for signal peptidase 
processing 
o Site of cleavage by unknown enzyme 
Adapted from Coia, 1988 
Fig 4.4. Organisation of the dengue virus proteins. Schematic diagram showing how the proteins of 
the dengue virus are organised within an infected cells. Adapted from Coia J 998 
4.1.5 Replication cycle of the dengue virus 
The dengue virus can replicate in a variety of cells in vitro, including cells of myeloid, 
lymphoid, epithelial, endothelial and fibroblastic lineages, but monocytes are the 
cells that are thought to support dengue replication in vivo (Diamond et aI, 2000a). 
The receptor for the dengue virus is yet to be found, but several different molecules 
from different cells have been postulated including a highly sulphated type of 
heparan sulfate present on Vero and BHK cells (Hung et aI, 1999), two 
glycoproteins of 40 and 45Kd identified on C6/36 cells (Aedes albopictus larvae cell 
line)(Salas-Benito & del Angel, 1997) and a lectin called DC-SIGN in dendritic cells 
(Tassaneetrithep et aI, 2003). The 45Kd protein from the C6/36 cells has recently 
been shown to bind to the dengue type 4 (Reyes-del Valle & del Angel , 2004) . After 
binding the virions are taken up by receptor mediated endocytosis and the viral 
nucleocapsid is released into the cytosol. A 3,391 a.a polyprotein is translated from 
the viral RNA at the surface of the endoplasmic reticulum (ER). Translation begins 
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at the first AUG codon of the RNA genome and while the ribosome moves forward , 
the polyprotein is processed into individual proteins. Proteases are encoded by both 
virus and host. Some proteolytic cleavages (c/prM, prM/E and NS4a/NS4b) occur in 
the ER and are mediated by host enzyme signal peptidases. The main protease 
activity is due to the serine protease domain of the NS3 in association with NS2b, 
which cleaves the viral protein between NS2a/NS2b, NS2b/NS3, NS3/NS4a and 
NS4a/NS5. 
During viral RNA replication, catalysed by the non-strucutral proteins, a negative 
strand RNA intermediate is generated which becomes the template for the synthesis 
of several positive sense RNA that serve as both mRNAs for large scale virion 
production and as virion RNA for assembly into progeny virions. Progeny virions 
assemble by budding through intracellular membranes into cytoplasmic vesicles. 
These vesicles follow the host secretory pathway, fuse with the plasma membrane 
and release mature virions into the extracellular compartment. 
o 
2 
C 
Fig 4.5 Life cycle of the dengue virus (Adapted 
from Fields). 
1 a. Attachment and binding 
1 b. Receptor mediated endocytosis 
2. Low pH dependent membrane fusion 
3. Uncoating 
4. Translation and polyprotein processing 
5. Membrane associated RNA replication 
6. Virion morphogenesis in intracellular vesicles 
7. Virion transport and glycoprotein maturation 
8. Vesicle fusion at the plasma membrane: virion 
release. 
148 
4.1.6 Determinants of disease severity 
Although the most common outcome of dengue IS an acute febrile illness (OF) 
similar to influenza, a minority of cases lead to spontaneous haemorrhaging (DHF) 
and most seriously to dengue shock syndrome (DSS), characterised by circulatory 
failure. Several factors are thought to contribute towards the pathogenesis of DHF, 
including virus type and host immune status. Peak viral titre, early in the course of 
dengue infection correlates with disease severity in humans (Vaughn et ai, 2000) 
and therefore anything that adds to or subtracts from the virus' ability to replicate 
can itself become a determinant of disease. Dengue occurs in four serotypes (Den 
1-4) and immunity from one serotype does not protect against infection from the 
others. Several studies have noted that sequential infection with the different 
serotypes are more likely to produce DHF(Chungue et ai, 1994;Morens, 1994) due 
to pre-circulating anti-dengue antibodies (known as antibody-dependent 
enhancement). These non-neutralising antibodies when bound by cells expressing 
the Fcy, increase viral replication in these cells and increase cytokine production 
and complement activation. Endothelial cells cross-reacted with anti Dengue NS1 
have been shown to have activated NF-KB leading to an increase in the expression 
of IL-6, and IL-8; elevated levels of which are also seen in the serum of cases with 
DHF (Lin et ai, 2005) . Expression of ICAM-1 (adhesion molecule) induced by anti-
NS1 is partly r~gulated by NF-KB and also by MCP-1 which is also increased in 
endothelial cells activated by the anti-NS 1 (Lin et ai, 2005). This is also elevated in 
DHF patient serum, which could contribute to the adherence of immune cells to 
endothelial cell~ in the inflammatory response associated with DHF. 
The genotype of the dengue virus also seems to be associated with a difference in 
disease severity. DHF was unknown in the Americas until an outbreak in Cuba in 
1981 , which introduced Den2, a genotype previously associated with DHF in South 
East Asia to a new continent and with 116,000 hospitalised patients, 34,000 cases 
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of haemorrhagic fever and 158 deaths. Although the four serotypes of dengue are 
capable of causing DHF cases, dengue 2 and 3 are most often associated with 
severe disease. Serotype 2 has been recently shown to have a selective advantage 
over its more penign counterparts by being able to replicate to a higher titre in 
human dendritic cells and infecting a greater proportion of the vector mosquito 
(Cologna et aI, 2005). 
4.1.7 Dengue and Interferon 
The immune factors that control Dengue virus infection or contribute to the severe 
disease are neither well understood nor easy to examine in humans. The A. aegypti 
is not a very efficient vector of the dengue virus. It requires a titre of 105-107 virus 
particles per ml of human blood, and thereby allowing only the highly virulent strain 
of the virus to be transmitted. Experimental evidence suggests that the I FN system 
may play an important role in limiting dengue virus replication, since knockout mice 
that lack type 1 IFN receptors develop severe infection after challenge with dengue 
virus (Johnson & Roehrig, 1999) and pre-treatment of cultured cells with I FN-a/~ 
dramatically reduces dengue virus replication (Diamond & Harris, 2001 ;Diamond et 
aI, 2000b). In this critical early phase of dengue infection, prior to full recruitment of 
antigen-specific defences, innate cellular antiviral mechanisms may play an 
important role in suppressing viral replication. 
However, I FN-a/~ has little effect on dengue replication if cells are treated with I FN 
after rather than before viral replication has been established (Diamond & Harris, 
2001 ;Diamond et aI, 2000b). Major IFN-regulated antiviral pathways mediated by 
PKR, 2' -5' CAS and MxA appear to exert little effect on dengue virus replication in 
cell culture. 
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In view of the data showing that early Dengue replication can be inhibited by type I 
IFNs and as Dengue is known to give rise to a self limiting infection we speculated 
that a Dengue replicon would be sensitive to IFN and, in view of the similarities 
between Dengue and HCV, would prove to be a useful model for examining the IFN 
inhibitory properties of HCV proteins. 
Therefore hum~n cell lines that continuously expressed self-replicating subgenomic 
dengue RNA (replicons) were established (cells kindly prepared in conjunction with 
Dr M. Jacobs). The cells containing the dengue replicons were then analyzed in 
regards to their response to IFNa/~ and their suitability as a reporter tested. 
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4.2 RESULTS 
4.2.1 Cell lines stably expressing dengue replicons. 
K562 (human leukoerythroblastic) and THP-1 (human monocytic) cell lines stably 
expressing the dengue replicon ~CprME-PAC2A were used (designated 
K562~CprME-PAC2A and THP-1 ~CprME-PAC2A respectively) . ~CprME-PAC2A 
corresponds to the genome of the New Guinea C strain of dengue virus type 2 but 
contains a large in-frame deletion in the structural region , retaining only the first 27 
codons of the C gene and the last 24 codons of the E gene. This replicon also 
contains an antibiotic selection cassette encoding puromycin N-acetyl transferase 
(PAC) followed by an artificial protein "cleavage" site (foot-and-mouth disease virus 
protein 2A) in place of the deleted structural genes. Replicon-containing cells were 
maintained in RPMI containing 10% FBS and 3lJg/ml puromycin (Sigma) and 
checked for replicon expression before use by indirect immunofluorescence for 
dengue NS1. K562 and THP-1 cells without replicons were maintained in the same 
medium without puromycin. (This work was carried out in Dr M. Jacob's lab at the 
Royal Free Hospital). 
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A. Construction of dengue repl icon backbone 
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Fig 4.6 Construction and expression of the Dengue replicon. A. The dengue replicon was 
predominately obtained from the 7 non-structural genes and the flanking UTR (untranslated regions) 
of the dengue virus. B. Construction of a Dengue replicon that contains an antibiotic selection cassette 
encoding puromycin N-acetyl transferase (PAC) and foot and mouth disease virus protein 2A instead 
of the dengue structural genes. C. Expression of dengue NS 1 protein detected by immunofluorescence 
with a fluoroscein labelled antibody in transfected cells, K562~CprME-PAC2a, (upper left) and non-
transfected cells, K562 (upper right). The lower panels show the stained live cells. 
4.2.2 Cured K562 cell line. 
K562 cells stably expressing ,1CprME-PAC2A were removed from puromycin 
selection and passaged continuously in RPMI containing 10% FBS and 500~g/ml 
glycirrhizic acid, a known antiviral compound. At intervals, cells were checked for 
replicon expression by indirect immunofluorescence for dengue NS1. Once the cell 
line appeared to be cured of the replicon, it was subsequently grown in RPMI 
containing 100/Q FBS. The continued absence of replicon in this cell line was 
checked by RT..,PCR for dengue RNA. 
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4.2.3 Interferon response (EMCV trans rescue assays) 
After continuous expression of the dengue replicon was established and confirmed 
by IF (Fig 4.6C) the sensitivity of the replicon to the antiviral effects of IFNa2a was 
tested. The basis of this technique is that inhibition of the antiviral action of IFN by 
dengue replicons results in rescue of EMCV replication I which is detected in a 
modified plaque assay on A549 cells. K562 cells with and without the dengue 
replicons were grown in RPMI containing 10% FBS with 10 and 100 IU/ml IFN-a2a 
(Roferon-A, Roche) for 24 hours. 1 x 106 cells (with or without the dengue replicon) 
were then infeqted with 5 x 105 pfu encephalomyocarditis virus (EMCV) in RPMI + 
2%) FBS for 1 hour. Cells were washed and cultured for a further 24 hours in RPMI + 
10% FBS. Culture supernatants were then harvested, and doubling dilutions were 
plated on to confluent A549 cells in a 96-well plate for 1 hour before replacing with 
RPMI + 10% FBS. After a further 24 hours, the A549 cells were fixed and stained 
with methyl violet and the optical density in each well was read at 570nm In an 
automated plat~ reader. 
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Fig 4.8 EMCV replication in the replicon containing cells is not affected in the presence of 
IFNa,2, suggesting that the dengue replicon inhibits the IFN antiviral pathway. Cells with and 
without the dengue replicon were treated with IFNa for 24hours before adding O. 5pfu EMCY for 
1 hour, the cells were then cultured for another 24hours before harvesting the supernatants. The 
supernatants were plated in a serial dilution onto a A549 monolayer for I hour before replac ing with 
fresh medium and grown overnight. The cells were stained for viabil ity the next day and the OD 
measured at 570nm 
As expected, pre-treatment of K562 cells with either 10 or 100 IU/ml IFN-a2a 
dramatically inhibited replication of EMCV. In contrast , pre-treatment of 
K562~CprME-PAC2A cells with the same concentrations of IFN-a2a had no effect 
on EMCV replication. The data implies that the antiviral action of IFN is inhibited in 
dengue replicon-containing cells and suggests that the dengue virus has evolved 
countermeasur~s to subvert the IFN response. 
4.2.4 Respon~e to Interferon 
As shown above, IFNa2a has no antiviral effect in the dengue replicon cells . This 
may also suggest that the dengue replicon is not sensitive to IFNa2a. To further test 
this hypothesis, the dengue replicon RNA and protein levels were measured. 
155 
K562~CprME-PAC2a cells were treated with up to 10000lU/mi IFNa2a for 24 hours 
before total RNA was extracted and reverse transcribed. The PCR reaction was 
performed and analysed on the Rotorgene (Corbett Research) using primers and a 
fluorescent probe designed to the NS 1 region of the dengue virus. The amount of 
replicon was quantified and normalised against GAPDH. 
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Fig 4.9 Dengue replicon RNA replication is resistant to IFNa. A. K562~CprME-PAC2A cells 
were grown in the presence of up to 10000IU/ml IFNa2a for 24 hours. Dengue replicon RNA levels 
were measured using quantitative PCR and normalised to GAPDH B. K562~CprME-PAC2a cells 
were grown in t~e presence of 100IU/m1 IFNa2a for 0, 6 and 24 hours_ Cell lysates (2x 1 05 
cells/reaction) were separated by SDS-PAGE and dengue NS 1 protein were analysed by 
immunob1otting. K562 ce]]s were included as a negative contro1. C. K562~CprME-PAC2A cells were 
grown in the absence (b1ack bars) or presence (white bars) of 100IU/ml IFNa2a for 24 and 48 hours. 
The cumulative concentration of NS 1 in the culture supernatants at each time point were measured by 
ELISA. 
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Interferon treatment up to 10,OOOIU/ml did not have any effect on the dengue 
replicon RNA levels (fig 4.9A). To confirm that this observation holds true for protein 
levels, the intracellular amounts of NS1 were measured with a Western blot (fig 
4.98) and secreted NS1 measured using a specific ELISA (fig 4.9C) . The protein 
levels confirmed that interferon alpha did not inhibit the expression of the dengue 
replicon. 
To ensure that the inhibition was not specific to Roferon, the same experiment was 
repeated using the natural interferons obtained from Wellcome (kind gift form N. 
Finter see materials and methods 2.1 .9). 
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F" 4 10 Dengue replicon RNA replication is resistant to natural IFNa2, other IFNa subtypes 
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These experiments demonstrate that dengue inhibits the cellular response to type I 
IFN. This clearly prohibits the use of a dengue replicon as a reporter for IFN 
inhibitors but provides an ideal system to analyse the effects of a flavivirus on the 
cellular respon&e to IFN. 
4.2.5 ISG gene induction is inhibited in replicon-containing cells. 
Viruses have eyolved a diverse range of mechanisms to counter the IFN response. 
In order to test whether the observed inhibition of the antiviral effect of IFN in 
replicon-containing cells was due at least in part to inhibition of I FN-induced signal 
transduction, we measured induction of MxA and PKR gene transcription. K562 cells 
with and without the replicon were stimulated with IFN-a2a for 6 and 24 hours and 
gene transcription analysed by quantitative RT -peR and normalised to GAPDH. 
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Fig 4.11 Real time peR to measure the effects of the dengue replicon on Interferon inducible 
genes. K562 and K.562~CprME-PAC2A cells were treate? with IOOIU/ml rF~a2a for 6 and 24 hours 
before measuring the interferon inducible genes by real tIme PCR. A. InductIOn of MxA, K562 cells 
(black), K562~CprME .PAC2A (white), B. PKR gene transcription. 
As shown (fig 4.11) I FN induced MxA and PKR gene transcription in K562 cells but 
the dengue replicon markedly decreased induction of both MxA and PKR genes 
suggesting that IFN signal transduction is not fully functional in cells containing the 
dengue replicon. 
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4.2.6 The effect of the Dengue replicon on ISGs, studied using macro-array 
Although the two ISGs tested showed a down-regulation in gene expression in the 
presence of the dengue replicon, to obtain a broader spectrum of the signalling 
pathway we us~d a macro-array specifically designed for the type I IFNs. 
Preparation of the macroarrays (representing 150 known ISGs), hybridisation of the 
radioactive cDNAs, scanning and analysis of the macroarrays were carried out in Dr 
J. Schlaak's lab in Essen, Germany. (Schlaak et ai, JBC, 2002). K562 cells with and 
without the dengue replicon were treated with 100lU/mi IFNa2a for 6 and 24 hours 
before extracting total RNA (RNA extraction was performed by myself in London, the 
macroarray was performed in Germany and results were analysed back in London) . 
Results shown are for 24hours but similar data was obtained at 6hours. 
Table 4.1 Table of macro-array data for ISGs. K562 cells with and without the dengue replicon 
where treated with lOOlU/ml IFNa2a for 24 hours before extracting total RNA which was then 
analysed using a type I interferon specific macroaaray. All genes with a two-fold or greater induction 
in K562 cells without the dengue replicon are shown. 
ISGs 
IFN-alpha induced protein 27(IF127) 
VCAM-1 
MxA 
IFN-alpha induced protein (clone IFI-616) 
met proto-oncogene (hepatocyte growth factor) 
PSMB9 
I FN-induced protein 17 
Vipirin( cig5) 
IL-15 
9-27mrna 
STAT 1 
STAT4 
IFIT1 
KlAA0284 
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24h no replicon 24h with replicon 
55.8 11.5 
30.6 2.6 
17.9 1.8 
12.9 1.1 
7.9 1.8 
7.9 0.4 
7.5 1.3 
7.2 1.3 
6.5 1.1 
6.4 1.2 
6.2 1.1 
6.2 1.5 
6.1 1.3 
5.6 1.5 
STAT1 (91kDa) 4.9 1.8 
IFN induced transmemberane protein 3(1- 4.9 1.4 
8U)(IFITM3) 
INDO 4.8 0.6 
IL6 4.8 0.6 
IFN induced transmemberane protein 2(1- 4.5 1.1 
8D)(IFITM2) 
MAP2K4 4.5 1.0 
IFI35 4.4 1.1 
Homo sapiens STAT 4.1 1.6 
Raf( c-raf-1 ) 3.6 2.0 
FK506 binding protein 6 3.6 1.9 
DEAD-box protein p72 3.5 1.4 
IFP 35 3.5 1.3 
IFN induced leucine zipper protein (IFIT4) 3.4 1.7 
c-myc 3.3 0.7 
MIP-1b/CCL4 3.2 1.5 
2-50AS 3.1 0.9 
c-myc 3.1 0.7 
Gadd45 3.1 0.7 
Reticulocalbin 3.1 2.3 
ISGF3G 3.1 1.2 
IRF1 3.1 1.6 
IL-1 alpha 3.0 0.8 
Pi3-kinase 2.9 1.9 
NF-IL-6 2.9 0.8 
TIMP-4 2.9 1.4 
GBP2 2.9 1.5 
TGF-bR3 2.8 1.2 
HLA-E 2.8 1.5 
DDX17 2.7 0.5 
TAP1 2.7 1.2 
Interleukin 2 2.7 1.2 
IFI44 2.7 1.1 
CBFA (core binding factor A1) 2.7 1.4 
I nterleukin 13 receptor, alpha 1 2.7 2.1 
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TIMP-3 - .. ~ ' ..... 2.7 2.9 
FKHRL 1 2.6 2.0 
p57Kip2 2.6 1.2 
Catechol o-methyltransferase 2.6 2.4 
MAPK6 2.6 0.7 
Phospholipid scramblase 1 2.5 1.3 
IFI16 2.5 1.1 
IFN induced protein with tetratricopeptide repeats 1 2.5 1.6 
translocation T(4: 11 )of ALL-1 2.4 1.0 
gene to chromosome 4 
TGIF (TG interacting factor) 2.4 1.6 
CBP (CREB binding protein) 2.4 2.2 
bcl-2 2.4 1.3 
SnoN 2.4 1.3 
PDGF-alpha 2.4 1.7 
IFN induced protein 44(IFI44) 2.4 2.0 
ADAM-10 2.4 1.1 
Trk oncogene 2.4 1.2 
CCR5 2.4 1.2 
DEAD box binding protein 1 2.4 0.7 
n-myc 2.3 1.7 
APOL3 2.3 1.1 
(cpp32) 2.3 1.7 
IFN regulatory factor 1 2.3 1.6 
collagen alpha 1 (I) 2.3 1.6 
IFN-GR1 2.3 1.2 
MAPK13 2.3 1.6 
Mad4 2.3 1.3 
ATF-2( creb-2) 2.3 1.4 
MAPKAPK2 2.3 1.0 
Transcription factor 3 (TFE3) 2.2 2.0 
Integrin-beta-6 2.2 1.5 
MAPK9 2.2 1.5 
Similar to small inducible cytikine subfamily B(Cys- 2.2 1.3 
X-Cys) ,member 11 
MAP3K1 2.2 1.2 
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Alpha-1-antiproteinase 2.2 2.1 
MCP-1/CCL2 2.1 O.B 
Integrin beta 7 2.1 1.B 
BST2 2.1 1.3 
L-selectin 2.1 2.3 
Placental calcium-binding protein 2.1 2.3 
Interleukin 2 receptor, gamma 2.1 1.4 
TIMP-2 2.1 1.5 
PDK1 2.1 1.9 
MAP2K2 2.1 1.7 
MAPKB 2.1 1.0 
MAPKBIP2 2.1 1.7 
STAT5B 2.1 2.4 
ubiquitin-conjugating enzyme E2L 6(UBE2L6) 2.1 1.B 
MAP3K14 2.1 1.B 
RGS2 2.0 1.4 
RHO 2.0 1.3 
Alpha-crystallin 2.0 1.9 
MAPKAPK3 2.0 1.6 
Cyclin D1 2.0 1.7 
Interferon regulatory factor 5 2.0 1.2 
Elastase 2 2.0 1.6 
Smad4 2.0 1.0 
akt-1 2.0 1.5 
STAT 6 2.0 1.2 
TIMP-1 2.0 1.B 
MAPK14 2.0 1.6 
Transcription of most, but not all, IFN-inducible genes are inhibited in cells 
containing dengue replicons, but, there are certain subsets of genes that appear to 
be up-regulateq. 
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Table .4.2 Subset of ISGs that are up-regulated in the presence of the dengue replicon. Cells with 
and wIthout the pre~ence of the dengue replicon were treated with lOOIU/ml IFt\a2a for 6 and 2-l 
hours before extractl~g tot~1 R~A and analysed using a type I specific macro-array. Genes with a 
greater than two fold mductlOn m the presence of the dengue replicons are shown. -
ISGs 24h no replicon 24h with replicon 
SOCS2 1.2 3.8 
Smad 5 1.9 3.5 
MAP3K5 1.4 2.9 
MAPK10 1.5 2.9 
Folate receptor 1.3 2.5 
5' nucleotidase 1.6 2.4 
P70 56 Kinase 1.7 2.3 
CCR1 1.8 2.3 
PDK2 1.9 2.3 
I nterferon omega 1 1.9 2.2 
IL-10R beta 1.3 2.2 
These experim~nts indicate that some ISGs can be up-regulated by IFN, although 
the fold induction is relatively slight. The gene of most interest in this set is SOCS2, 
(Suppressors of cytokine signalling 2). SOCS2 is one of 8 family members: cytokine-
inducible SH2 protein (CIS) and SOCS-1 to SOCS7, all of which share a central 
SH2 domain ard a C-terminal SOCS box. SOCS2 came to prominence when a 
SOCS2 knockout mouse displayed dramatic gigantism and has since been found to 
playa role in the negative feedback of cytokine signalling and could be important for 
the suppression of type I interferon signalling seen in the dengue replicon cells. 
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4.2.7 Immunot)lotting for total and phosphorylated ST AT1 and ST Al2. 
During the course of these experiments, a paper was published pinpointing ST AT1 
as the area in which the dengue exerts its effect (Munoz-Jordan et ai, 2003). STAT 
(signal transducer and activator of transcription) proteins are transcription factors 
located in the cytoplasm that become activated by tyrosine phosphorylation. The 
activated forms dimerize and translocate to the nucleus to activate specific genes. In 
the case of type I interferons STAT1 and STAT2 form a heterodimer to activate the 
ISGs and for I FNV STAT1 forms homodimers. 
Although most of the immunoblots worked according to the manufacturer's 
instructions for the antibodies, STAT2 blots proved to be problematic and required 
optimisation. TYJo different primary antibodies (Epitomics and SO) were tested at 
various concentrations and using different blocking conditions, but the results were 
inconsistent. Therefore another method of extracting the protein was tested . Cells 
were lysed using whole cell lysis (WCl) buffer with added PMSF and protease 
inhibitor cocktail and incubated on ice for 10 minutes before centrifuging at 
13,000rpm for 15 minutes at 4°C. The DNA pellet was removed and 20JlI of the 
supernatant was added to 2.5JlI DDT [1 M] and 7.5JlI SOS loading buffer (Invitrogen) 
before being heated to 60°C for 10 minutes and loaded onto a gel. The protein was 
then transferred onto a nitrocellulose membrane (the new blocking buffer 5% PVP 
was not compatible with PVOF membrane) and blocked for an hour with PVP 
blocking buffer (see materials and methods) before incubating overnight with 1 :500 
dilution of the BO uSTAT2 antibody. The next day the membrane was washed 4 
times in 0.20/0 TweenlTBS before incubating for an hour with Oako amouse 
secondary antibody at a 1 :5000 dilution, before detection with ECl +. For summary 
of optimisation techniques see table 4.3 
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Fig 4.12 STAT2 Immunoblot optimisation. 
To optimise the ST A T2 western different 
secondary antibodies were tested and as 
shown in this figure the DAKO secondary 
Antibody gave cleaner blots. 
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Protein extraction Block 1° 2° 
------
Cells lysed in SOS-PAGE 
sample buffer and heated to 
60°C before loading 
Cells lysed in SOS-PAGE 
sample buffer and heated to 
60°C before loading 
Cells lysed in SOS-PAGE 
sample buffer and heated to 
60°C before loading 
Cells lysed in WCL buffer 
with added Protease inhibitor 
and PMSF, DNA pellet 
removed (see materials and 
methods) 
Cells lysed in WCL buffer 
with added Protease inhibitor 
and PMSF, DNA pellet 
removed (see materials and 
methods) 
5°1o Milk powder aSTAT2 Mouse mAb, BO GoataMouse 
in PBS O/N @ transduction lab. 1 :500 in Jackson 
4°C 5°loMilklPBS 2hrs @ RT Laboratories 
5°1o Milk powder aSTAT2 Mouse mAb, BO 
in PBS for 2hrs @ transduction lab. 1 :500 in 
RT 5°loMilklPBS left O/N @4°C 
5°1o Milk Powder 
in PBS O/N @ 
4°C 
1 xTBS, 0.2°10 
Tween20, 5°1o w/v 
PVP and 0.05% 
w/v FBS for 1 hr 
1 xTBS, 0.2% 
Tween20, 5% w/v 
PVP and 0.05% 
w/v FBS for 1 hr 
aSTAT2 Rabbit mAb, 
Epitomics 
1 :500 in 5°loMilklPBS 
aSTAT2 Mouse mAb, BO 
transduction lab. 1 :500 in 
1 xTBS, 0.2% Tween20, 5°1o 
w/v PVP and 0.05% w/v FBS 
and left O/N @ RT 
aSTAT2 Mouse mAb, BO 
transduction lab. 1 :500 in 
1 xTBS, 0.2% Tween20, 5% 
w/v PVP and 0.05% w/v FBS 
and left O/N @ RT 
1 :10,000 
GoataMouse 
Jackson 
Laboratories 
1 :10,000 
OonkeyaRabbit 
IgG-HRP 
Jackson 
Laboratories 
1 :10,000 
GoataMouse 
Jackson 
Laboratories 
1:10,000 
GoataMouse 
Oako 
Laboratories 
1 :5,000 
Result 
Unsuccessful, dirty blots. 
Variable (worked approx 
30% of the time). Weak 
signal. 
Unsuccessful, 30min for 
weak signal. 
Unsuccessful, dirty blots. 
Successful (worked 
approx 90% of the time). 
Clean blots. 
Table 4.3 Optimisation of STAT2 Immunoblotting. Several conditions and combinations of Antibodies were tested and a summary of the optimisation 
experiments are shown above. 
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K562 cells (2.5 x 105 per reaction) that did and did not contain replicon were 
stimulated with 100 IU/ml IFN-a2a or IFN-y (R&D Systems) for 30 min. Unstimulated 
cells were included as a negative control. Cells were harvested and lysed in 250 ~I 
SDS loading buffer (0.0625 M phosphate, pH 7.0, 10% glycerol , 20/0 SDS, 0.001 % 
bromophenol blue) pre-warmed to 60 °C, 10~1 of each sample was separated by 
SDS-PAGE electrophoresis, and proteins were then transferred to a polyvinylidene 
difluoride membrane (Hybond-P, Amersham). Mouse monoclonal antibodies to 
either STAT1 or phosphorylated STAT1 (Tyr-701) (both Zymed) were used as 
primary antibodies. Detection was performed using a goat anti-mouse-horseradish 
peroxidase conjugate (Jackson Immunochemicals) 
chemiluminescence reagents (ECL+, Amersham). 
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Fig 4.13 Dengue replicon inhibits ST ATI phosphorylation in response to IFNa. A. K562 cells, 
K562.~CprME-PAC2A and "cured" cells or B. ThPl cells and ThPl.~CprME-PA~2A cells w~re 
treated with and without 1001U/ml IFNa or 1001U/ml IFNy for 30 min, and then lys~d m ~DS load~ng 
buffer. Proteins were separated by SDS-PAGE and then analysed by immunoblottmg usmg speCIfic 
antibodies for STAT 1 and phosphorylated ST AT 1. 
Cells containing the dengue replicon are shown to inhibit the STAT 1 
phosphorylation in response to IFNa treatment, but no apparent change can be 
seen at the unactivated STAT1 level. Dengue RNA replication did not reduce STAT1 
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phosphorylation in response to IFNy treatment. Indeed in comparison to cells 
without the replicon a slight increase in STAT1 phosphorylation is seen with I FNy 
treatment. 
In the IFN type I signalling pathway the STAT2 is phosphorylated by Tyk2 after 
binding to the Tyk2-phosphorylated IFNAR2, which then leads to the 
phosphorylation of STAT 1 by JAK1. To determine whether the observed defect in 
STAT1 phosphorylation is due to a defect in STAT2 activation we studied STAT2 
activation in dengue replicon containing cells. 
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Fig 4.14 Dengue replicon diminishes STAT2 steady state levels. A. K562 cells, K562.~CprME­
PAC2A and "cured" cells or B. ThP 1 cells and ThP 1.~CprME-PAC2A cells were treated with and 
without 100IU/mi IFNa 30 min, and then lysed in SOS loading buffer. Proteins were separated by 
SOS-PAGE and then analysed by immunoblotting using specific antibodies for STAT2 and 
phosphorylated ST A T2. 
4.2.8 Phosphprylated STAT1 and STAT2 levels in Dengue Infection 
To ensure that our results correlated with those of the infectious dengue virus, K562 
cells were infected with the virus and ST A T1 and ST A T2 levels assessed by 
western blotting. STAT2 expression was analysed in individual cells using dual-label 
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immunofluorescence. [Experiments done In II b co a oration with Andrew Davidson 
(Bristol)]. 
c. 
NS· 
STATf 
STATZ 
Fig 4.15 Dengue virus infection reduces ST A T2 levels. K562 cells were infected with dengue virus 
for 48 hours and then dual stained with A. anti-dengue NS} mouse monoclonal antibody followed by 
Texas Red-labelled secondary to detect dengue-infected cells, and B. anti ST AT2 rabbit polyclonal 
antibody followed by fluorescein-labelled secondary antibody to detect ST A T2. Cells were visual ised 
by confocal microscopy. The arrow shows an infected cell. (This work was done in A. Davidson and 
M. Jacobs labs). C. Cell Iysates were separated by SDS-PAGE and then analysed by immunoblotting 
using specific antibodies for dengue NS 1, STAT} and STAT2. Mock infected cells were included for 
comparIson. 
The dengue infected cells showed a marked decrease in steady state STAT2 
staining in comparison to the neighbouring, uninfected cells (fig 4.13 A and 8) . 
Whole populations of cells analysed by immuno-blotting where 30-50% of the cells 
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were infected as shown by staining for dengue NS1 protein , the STAT2 levels were 
diminished in comparison to the mock infected control. 
3.2.9 Receptor levels 
To ensure that the dengue replicon acts at the STAT2 and does not suppress the 
type I interferon receptors in our chosen cells, the IFNAR1 and IFNAR2 levels were 
measured by Western blotting and FACS scanning. 
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Fig 4.16 Dengue RNA replication does not affect IFNAR protein levels. A. Celllysates from K562 
cells and K562.L\CprME-PAC2A cells were separated by SDS-PAGE and then analysed by 
immunoblotting using specific antibodies for IFNARI and IFNAR2. B. K562 cells and 
K562.tiCprME-PAC2A were stained with specific anti-IFNAR2 antibodies and analysed by flow 
cytometry. Cells stained with secondary antibody alone (grey-filled) were included as a negative 
staining control. 
No distinguishable difference could be seen between the dengue replicon cells and 
the K562 controls. We therefore concluded that the dengue replicon acts upon the 
steady state levels of STAT2 to inhibit the type I interferon signalling pathway. 
170 
4.2.10 Steady state STAT2 mRNA 
To ensure that the dengue replicon was degrading STAT2 at the translational and 
not at a transcriptional level, steady state STAT2 mRNA levels were measured by 
quantitative PCR in K562 cells with and without the dengue replicon. 
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Fig 4.17 Dengue replicon does not affect transcriptional levels of STAT2. STAT2 mRNA levels 
were measured in K562 and K562 ~CPAC2A cells by real time peR 
4.2.11 Restoring STAT2 expression 
To determine how the dengue replicon degrades STAT2 protein, K562~CPAC2a 
cells were treated with a novel proteasomal inhibitor, Bortezomib (PS-341) 
(Richardson et aI, 2003). Protein degradation by the proteasome is a highly 
selective process which is essential to maintain cellular homeostasis. Generally, 
proteins are targeted for destruction by the attachment of a small protein marker 
such as ubiquitin to a lysine side chain, leading to the attachment of further ubiquitin 
molecules and creating a poly-ubiquitin chain . The proteasomes recognise the poly-
ubiquitin chain and degrade the targeted protein to small peptides which are then 
further hydrolysed by other cellular proteins. K562 and K562~CPAC2A cells were 
treated with 10nM Bortezomib for 24 hours, cells were then counted by trypan blue 
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exclusion and an equal amount of viable cells were lysed In SOS lysis solution 
before being separated by SOS-PAGE. 
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Fig. 4.18 The degradation of STAT2 by dengue is reversed using a proteasomal inhibitor. K562 
and K562~CPAC2A were grown in the absence or presence of the proteasomal inhibitor, Bortezomib 
[10nM] for 24hrs. Cells were then harvested in SDS lysis buffer and proteins were separated by SDS-
PAGE and analysed by Immunoblotting using a specific antibody for STAT2, a ~-Actin control was 
inc1uded as a loading control. 
The above figure suggests that ST A T2 is targeted for proteasome-mediated 
degradation in the presence of the dengue replicon and treatment with a 
proteasomal intlibitor leads to an accumulation of the STAT2 protein. The lack of 
STAT2 in the dengue replicon cells is not as a result of a transcriptional (Fig. 4.1 7) 
or a translationejll block. 
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4.3 DISCUSSION 
Our results show that the presence of dengue replicons blocks early events in I FN-a 
signal transduction not only by reducing phosphorylated STAT1 levels [as shown in 
a related study published by Munoz-Jordan et al (2003) whilst our work was 
ongoing] in response to IFNu, but also reduces phosphorylated STAT2 levels as a 
consequence of diminished steady state levels of STAT2. As STAT1 activation 
depends upon the phosphorylation of ST A T2 in response to I FNa, it appears that 
the dengue replicon acts specifically on STAT2 as the replicon has no effect on 
STAT1 levels in response to IFNy which utilizes a distinct cell-surface receptor and a 
separate but overlapping signal transduction pathway. Munoz-Jordan et al also 
showed that the most profound affect on STAT1 phosphorylation was by the NS4b 
protein, but the inhibitory effect was enhanced when NS4b was co-expressed with 
other NS proteins. Using the replicon system it will be possible to examine the effect 
of NS4b upon the IFN signalling pathway by introducing mutations. 
Whilst this work was on-going there have been several publications on other viruses 
of the Flaviviridae that inhibit the signal transduction pathway of type I interferon. For 
example, West Nile virus, which infects migratory birds and can cause human 
meningoencephalitis has been shown to prevent phosphorylation of STAT1 and 
STAT2 by blocking the phosphorylation of JAK1 and Tyk2 (Guo et ai, 2005). 
Our data shows that STAT2 is targeted for proteasomal-mediated degradation by 
dengue infection, which may occur by direct interaction between one or more of the 
dengue non-structural proteins with STAT2. The non-structural proteins of the 
Flaviviridae CQuid directly interact with JAK1 and TYK2 to inhibit their 
phosphorylation in a similar way to the V protein of human parainfluenza virus, 
which induces the proteasome-dependent degradation of STAT proteins (Parisien et 
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aI, 2001) or the degradation may be an indirect effect through a cellular pathway that 
modulates protein degradation such as the PIAS proteins which specifically target 
the activated STATs for ubiquitination. So far most of the work has concentrated on 
PIAS 1 which specifically targets STAT1 homodimers and no known PIAS has yet 
been found for STAT 1 /2 heterodimers. Although this area is of interest to this 
researcher it is beyond the scope of this thesis and due to limitations of time shall 
not be explored further at this moment. 
This chapter has focused primarily on how the dengue virus counters the antiviral 
action of type I IFN. However, we also found evidence of increased IFNy signalling 
in replicon containing cells (Fig. 3.12) which was later confirmed in a study by Ho et 
al. They also found that dengue virus inhibits IFNa signalling but enhances IFNy 
signalling in human dendritic cells. It has previously been suggested that IFNy plays 
a key role in the immunopathogenesis of OHF through enhanced activation of 
dendritic cells resulting in excessive amplification of the cellular immune responses 
and cytokine production. Although STAT2 expression is not involved in the IFNy 
signalling pathway it is plausible that the reduced levels of STAT2 may affect the 
functional activity and/or levels of components that are common to both pathways, 
such as STAT1 resulting in enhanced IFNy responses. 
Although we have shown that the dengue virus replicon specifically inhibits IFNa 
signalling by down-regulating the expression of STAT2, different serotypes of the 
dengue virus are differentially sensitive to the effects of IFNa and differences in the 
amino acid sequence within a serotype have also been shown to lead to OHF. The 
ability of the different proteins of the dengue virus to antagonise the interferon 
system was compared in a recent study by Munoz and colleagues. The dengue 
proteins were expressed individually in A549 cells with a GFP labelled NOV 
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(Newcastle disease virus). Enhanced replication of the NDV-GFP was seen in cells 
expressing NS2, NS4a and NS4b with NS4b being the best antagonist. Although 
there are several different strains of each dengue serotype, DHF did not occur in the 
Americas until the emergence of the South East Asia strain of Den 2. Although there 
are several amino acid differences between these two strains , a notable one from 
serine to histidine is in the NS4b region, which would be one of the candidates to be 
mutated and te$ted to see if the interferon sensitivity is altered. 
In conclusion the dengue replicon down-regulates the type I Interferon responses by 
degrading STAT2, a major component of the signalling pathway and therefore is not 
a suitable reporter assay for this thesis. 
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5. Results: Using a BVDV Replicon as a IFN reporter system 
Although the dengue replicon was not suitable as a reporter system, another 
replicon derived from the Flaviviridae family, BVDV was recently shown to be 
sensitive to the effects of type I interferon and therefore was tested . 
5.1.0 Background 
In the 1940s an outbreak of gastroenteritis and severe diarrhoea was noted in a 
herd of dairy cattle in New York State. It was later described as a disease with two 
conditions; subacute and acute. The sUbactute form had probably been circulating in 
the region for q few years, affecting a couple of animals in a herd, whilst the acute 
form was characterised as a 7-10 day illness in young animals leading to their 
death. This also caused more severe disease in more mature cattle, but led to their 
death within 3-4 days. The new disease was termed bovine viral diarrhea virus 
which was later classified into the Pestivirus family. 
The Pestiviruses are another genus of the Flaviviridae, whose members include 
classical swine fever virus (CSFV), border disease virus (BDV) of sheep and bovine 
viral diarrhea virus (BVDV). They are animal pathogens of major economical 
importance which are responsible for a spectrum of disease in animals. BVDV is 
found worldwide and can replicate in wild ruminants such as camels, deer, elk and 
bison to maintain a viral reservoir (Sandvik et ai, 1997;Vilcek et ai, 1994), but the 
economic importance of BVDV is due to its effect on the beef and dairy industries. 
The virus is widespread; about 60-70% of adult cattle have experienced BVDV 
infection by 4 years of age and animals persistently infected with BVDV represent 
up to 1 % of the cattle population. BVDV infection has a detrimental economic effect 
on the herd by reducing milk production, reduced reproductive performance, growth 
retardation and increased mortality among young stock. The estimated losses in 
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individual herd outbreaks have varied from a few thousand up to $100,000 per herd 
(Duffell et a', 1986). 
5.1.1 Clinical Manifestation 
The crucial outcome of the pathogenesis of BVDV infection is the transplacental 
infection of the foetus. The outcome of a BVDV infection depends on the gestation 
stage of the infected animal; when a foetus is infected at a later stage in gestation, 
the foetus will produce antibodies and therefore have an active immunity to BVDV 
(Howard, 1990), probably leading to a weakened newborn calf. However, infection in 
the first trimester, prior to immunocompetence, can result in a persistent infection of 
the foetus. 
Persistently infected animals are normally antibody negative to BVDV, but can 
produce antibodies to other BVDV isolates. Persistently infected animals are key 
transmitters of the infection as they continually shed virus in large quantities. 
Perisistently infected animals can have an impaired immune system, leaving them 
susceptible to other infections. Also, only persistently infected animals will succumb 
to fatal mucosal disease. Mucosal disease is a rare manifestation of BVDV infection 
which occurs when the persistently infected animal becomes superinfected with an 
antigenically similar but different biotype of virus. BVDV exists as two biotypes, but 
only one of these can cross the placenta and establish a persistent infection. 
5.1.2 Biotyp~s and genotypes 
The two biotypes of BVDV are; cytopathiC (cp) and non-cytopathic (ncp). They are 
classified according to their lytic effect on cultured cells; the non-cytopathic form 
being non-lytic. Only the non-cytopathic version of the virus can establish persistent 
infection which is characterized by immunotolerance. The ncp form arises as a 
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result of infection of the embryo early in its development, usually if infected between 
125-150 days. The calf may be born normally but will remain perSistently infected for 
their lifetime, usually being asymptomatic or causing only mild clin ical symptoms. 
The cp biotype of BVDV arises through mutation from the ncp form . The mutation 
generated via RNA recombination events are numerous and can arise from insertion 
of cellular sequences, gene duplication, deletion or single nucleotide changes. The 
cp virus is unable to establish a persistant infection (Brownlie et aI, 1989) 
Not only does the virus separate into two biotypes but it recently has also been 
divided into two genotypes; 1 and 2. Although both genotypes have been known 
about for a while , new developments in diagnostic tests were required so that they 
could be differentiated. The basic differenece between the genotypes is the disease 
severity; type 2 BVDV being responsible for more severe disease within the last few 
years. 
5.1.3 Structure and Genome 
BVDV is a small virus of approximately 50nm, consisting of a single capsid protein , 
surrounded by ~n envelope containing three glycoproteins. The genome is similar to 
that of the Flaviviridae with a few notable differences. The genome consists of a 
single-stranded RNA of about 12.3Kb and consists of a single large ORF flanked by 
untranslated regions at the 5' and 3' end (Meyers & Thiel , 1996). The 5' NTR 
contains an internal ribosome entry site that initiates translation of BVDV mRNA in a 
cap-independent manner. The secondary structure of the 5' NTR is involved in the 
regulation of both translation and genome replication . Similar to HCV, the BVDV 
I RES has been shown to bind to ribosomal 40S subunit, independent from the 
translation initiation factors eIF4A, elF4B and e1F4F. The BVDV proteins are 
translated from genomic RNA as a a large single polypeptide of -4000 a.a. wh ich is 
178 
co- and post-translationally cleaved into mature proteins by both viral and host 
proteases (Grassmann et ai, 2001). 
5.1.4 Structural Proteins 
BVDV consists of 4 structural proteins; the capsid protein (C) and three envelope 
proteins; ERNS (riblonuclease, soluble), E1 and E2. The C protein is the virion 
nucleocapsid a conserved, highly basic protein. The ERNS glycoprotein is heavily 
glycosylated, does not contain a potential membrane-spanning domain and is found 
associated with released virus particles. The other two E proteins are E 1 and E2, 
which can either associate together as a heterodimer or E2 can form homodimers. 
Monoclonal antibodies to E2 and ERNS can neutralize virus infectivity and mutations 
in the ERNS give rise to viruses that are attenuated in vivo. 
5.1.5 Non-Structural Proteins 
One of the major differences between the Pestiviruses and the Flaviviruses is the 
addition of a non-structural protein, Npro on the 5' end of the genome. The NPro is an 
autoprotease which cleaves itself from the rest of the genome at a highly conserved 
Cys-Ser site, b~t it is dispensable for autonomous RNA replication. The other non-
structural proteins follow the E2 protein as found in the Flaviviruses. 
The NS2 protejn is present as the N-terminal portion of NS2/3 and is found as a 
mature cleavage product only for some cpBVDV strains. Isolates of ncpBVDV do not 
proceed with NS2/3 cleavage but in cpBVDV biotypes the NS2/3 cleavage IS 
efficient but incomplete so that both NS2/3 and NS3 proteins are found. 
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The NS3 protein, similar to its function in the Flaviviridae, is a RNA helicase which 
and also contains a protease activity, requiring NS4 as a co-factor, but the NS3 
protease in the pestiviruses has an additional function . 
Although the cp biotype can be caused by different mechanisms, the biotype 
depends on the production of NS3; in the cp-BVDV both the cleaved NS3 and the 
un-cleaved NS2/NS3 can be detected. The last 27 nucleotides in the NS2 coding 
region are sufficient to mediate the NS2/NS3 cleavage and are therefore essential 
for the cytopathicity of the BVDV. This raises the possibility that NS3 is directly 
cytopathic to the cells and that the relative abundance of NS3 would be important to 
mediate this effect, or the greater RNA replication efficiency of the cp-BVDV form 
might arise as a consequence of the NS2/NS3 cleavage, leading to greater 
cytopathicity. 
Except for the co-factor function of NS4a little is known about either NS4a or the 
NS4b proteins. They are similar in size, composition and hydropathicity to the 
corresponding proteins in the Flaviviridae. 
The NS5a and NS5b proteins of BVDV can be found as individual proteins (-58KD 
and -75KD respectively) or as a large uncleaved protein (133KD). The NS5b 
protein contains the motifs characterisitic of RdRp and has been characterized in 
vitro and found to extend template-primed RNAs into double stranded copy back 
products or to catalyse de novo inititation from short synthetic RNA or DNA 
templates. 
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5.1.6 RNA Replication 
The RNA replication is similar to that of the flaviviruses. Negative and positive 
stranded RNA are detected early in the replication cycle followed by an 
accumulation of positive strand later on. 
5.1.7 BVDV and Interferon 
The mechanism of immune suppression in persistently infected animals by BVDV is 
still unclear, but the effects are multiple: 
Table 5.1 Effects of in vitro infection on bovine macrophage function (Peterhans et aI, 2003 ) 
Effect 
------------ -_._ ... ..... . 
IFN type I synthesis 
Induction of apoptosis 
Prostaglandin E2 synthesis 
NO synthesis after LPS or S. Dublin 
treatment 
TNF-a synthesis after LPS treatment 
Superoxide production induced by PMA 
Procoagulant activity induced by S. Dublin 
IL-1 inhibitor activity induced by LPS 
Ncp 
BVDV 
-* 
= 
= 
i 
= 
i 
Cytokine-induced chemotaxis t 
"' =; no effect compared to mock, i ; enhanced, l; reduced 
Cp 
BVDV 
i 
i 
i 
t 
= 
The differences in I FN synthesis between the two biotypes of BVDV could be a 
possible mechanism for the virus to establish a persistent infection. 
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The cytopathic form of BVDV has been shown to induce a type I interferon response 
in bovine macrophages (Adler et aI, 1997) whereas ncp-BVOV infected 
macrophages do not produce type I interferon and have been shown to block the 
induction of IFNa/~ by dsRNA (Rossi & Kiesel, 1980). Although viral replication was 
detected in the spleen of foetuses infected with either ncp or cpBVOV, type I IFN 
was only detected in the amniotic fluid of the foetuses infected with cpBVOV. The 
interferon inducible gene Mx was reduced in the ncpBVOV infection, suggesting that 
the failure of ncpBVOV to induce IFNa/~ enables the virus to establish a persistent 
infection in the early foetus (Charleston et aI, 2001). 
5.1.8 BVDV Replicon System 
It has been shown that when a full length complementary RNA of the BVOV is 
transfected into eukaryotic host cells, a subgenomic RNA molecule 019c, 
[previously described as a defective interfering particle (01)] functions as an 
autonomous replicon. D19c comprises the 5' and 3'UTR, the autoprotease NPRO and 
the NS proteins NS3 through to NS5b, which is sufficient to support complete RNA 
replication . 
... 
3 
Fig 5.1 Schematic drawing of the D19c BVDV replicon. 
The selectable, bi-cistronic, subgenomic BVOV replicon was obtained from Dr 
Zhong (Horscroft et aI, 2005). The structural genes of the BVOV were replaced with 
a luciferase-ubiquitin-neomycin phosphotransferase cassette and the expression of 
the non-structurF31 genes was driven by an EMCV IRES. 
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Fig 5.2 Schematic representation of the BVDV replicon containing the luciferase reporter cassette and 
Neomycin selection gene. 
pLN-BR 
After showing that the BVDV replicon efficiently replicates in Huh? cells and that no 
adaptive mutations were seen in the replicon, Halcroft et al. demonstrated that the 
replicon was sensitive to interferon treatment. The group treated the Huh?-BVDV 
cells with up to 10lU/mi IFNu, p or y for 48 hours before determining the effects 
upon the RNA replication. The results were found to be comparable to the Huh7-
HCV cells with IFNu being the most effective with an EC50 value of O.21U/ml. 
Fig 5.3 
Effects of interferons on BVDV and HeV replicon RNA replication in Huh7 cells. 
Luciferase expressing BVDV/Huh7 or HCV/Huh7 cells in 96 well plates were treated with 
indicated amount of IFNa (A), ~ (B) or y (C) for 48 hours. (Horscroft el ai, 2005) 
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The BVDV replicon pLN-BR (Iuciferase Neomycin-BVDV replicon) IS therefore 
suitable as a reporter system for this thesis. 
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5.2 BVDV Results 
5.2.1 In vitro transcription of the BVDV replicon 
peR primers were designed to amplify the BVDV repl icon containing the T7 
promoter of the plasmid required for the in vitro transcription (see Table 2.5). Two 
different forward peR primers were designed to accommodate the T7 promoter site, 
which requires upstream nucleotides for efficient initiation. 
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Fig 5.4 Amplification of the BVDV replicon. The T7 promoter sequence 
included in the forward primer to allow direct priming from the pe R 
product. 
The T7 15-BVDV peR product was cleaned using a Qiagen peR purification kit and 
used to make q full length RNA copy by in vitro transcription using a T7 MegaScript 
kit (Ambion) and transfected into Huh7 cells using electroporation. Whilst this 
experiment was ongoing, Huh7 cells containing the BVDV replicon (Huh7/LN-BR) 
were kindly received by Zhong from Valeance Pharmaceuticals and these were 
used for all subsequent experiments. 
5.2.2 IFN sensitivity of the Huh7/LN-BR cells 
The Huh7/LN-BR cells were first tested to ensure that our results duplicated the 
results obtained by Horscroft et al (2005). Huh7/LN-BR cells were plated out in a 96 
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well plate and left to grow overnight before being treated with IFNa2a for 24 hours. 
The cells were then lysed and luciferase activity measured. 
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Fig 5.5 Interferon decreases 
BVDV replicon replication as 
measured by luciferase acti\"ih. 
3 • 
lxlO cells were plated out and 
left to grow to 70% confluence 
before being treated with 10 fold 
dilution of IFNala (Roferon). The 
cells were lysed using PLB 
(Promega) and Luciferase 
measured (Promega). 
Fig. 5.5 shows that the BVDV replicon is sensitive to the effects of IFNa2a as 
previously described by Horscroft et al. and therefore could be suitable for our 
purposes. The inhibitory effects of IFNJ3 and IFNy have already been reported by 
Horscroft et at although the effects of the I FNa subtypes have not. The above 
experiment wa$ repeated with the IFNa subtypes (Wellcome) and the percentage 
inhibition of the luciferase activity plotted against the IFN concentration. 
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Fig 5.6 Eff~ct of IFNu subtypes on the replication of the BVDV replicon. Huh7, LN-BR 
cells were plated and left to grow overnight before being treated in triplicate with a 10 fold 
dilution of the IFNa subtypes (Wellcome). The cells were lysed using PLB (Promega) and the 
luciferase activity assessed. The average of the triplicates was taken and the percentage 
inhibition from the negative control (arbitrarily set as 100%) calculated and plotted against IFN 
(ng). 
Although all the subtypes show a decrease in the luciferase activity with increasing 
amounts of interferon, there is a kinetic difference, with IFNa7 being the best and 
IFNa5 and IFNa1 being the worst. Interestingly the antiviral activity of IFNa1 has 
already been reported to be poor against several other viruses (Foster et aI, 1996). 
5.2.3 Interferpn stimulated genes 
The effect of interferon on the BVDV replicon was further investigated in respect to 
the interferon stimulated genes using real-time PCR as used in previous 
experiments with the dengue replicon. Huh7/LN-BR cells were plated in 6 well plates 
and left to grow overnight. The following day the cells were stimulated with IFNa2a 
for 6 hours befQre extracting total RNA. Real time PCRs for ISGs were performed as 
previously described in chapter 4. 
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Fig 5.7 Real time PCR to measure the effects of the BVDV replicon on Interferon 
inducible genes. Huh7/LN-BR cells were treated with IOOIU/ml IFNa2a for 6 hours before 
measuring the interferon inducible genes by real time peR. A. Induction of MxA B. PKR gene 
induction and C. 2 ' 5 'OAS gene induction 
BVDV does not appear to inhibit the induction of interferon stimulated genes as 
demonstrated by real-time peR (fig. S.7). BVDV does not completely abrogate the 
effects of I FNa as seen earlier with the dengue replicon and therefore the BVDV 
replicon shall be further tested for use as a reporter for interferon inhibition. 
5.2.4 Validating the BVDV replicon as a reporter assay. 
To confirm that the BVDV replicon would be suitable as a reporter assay for 
interferon antagonists, it was tested using the known IFN inhibitor SVS-V (kind gift 
from Prof. R. Randall) . SVS-V has been shown to be one of the most powerful 
inhibitors of th~ type I interferon system which works by targeting STAT1 for 
proteasomal degradation (discussed previously in 1.2.3). To ensure that the SV5-V 
plasmid was functional , it was transfected into KS62 cells using Fugene6 and stable 
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cells selected using 500J.lg/ml G418. After approx 2 weeks in G418 selection the 
cells with and without the SV5-V plasmid were treated with 100lU/mllFNa2a or IFN'/ 
• 
for 15min before lysing the cells and detecting STAT1 , STAT1P and SV5-V by 
Immunoblotting using specific antibodies. 
Fig 5.8 SV5-V inhibits IFNa./y signalling by degrading STATl. A. K562 cells (negative control) 
and K562 cells transfected with the SV5-V plasmid were treated with and without a IOOIU/ml IFNa 
and (FNy for 15 min and then lysed in SDS loading buffer, Proteins were separated by SDS PAGE 
and analysed by Immunoblotting using specific antibodies for STAT I and STAT I P. B. The presence 
of the SV5-V proteins was confirmed using a specific antibody agains PK Tag, which is present in the 
plasmid. 
After confirming that the SV5-V plasmid was functional it was tested as an IFN 
inhibitor using the BVDV assay. Huh7/LN-BR cells were seeded at a density of 
1 x1 03 cells per well in a 96 well plate and left overnight until -700/0 confluent. The 
cells were then transfected in triplicate using 5J.l1 of a mixture of Fugene6 with 2Jlg 
SV5-V, and 0.1 J.lg pSV-~-Galactosidase . After 24 hours, cells were treated with 
IFNa2a and approximately 24 hours later, cells were harvested for analysis of 
luciferase and f3-gal production. The results are displayed as percentage inhibition of 
the luciferase activity, normalised to ~-gal. 
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Fig. 5.9 SV5-V inhibits the antiviral action of interferon on the BVDV replicon. Huh7/LN-
BR cells were transfected in triplicate with SV5-V protein (a known viral inhibitor of type I 
IFN) and an empty vector control. Cells were grown overnight before being treated with I FN 
for a further 24hrs. Cells were lysed and luciferase expression measured and normalised to Beta 
Gal. 
The BVDV-Iuciferase replicons stably expressed in Huh? cells have previously been 
shown to be highly sensitive to the antiviral effects of IFNa (Fig. 5.5) . This effect can 
be inhibited by transient expression of a known IFN antagonist. The V protein of 
simian virus 5 (fig 5.9) at a concentration of 11U/ml IFNa but this effect is not seen 
with higher IFNa concentrations, as the higher concentration overcome the inhibition 
of the SV5-V protein. 
5.2.5 Using the BVDV replicon as a reporter assay 
After validating the BVDV reporter system using a known I FNa antagonist it was 
further tested l,Jsing two NS5a proteins derived from patients whose treatment 
outcome was known. The Huh?/LN-BR cells were plated out and transfected in 
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triplicate as previously mentioned uSing 2 Ilg of the NS5a-CR or the NS5a-NR 
plasm ids and 0 11lg of the R_g I I·d . 
. ..... a p asml as a transfectlon control. The cells were 
treated with IFNa for 24 hours before being lysed and the luciferase activity 
measured and analysed to the ~-gal activity, results are shown as percentage 
reduction of the luciferase activity. 
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Fig. 5.10 Different NS5A proteins vary in their effect on the action of interferon. NS5a 
protein derived from an interferon non-responsive (NR) patient reversed the reduction in 
luciferase activity but this was not the case in the NS5a protein derived from an interferon 
responsive patient (CR). 
5.2.6 Optimi$ing the BVDV reporter assay 
Although there appears to be an inhibition of the antiviral effect of IFNa in the 
presence of SV5-V at 11U/ml this is not seen at higher IFNa concentrations, SV5-V 
is a strong inhibitor of type I IFN and more subtle effects by weaker inhibitors could 
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be missed due to the lack of sensitivity in this assay. To overcome this we have 
altered the assay so that the results can be analysed by flow cytometry. 
The luciferase reporter within the BVDV replicon was replaced by a commercially 
available destabilised green fluorescent protein (dsGFP) (Clontech) . The dsGFP 
displays a rapid turnover therefore making it ideal for use in a reporter assay. The 
dsGFP is fused to a portion of a mouse ornithine decarboxylase (MODC) which 
contains a PEST domain that targets the protein for degradation. This allowed us to 
analyse the BVDV replicon in individual cells using flow cytometry and improve the 
sensitivity of the assay. 
5.2.7 Overlapping peR strategy 
To replace the luciferase cassette with the dsGFP an overlapping PCR strategy was 
employed; primers were designed to incorporate Sac I and Pmel restriction sites to 
allow the introquction of the cassette back into the BVDV replicon . The first PCR 
used the pLN-6R DNA as a template, the 5' primer contained the Sacl restriction 
site and the 3' primer included an overhang which would overlap with the second 
PCR product from the pZsGreenDR1 (Clontech). The second PCR used the 
pZsGreenDR 1 plasmid as a template and incorporated a Pmel site at the 3' end and 
an overhang at the 5' end to overlap with the first PCR. 
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Fig 5.11 Overlapping PCR strategy to replace the luciferase cassette in pLN-BR with a 
destabilised GFP. A. Schematic representation of the overlapping PCR. B. Both PCR products 
were amplified individually. C. PCR products fro m B. were mixed in an equimolar ratio before 
being diluted to be used as template for the final PCR reaction. 
The overlapping PCR fragment was then A-tailed and sublcloned into pGEM-T and 
checked by sequencing before being digested with Sac I and Hpal (Hpal replaced 
Pmel, they are both restriction enzymes that produce blunt end products and could 
subsequently be ligated with one another) to release the fragment and insert into the 
correspondingly digested and de-phosphorylated pLN-BR plasmid. 
5.2.8 Vector and insert preparation 
Although sever~1 attempts were made to release the fragment from the pGEM-T 
vector, none were satisfactory and therefore a PCR was performed using SP6 and 
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T7 primers that flanked the required fragment which was then subsequently 
digested to release a fragment of the correct size (1042bp). 
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Fig 5.12 Preparation of green 
insert from pGEM-T. Using 
the SP6 and T7 primer sites 
present in the pGEM-T \'ector. 
the insert with the flanking 
vector regions was amplified. 
This PC R product was then 
digested with HpaI and SacI 
and gel purified form the above 
agarose ge I. 
The digested insert was then gel purified to be inserted into the prepared pLN-BR 
vector. The vector was digested with Pmel and Sac I before being dephosphorylated 
to prevent self-ligation. Due to the size of the pLN-BR vector, single digests were 
performed sequentially to ensure that both restriction digests were carried out to 
completion. 
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Fig 5.13 Vector preparation. pLN-BR was digested with Pmel restriction enzyme 
overnight at 37°C before being heat inactivated at 65°C for 20 minutes and adding 
Sacl enzyme for a further 24 hrs. 
After dephosphorylation, to ensure that only the digested vector was present, pLN-
BR PmeliSacl was gel purified using QIAEX " beads. 
5.2.9 Screening for the green insert 
Although both insert and vector had been purified and several attempts were made 
the new pGN-BR (Green Neomycin - BVDV replicon) was proving difficult to ligate, 
resulting routinely in a 3Kb band of unknown origin, possibly as a result of gene re-
arrangement with the E. coli. To overcome this, a new T4 rapid ligase kit from 
Roche was used and the correct clone was made and tested for the presence of the 
green insert by peR. 
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Fig 5.14 peR screening for the presence of tbe 
green insert. Using the primers designed to make 
the overlap fragment, a PCR reaction was carried 
out on a potential clone. 
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~fter showing that the green insert was present in the clone, it was grown up further 
before being checked again by sequencing. 
A. pLN-BR Green insert 
-----. -----. 
oc 
B. 
CTGAGCCAGGGCCACTATTTTACCAGGACTATAAAGGTCCCGTCTATCACAGGGCCCCGCT 
TTGAGGAGGGATCCATGTGTGAAACGACTAAACGGATAGGGAGAGTAACTGGAAGTG 
ACGGAAAGCTGTACCACATTTATGTGTGTATAGATGGATGTATAATAATAAAAAGTGCCACGA 
GAAGTTACCAAAGGGTGTTCAGGTGGGTCCATAATAGGCTTGACTGCCCTCTATGGGTCACAA 
GTTGC 
:AGTCCAAG~ACGGCCT~ACCAAGGAGAmGACCA7GAA~rA 
~TGGACGGCCACAAGTTC~TGATCACCGGCvAGGG~ATCG~C7AC 
GCCATCAAcnTGTGCG~GG7GGAGGGc~~crCl.TrG~CCTT G~ 
GCC:T':ArGrAC~GCAACCGCG':'GT ~CAr CGA',':'Ac,.,r ~ AG 
AACTCC7GCCCCGCCGGCTACACCTG~GA~CGc:rrTT~~ 
ATCT~CAA~GCCGACATCACSGTGAGnCTGGA GAGAACL ,~ rl 
TACGGCG7GAACTTCCCCGCCGACGGCCCCG7GATGAAGAA0A7 Acr 
TCC':'GCGAGAAGATCATCCCC":G7GCCCAAGCAr.,GGCA 7CTTGAA ~ ~ 
CTGCTGCTGAAG~ACGG7GGCCGCTTGCG~~GCCAGTTS ACAC~~ r 
GTGC~CCGCAAGA~G"'CC~AC~GGCAC:TCA~CCA~~ACAA 
GACGCCAAGAACCAGAAG7GG~AC~TGACCGAGCA"'~C A 
CCTCCGGCTCCGCCTTGCCCAAGCTTCCGCGGAGCCATGGCTTCCCGCCGGCGG7GGCGGCGC 
AGGATGATGGCACGCTGCCCATGTCTTGTGCCCAGGAGAGCGGGATGGACCGTCACCC7GCAG 
CCTGTGCTTCTGCTAGGATCAATGTGG TGCAGAT 
Fig 5.15 Sequence confirmation of the presence of the dsgreen insert in the BVDV 
replicon. A. Chromatogram showing the area where the BVDV replicon is ligated 
with the dsGreen insert. B. The forward and reverse sequences were aligned using 
Blast2, restriction sites used during the cloning are highlighted in blue. The black is 
the original pLN-BR vector, green is the insert from the pZsGreen vector and the red is 
the PEST sequence also obtained from the pZsGreen vector. 
5.2.10 In vitro transcription of the BVDV green replicon 
After sequence confirmation the pGN-BR (Green, Neo, BVDV, Replicon) was used 
as a template for in vitro transcription to obtain RNA to transfect into Huh 7 cells 
using a forward primer that contained the T7 promoter site. After confirmation that 
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the PCR worked, the reaction was scaled up 25 times and the resulting products 
pooled before being purified using a Qiagen PCR purification column in order to 
obtain not only a high yield of product but also without any contaminants . 
- 10 .5Kb 
-
Fig 5.16 Preparing template for in vitro 
transcription. 25 peR reactions were pooled together 
and purified through a column 
The purified peR product was used as a template for an in vitro transcription 
reaction. Although in vitro transcriptions normally function better with long 
transcripts, due to transcription initiation events, a 10.5Kb is more than the 
recommended length. Therefore, the protocol was scaled up and due to short 
transcripts it was also modified to a 37°C step for 15 minutes before incubating the 
reaction at 4°C overnight. Although this significantly lowered the yield, full length 
transcripts of the BVDV green replicon were achieved. 
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Fig 5.17 III vitro transcription to produce BVDV green RNA. Purified peR product 
was used as a template for an in vitro transcription. 
5.2.11 Transfection of the BVDV green replicon 
The prepared RNA was then transfected into Huh? cells either by TransMessenger 
or by electroporation and left for 48 hours before visualising the GFP by IF. Although 
numerous attempts have been made to transfect Huh? cells with the RNA so far 
they have not been positive by IF. There are several possible explanations for this : 
1. The PEST sequence is normally used in the C terminus of the protein. Here we 
have the BVDV replicon following on from the PEST sequence, which could have 
rendered the GFP protein unfunctional. 2. The insertion of the PEST sequence 
might render the BVDV replicon unstable and unable to replicate. 
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5.3 Discussion 
The BVDV reporter assay has several potential advantages: the whole of the 
signalling pathway of the antiviral action of IFN could be tested and a positive strand 
RNA virus closely related to HCV was used. Although clear differences between the 
vector control and the putative IFN inhibitors were seen, the variability within the 
assay did not allow subtle differences to be interpreted. Replacement of the 
luciferase reporter from within the BVDV replicon with a dsGFP, will improve the 
sensitivity of the assay. The putative IFN inhibitors are cloned into a bicistronic 
expression vector encoding a red fluorescent protein (pIRES2DsRed2, see chapter 
3) and transiently transfected into the Huh? cells stably expressing the BVDV-
dsGreen. A two colour flow cytometry will be used to quantify the antiviral effects of 
I FNa on the BVDV replicon (green FL 1 channel) in cells also expressing the 
putative inhibitors (red FL2 channel) whilst untransfected cells (not red) will act as 
an internal control. 
Although it was demonstrated that BVDV could be used as a reporter for IFN 
inhibitors, in the long term, the analysis of the putative inhibitors would be greatly 
facillitated by being analysed by flow cytometry. Unfortunately within the time 
constraints of this thesis it was not possible to transfect the BVDV-Green replicon 
RNA into Huh? and tests its viability. Other cell lines, which have previously been 
shown to support BVDV replication should be tested to ensure that the replicon is 
viable. 
In conclusion, it was shown that a BVDV replicon was a feasible reporter assay for 
putative I FN inhibitors but more work is required to develop the assay in terms of 
sensitivity and ease of use. 
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Reporter assays for interferon stimulated genes. 
6.1 Background 
The effects of the HCV genes on the proteins mediating the antiviral effects of IFNa 
were investigated in human hepatoma cells. Since the discovery of interferon, 
several reporter systems have been constructed. In this chapter, a reporter system 
for the MxA promoter was used to investigate the effects of various patient derived 
NS5a plasmids. 
6.2 MxA 
As previously described, MxA is a key component of the antiviral action of interferon. 
The Mx1 protein was first identified in an A2G inbred strain of mouse that showed 
resistance to otherwise lethal doses of mouse-adapted influenza virus (Haller et aI, 
1981). The Mx1 localises to the nucleus suggesting exertion of its antiviral activity by 
inhibiting virus transcription. In contrast the human homologues are cytoplasmically 
located. These differences in sub-cellular localization suggest different mechanisms 
of antiviral action. 
The association between MxA and HCV infection is vague at best; MxA proteins are 
not found in the whole blood of HCV patients pre-treatment (Chieux et aI, 1998), 
even those with a high viral load, nor is MxA expressed in the PBMCs during the 
acute phase of HCV infection (Jakschies et aI, 1994). In contrast, high levels of MxA 
expression were found after IFNa treatment (Chieux et aI, 1998) and also in the 
PBMCs of patients with chronic HCV (Antonelli et aI, 1999;Giannelli et aI, 2004) . 
However, it hasn't been conclusively shown whether the increase in MxA expression 
is due to the IFNa regime or if it is dependent upon the virus (Meier et aI, 2000). 
Although MxA expression in liver biopsies taken from patients prior to I FN treatment 
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showed elevated MxA expression levels in hepatocytes in >800/0 of the samples, the 
antiviral effect of MxA on HCV replication is unclear (MacQuilian et al. 
2002;MacQuillan et aI, 2003). HCV RNA replication within the replicon system was 
not affected when MxA was transiently overly expressed, and a dominant negative 
mutant of MxA did not interfere with the antiviral activity of IFNa against HCV RNA 
replication (Frese et aI, 2001). Although these results imply that the antiviral effect of 
IFNa on HCV replication is MxA independent, it has been shown that a single 
nucleotide polymorphism (SNP) in the promoter region of the MxA was associated 
with the IFN response of HCV patients (Hijikata et aI, 2000), [later shown to be true 
only for patients with a low viral load (Suzuki et aI, 2004)] and that the expression of 
MxA was significantly lower in patients who responded to interferon treatment 
(Giannelli et aI, 2004). 
6.2.1 Assay development 
The MxA promoter linked to a luciferase construct as previously described (Ronni et 
aI, 1998) was kindly donated by Dr. IIkka Julkunen. 
The level of luciferase (reporter gene product) expression was used to measure 
transcription from the MxA promoter. Firefly luciferase is a monomeric enzyme of 
61 KD that catalysed a two step oxidation reaction to yield light. The luciferyl 
carboxylate is activated by ATP to give a reactive mixed anhydride which then 
reacts with oxygen to create a transient dioxetane that breaks down to oxyluciferin 
Transfection based experiments are notoriously variable; to control for experimental 
variation, a transfection control of a pSV-J3-Galactosidase vector control was 
included at a 1 in 20 of the concentration of the luciferase vector in each 
transfection. The SV40 early promoter and enhancer drive transcription of the lael 
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gene, which encodes the ~-Galactosidase which can b '. 
e assayed qUickly In cell 
extracts using spectrophotometric, fluorescent or chemiluminescent techniques. 
Using Fugene6 the MxA plasmid was transfected into Huh? cells , with a beta-gal 
plasmid (Promega) for a normalisation control to determine the optimum 
experimental conditions. The cells were treated with IFNa2a (Roferon) for 24 hours 
before the MxA activity was measured and normalised. 
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Fig 6.1 Optimisation of transfection: MxA into Huh7 cells. I x 1 03 cells were plated overnight in a 
96 well plate before being transfected with MxA-luc and ~-Gal using a variety of Fugene6:[ONA] . 
The cells were left for another 24 hours before stimulating with IFNa2a. After a further 24 hours, the 
cells were lysed using PLB and luciferase and ~-gal activity measured. 
From fig 6.1, a ratio of 3:2 Fugene6:[ONA] was decided upon as the optimum 
condition for subsequent experiments. Although the background luciferase reading 
was high, changing the timing of the experiments, i.e. to shorter and longer 
exposure to IFNa did not significantly lower the background levels of MxA-
luciferase. Therefore for convenience sake, a 24 hour stimulation was chosen . 
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6.2.2 Summary of Optimised Method 
Huh7 cells were seeded at a density of 1 x1 03 cells per well in a 96 well plate and left 
overnight until -70% confluent. The cells were then transfected using a mixture of 
Fugene6 with 2119 MxA-h.Jc, and 0.1119 pSV-r3-Galactosidase, 5~1 of the mix was 
added to each well. After 24 hours, cells were treated with IFNa2a and 
approximately 24 hours later, cells were harvested for analysis of luciferase and ~_ 
gal production. 
6.2.3 Effect of patient derived NS5a on MxA 
Using the above conditions, luciferase analysis was performed on Huh7 cells co-
transfected with patient derived NS5a, MxA-Luc and r3-gal and treated with IFNa2a. 
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Fig 6.2 The effect of patient derived NSSa on IFNa stimulated transcription fr~m M \A 
promoter, measured using a ~uciferase reporter. Growing Huh7 cells were transfe.cted With MxA-
Luc pSV -p-Gal and patient derived NS5a. After 24 hours, cells were treated With I FNa2a and ha~ested after a further 24 hours and luciferase and p-gal production measured. Assays were 
performed in duplicate and mean data shown. 
The above Fig (6.2) shows the level of MxA promoter activity with different NS5a 
samples using increasing concentrations of Interferon. The experiment 
repeated several times and the above figure illustrates a typical result. 
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was 
It was observed that NS5a samples from patients 7855, #002 & #003 superinduced 
the luciferase activity i.e the MxA promoter activity, in the absence of IFNa2a. but 
that the luciferase activity also increased with increasing IFNa2a concentration . This 
finding is against the perception that the HCV NS5a gene inhibits the MxA protein in 
order to evade the antiviral response and achieve chronicity. In comparison the 
luciferase levels from clone 8414 were comparable to the negative and vector 
control. 
6.2.4 Superinduction of MxA promoter activity; measured with the luciferase 
assay 
The above results were used to gain the fold induction of MxA promoter with 
increasing concentrations of IFNa2a 
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Fig 6.3 Fold induction of M~A-Iuciferase actIVity m t e presence 0 . 
was measured from the negativy IFNa2a control. 
. . d no detectable difference was seen Although when luciferase activity was measure , 
d . Ie #002 when analyzing 
in sample 8414 and only low activity was detecte In samp , 
IFNa2a concentration , it was clear that the fold the fold induction with in~reasing 
14 II as comparable if not greater induction of MxA promoter activity in the 84 ce s w 
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than in the other NS5a transfected cells. It appears that although samples 7855 and 
#003 show greater luciferase activity in the absence of IFNa2a, the fold induction 
shows converse results with samples 8414 and #002 at higher IFNa concentrations 
inducing greater MxA promoter actitivty. 
6.2.5 Superinduction 9f MxA in the presence of NS5a patient derived 
samples. 
To further investigate the ~ffect of the different patient derived NS5a proteins on the 
MxA promoter, the endogenous MxA was measured in the presence and absence of 
NS5a. Huh7 cells were transfected with the patient derived NS5a for 24 hours and 
total RNA was extracted, MxA gene transcription was analysed by quantitative RT-
peR and normalised to the Neomycin resistance gene found in the vector. 
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Fig 6.4 Endogenous MxA i~duction by patient derived NS5a. Patient. derived .NS5a. wer~ 
transfected into Huh7 cells for 24hours before extracting total RNA an~ me.as~nng MxA Induct'O~ b. 
real time peR, nonnalized to Neomycin. Experiments were performed In tnpllcates and the mean ata 
shown ± standard error of the Illean. 
In correlation with the previous data, patient derived NS5a was found to induce 
MxA, basal MxA was not detectable in non-transfected Huh7 cells . In previous 
experiments, the amount of basal MxA activity induced in the 8414 sample was 
h th . d ction of endogenous MxA in significantly less than the others, but althoug e In u 
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the 8414 was less than in the 7855 sample it did not represent s h ° °fo 
, uc a slgnl Icant 
difference. 
Discussion 
MxA has been reported to be one of the most specific parameters for IFNu/rJ action, 
but as shown in this chapter, using the MxA promoter linked to the luciferase 
cassette may not have been the best way of evaluating the effects of different HCV 
proteins on the interferon system. Several of the HCV proteins appear to activate 
the MxA promoter in the absence of exogenous IFNa, and the promoter activity was 
increased further after the addition of exogenous IFNa. The data was re-analysed, 
using a fold-increase of the MxA promoter activity from the samples without IFNa, 
thereby negating the effect of the samples on the promoter without IFNa. The 
samples which had previously been shown to activate the MxA promoter without 
exogenous IFNa appeared to increase the MxA promoter activity less in comparison 
with the pIRES2-DsRed2 vector control. The MxA reporter assay has raised more 
questions than answered. It appears counter-intuitive that NS5A induces MxA 
promoter activity and thereby MxA expression when the virus is trying to evade the 
antiviral effects of the IFNa/f3 system. The difference in the basal induction of MxA 
with NS5a derived from different patients needs to be explored further. It is 
especially interesting to note the differences between the plasm ids that have 
previously been described as being derived form a non-responding and a 
responding patient. Further samples from well-defined patients are necessary to 
explore the interaction between the MxA promoter and the HCV proteins and 
whether or not this leads tp an inhibition of the IFNa/f3 system. As a reporter system, 
the MxA is of limited value until these questions are answered. 
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7.1 Discussion 
The Hepatitis C Virus which was first identified In 1989 (Choo et ai, 1989) , is 
transmitted via blood to blood contact. Of those who become infected 
, 
approximately 85% develop chronic infection and about a quarter of these patients 
go on to develop cirrhosis of the liver and are also at risk of developing 
hepatocellular carcinoma. HCV infection is currently the leading cause worldwide for 
liver transplantation. 
The current standard treatment for HCV infection is pegylated IFNa in combination 
with ribavirin. Although clinical trials with combination therapy have demonstrated 
high rates of sustained virological response amongst chronic HCV patients, 24% of 
patients with genotype 2 or 3 and 54% of patients with genotype 1 fa il to achieve 
sustained virological response. Poor response to IFNa therapy, particularly amongst 
patients infected with HCV genotype 1 is a major consideration for cl inicians starting 
patients on a costly course of IFNa therapy, a treatment that also includes several 
adverse effects for the patient. Predictive markers of response to IFNa therapy 
could be of benefit in this decision making process. 
HCV has clearly developed strategies to evade antiviral immune reponses. In th is 
thesis, three different systems have been investigated as a potential reporter assay 
for testing the ability of individual HCV proteins to inhibit the antiviral effects of IFNa. 
Although the Dengue replicon did not prove to be a suitable reporter assay due to its 
insensititivity to type I IFN, the mechanism by which it subverted the effects of 
interferon were further investigated. The replicon system was used to pinpoint 
STAT2 as being the target of the dengue virus and its degradation was instrumental 
. . . t rf athway As the viral load of In the way the dengue virus aVOids the In e eron P . 
207 
dengue early in disease is an important marker for progressl'on a h ' ny mec amsm that 
the virus can use to increase its peak viral titre has severe consequence. By 
evading the effects of interferon by reducing steady state STAT2 levels, the dengue 
virus has tipped the balance of virus vs immune system in its favour. 
STAT2 is an important target in the type I IFN signalling pathway and several 
viruses have used different mechanisms to block its function. Human parainfluenza 
virus 2 (HPIV2) has been demonstrated to act on STAT2 by degradation via the 
proteaseone. As demonstrated in this thesis with dengue virus, Parisien et al (2002) 
showed that expression of HPIV2 V protein in cultured cells does not influence 
STAT2 mRNA levels but reduces STAT2 steady state levels by targeting the protein 
for degradation. 
In conjunction with our studies, several other members of the flaviviruses have 
recently been shown to inhibit the interferon signalling pathway by acting on the 
STAT proteins e.g. Best et al (2005) showed that Langat virus (LGTV) prevented the 
phosphorylation of STAT1/2 in response to IFNa and IFNy. 
In 2003, Munoz-Jordan et al suggested that the viral proteins NS2a, NS4a and 
NS4b were responsible for the inhibition of the IFN signalling pathway. In this study, 
NS4b appeared to block both IFNa/~ and IFNy signalling by acting on STAT1. The 
study was performed in a monkey kidney cell line, but STAT2 is not well conserved 
among species. It will be interesting to study the individual non-structural proteins of 
the dengue virus within the replicon system by either mutational analysis or 
individually expression to assess their individual effects on STAT2 in a human cell 
line. Although studies were attempted to pinpoint which of the dengue non-structural 
. d t' f STAT2 using immunoprecipitation . proteins was responSible for the degra a Ion 0 
the lack of antibodies against all the non-strucutral proteins and the difficulties in 
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reaching a balance between cell death and an effective proteasomal inhibitor proved 
too problematic. 
Another system investigated within this thesis was the BVDV replicon system which 
could potentially be used as an effective reporter system. We have shown that it is 
sensitive to the effects of interferon and cells containing the reporter can still 
respond to exogenous type I IFN. The reporter was then tested using a known 
interferon inhibitor, SV5-V and shown to be effective at low interferon 
concentrations, but that higher concentrations of IFNa masked the effects of the 
inhibitor on the reporter system. Using two different and well established HCV -NS5a 
clones the BVDV reporter system showed differences in their inhibition of the 
reporter assay. The BVDV reporter system needs to be examined further with 
known IFN antagonists, before its usefulness as a reporter system is verified . 
Although the assay works in principle, a lack of sensitivity of the luciferase reporter 
will not allow us to study subtle changes in inhibition, therefore the assay needs to 
be modified. The luciferase cassette has been replaced with a destabilised GFP 
which will allow us to study the inhibitors in a FACS based assay that will improve 
the sensitivity. Although a cloning strategy was designed for the removal of the 
luciferase cassette with the destabilised GFP so far it has not been possible to 
transfect this construct into Huh? cells. Other cells lines that support BVDV 
replication should be utilised as well as detecting the BVDV replicon using specific 
antibodies and not relying on the GFP. 
The MxA reporter assay has raised more questions than answers. It appears 
counter-intuitive that NS5A induces MxA expression and the difference in the basal 
induction of MxA with NS5a derived from different patients needs to be explored 
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further. As a reporter system, the MxA is of limited value u t'l th ' 
n I ese questIons are 
answered, 
7.2 Future work 
1. HCV cloning and expression 
Although it was shown that the NSSa protein derived from different patients could be 
expressed in vitro by using specific antibodies against the protein, the pIRES2-
Dsred2 vector was unsatisfactory. Expression of the RFP could be detected in BHK 
cells by FACS but, the same could not be achieved in more relevant human liver 
cells such as Huh7 and HepG2. This could be due to the EMCV IRES, present in 
this bicistronic vector, which has been shown to be susceptible to the introduction of 
mutations during the cloning process. Several others groups have reported 
problems with the expression of RFP in human cells using the bicistronic vector. To 
overcome this problem, additional vectors should be explored. Lentiviral vectors 
containing the MESV leader sequence, have been shown capable of transducing 
several mammalian cell lines and express the protein of interest at a high enough 
level level to be detected by Western blots (Mazzon and Jones, unpublished data), 
The lentiviral vector is a dual promoter vector, containing GFP, For use with the 
BVDV replicon system, the GFP would be changed to RFP to allow both the replicon 
and the individual protein to be detected within the same cell by FACS, Historically, 
viral vectors were avoided when studying the IFN system as they were thought to 
induce IFN. Recent evidence suggest that the IFNa/~ induced by these viral vectors 
was below the level of detection using an antiviral assay (Hibbert et al unpublished 
data). Another way of ensuring that exogenous IFNa/~ does not interfere with the 
experiment would be to use KS62 cells which although responsive to type I IFN they 
are unable to produce I FNa/~. 
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2. Dengue virus and its inhibition of the IFNaJP system 
In this thesis it was shown that ST A T2 was targeted for proteosome-medlated 
degradation in dengue replicon-containing cells. As the replicon consists only of the 
non-structural proteins, we thereby excluded the requirement for dengue structural 
proteins for this effect. Work is ongoing to determine which of the non-strucutral 
protein/s of the dengue virus is responsible for this phenomenom. Using a lentiviral 
system, the individual non-structural proteins of dengue have been transduced into 
K562 cells and currently no individual protein alone can be shown to be responsible 
for the degradation of STAT2 (Jones and Mazzon, unpublished data). A combination 
of the non-strucutral proteins will be tested in the future, concentrating on the effects 
of NS4b. This had been pinpointed by Munoz-Jordan et al and using bioinformatic 
analyses we have identified a putative Elongin BC motif within this gene. We are 
currently mutating this site by overlapping PCR with the aim of testing the mutation 
within the replicon system for its affect on STAT2 degradation. Another avenue to be 
investigated, is the re-constitution of wild type STAT2 into the cells containing the 
dengue replicon. Results so far indicate that exogenous STAT2 only partially 
restores IFN mediated signal transduction and after IFNa treatment does not appear 
to inhibit the RNA replication of the dengue replicon (Jones and Mazzon 
unpublished data). It is possible that dengue virus, like some other viruses, inhibits 
the IFN system by more than one way, which will be investigated further. 
3. The BVDV reporter system 
We have developed a novel BVDV reporter replicon containing a dsGFP which will 
enable us to study the effect of individual non-structural proteins on host innate 
immune responses. This has potential as a dynamic reporter of whole cell IFN 
. of potential I FN antagonists 
function, and may allow increased-throughput screening 
f th BVDV replicon has been replaced using FACS. So far, the luciferase cassette 0 e 
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by a destabilised GFP and verified by sequencing, but we have been unable to 
establish cell lines expressing the pGNBR. This could be due to the presence of the 
PEST, which could limit our ability to detect GFP by FACS or that by altering the 
sequence of the replicon we have inadvertently changed the secondary structure 
thereby rendering it replication incompetent. Further investigastion is needed before 
being able to use the BVDV system as a reporter for IFNa/~ antagonists . 
The overall aim of this thesis was to identify IFNa/~ antagonists by developing a 
reporter assay. This in turn could lead to the development of novel antiviral drugs, 
preventing the inhibition of IFNa/~ antiviral system. The BVDV system, with several 
modifications, could be used as such a reporter. 
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ABSTRACT 
Dengue is a mosquito-bome viral disease of immense global importance. 
Intensity of viral replication in the first days of infection determines clinical 
outcome, which ranges from benign febrile illness to life-threatening disease 
(dengue haemorrhagic fever) . During this critical early period, innate immunity 
serves to limit viral replication . The interferon (lFN) system, a key component 
of Innate antiviral responses , has been shown to inhibit early events in dengue 
replication but have little effect on subsequent steps in the virus cycle . We 
hypothesized that the dengue virus, in common with several other RNA 
viruses, has evolved countermeasures to subvert the IFN response. 
METHODS 
In order to investigate events downstream of input strand translation, we 
developed human cell lines that continuously express dengue replicons 
(self-replicating subgenomic fragments) . Cells with and without dengue 
replicons were treated with IFNa. and the events studied. 
RESULTS 
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Dengue Virus Inhibits Alpha Interferon Signaling by Reducing 
ST A T2 Expression 
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Alpha/beta interferon (IFN-a/Il) is a key mediator of innate antiviral responses but has little effect on the 
~stablished replication o~ dengue viruses, which are mosquito-borne flaviviruses of immense global health 
1II~~orta~ce: Und~rstan~mg how the IFN. system is inhibited in dengue virus-infected cells would provide 
cnhcal IOslghts mto disease pathogeneSIs. In a recent study analyzing the ability of individual dengue 
virus-encoded proteins to antagonize the IFN response, non structural (NS) protein 4B and possibly NS2A and 
NS4A were identified as candidate IFN antagonists. In monkey cells, NS4B appeared to inhibit both the 
IFN-a/Jl and IFN-'Y signal transduction pathways, which are distinct but overlapping (J. L. Munoz-Jordan, 
G. G. Sanchez-Burgos, M. Laurent-Rolle, and A. Garcia-Sastre, Proc. Natl. Acad. Sci. USA 100:14333-14338, 
2003). For this study, we examined the effects of dengue virus on the human IFN system, using cell lines that 
were stably transfected with self-replicating subgenomic dengue virus RNA (replicons) and that expressed all 
of the dengue virus nonstructural proteins together. We show here that in replicon-containing cells dengue 
virus RNA replication and the replication of encephalomyocarditis virus, an IFN-sensitive virus, are resistant 
to the antiviral effects of IFN-a. The presence of dengue virus replicons reduces global IFN-a-stimulated gene 
expression and specifically inhibits IFN-a but not IFN-'Y signal transduction. In cells containing replicons or 
infected with dengue virus, we found reduced levels of signal transducer and activator of transcription 2 
(STAT2), which is a key component ofIFN-a but not IFN-'Y signaling. Collectively, these data show that dengue 
virus is capable of subverting the human IFN response by down-regulating STAT2 expression. 
Dengue viruses are mosquito-borne flaviviruses of immense 
global public health importance, causing tens of millions of 
human infections worldwide each year (11). The intensity of 
viral replication in the first days of infection determines the 
clinical outcome, which ranges from benign febrile illness to 
life-threatening disease (dengue hemorrhagic fever) (39). Dur-
ing this critical early phase, prior to the full recruitment of 
antigen-specific defenses, innate cellular antiviral mechanisms 
mediated by alphalbeta interferon (IFN-a/J3) are potentially 
the most important pathways of the host defense limiting viral 
replication. Virus infection classically induces the secretion of 
IFN-a/~, which binds to cell surface IFN-a receptors (IFNAR, 
comprising IFNARl and IFNAR2 subunits) on infected and 
nearby cells. The binding of IFN-a/J3 to IFNAR leads to the 
activation of Jakl and Tyk2 kinases via tyrosine phosphoryla-
tion (4). In turn, signal transducer and activator of transcrip-
tion 2 (STATZ) and then STAT1 are phosphorylated and form 
heterodimers, which then associate with p48/1RF-9 to form 
ISGF3 complexes (12). ISGF3 complexes translocate to the 
nucleus and initiate the transcription of interferon-stimulated 
genes (ISGs) by binding interferon-stimulated response ele-
ments, leading to the transcriptional up-regUlation of hundreds 
of cellular genes and the induction of an antiviral state (35). 
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5..l1..l 
Experimental evidence suggests that the I FN system plays an 
important role in limiting dengue virus replication, since 
knockout mice that lack IFN-a/J3 receptors develop severe 
infections after a challenge with dengue virus (15, 34). Also, 
the pretreatment of cultured cells with IFN-a/J3 dramatically 
reduces dengue virus replication (5, 6). This occurs primarily 
through the inhibition of translation of input-strand dengue 
virus RNA by an unknown mechanism (5). In contrast, IFN-
a/J3 has little effect on dengue virus replication after viral 
replication has been established (5, 6), suggesting that the IFN 
system cannot fully engage in dengue virus-infected cell". In 
keeping with this observation, dengue virus can achieve high 
titers « 109 infectious doses per ml) in humans despite the 
induction of high levels of circulating IFN-a (21, 36, 39). It 
therefore seems likely that dengue virus has evolved mecha-
nisms to counter the IFN response, although not absolutely, 
which is a characteristic that may be shared by many patho-
genic viruses (9, 42). 
Munoz-Jordan and colleagues recently published an in \-itrl) 
study that analyzed the ability of individual dengue virus pro-
teins to block the IFN system, in which they concluded that 
NS4B and possibly NS2A and NS4A act as IFN signaling 
inhibitors (25). They showed that NS4B and dengue virus in-
fection blocked signal transduction in response to both IF~-J3 
and IFN--y in a monkey kidney cell line, suggesting that the 
target for NS4B-mediated inhibition of IFN signaling may be a 
component (possibly phosphorylated STATl [STATI-P)) that 
is common to these distinct but overlapplflg '-Ignal transduction 
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FIG. 1. Schematic showing construction of plasmid pDENa 
CprME-PAC2A (A) Dengue virus type 2 infectious clone cDNA (in 
plasmid pDVWS601 [29]), showing a single open reading frame car-
rying three structural genes (C, core; prM, premembrane; E, enve-
lope), seven nonstructural (NS) genes, and flanking~' and 3' untr~­
laled regions (UTR). (8) pDENaCprME. A large tn-frame deletton 
was introduced within the region carrying the structural genes. 
(C)pDENi1CprME-PAC2A An antibiotic selection cassette encoding 
PAC and the foot-and-mouth disease virus protein 2A was cloned in 
place of the deleted structural genes. 
pathways (25). We adopted a complementary experimental 
approach specifically aimed at studying the effect of dengue 
virus replication downstream of the translation of input-strand 
RNA on the human IFN system. We first established human 
cell lines that continuously expressed self-replicating sub-
genomic dengue virus RNA (replicons). Flavivirus replicons 
express all of the viral nonstructural proteins together in a way 
that mimics expression during authentic viral infection, and 
they have proved to be powerful tools for studying the func-
tional roles of nonstructural proteins in RNA and virus repli-
cation (16-18, 24). We show here that the presence of dengue 
virus replicons in human cell lines inhibits the antiviral effect of 
IFN-a by blocking early events in lPN-a signal transduction, 
resulting in reduced levels of STATI-P. In contrast, STAT1-P 
levels in replicon-containing cells are increased rather than 
reduced in response to IFN-'Y. We show that steady-state levels 
of STATI are reduced in cells containing dengue virus repli-
cons, which is consistent with the observed responses to IFN-a 
and IFN-'Y. Reduced STAT2 levels are also found in cells 
infected with dengue virus, suggesting that dengue virus is 
capable of subverting the human IFN response by down-reg-
ulating STAT2 expression. 
MATERIALS AND MEmODS 
Celliioes stably expressing dengue virus replicons. A series of cell lines that 
continuously express dengue virus replicons have been established in our labo-
rato!)' (unpublished data). For this study, K562 (human chronic myeloid le~e­
mia) and THP-I (human monocytic) cell lines stably expressing the dengue VITUS 
replicon ACprME-PAC2A were used (designated K562.ACprME-PAC2A and 
TIiP-l.ACprME-PAC2A, respectively). The plasmid pDENACprME-PAC2A 
was used for in vitro transcription of ACprME-PAC2A re~licon R~As. 
pDENACprME-PAC2A was derived from pDVWS601 (29), WhICh contams a 
genome-length dengue virus type 2 (New Guinea C strain) cDNA clo~~, by the 
introduction of a large in-frame deletion in the structural region, retammg only 
tbe first 27 codons of the C gene and the last 24 codons of the E gene. In 
ad~tion, pDENACprME-PAC2A contains an antibiotic selectio~ ~sette e~~ 
COding puromycin N-acetyltransferase (PAC) followed by an artifiCIal prote 
cleavage site (foot-and-mouth disease virus protein 2A) in place of the deleted 
. r RNA were structural genes (Fig. I). Cells stably expressing dengue VITUS rep Icon .' 
generated by transfection with ACprME-PAC2A RNA and then propagatIon m 
RPMI containing 10% fetal bovine serum (FBS) and 3 ,....g of puromycin (Si~a)/ 
mi. Cells were removed from puromycin selection and checked for .repltcon 
t:lJlression before use by indirect immunofluorescence of the dengue VIruS NSI 
protein with a specific monoclonal antibody (5H5.4) (7). K562 and THP-I cells 
without replicons were continuously maintained in the same medium \\ithout 
puromycin. 
Cured KS62 cell line. K562 cells that stably expressed .1CprME-PAC2A wen: 
removed from puromycin selection and passaged continuously in RPMI contain-
ing lO% FBS and SOO ,....g of glycyrrhizic acid (Auka ChemicaIs)/ml, which has 
activity against RNA viruses through an unknown mechanism (3). At inter-als. 
cells were checked for replicon expression by indirect immunofluorCSQ!nL'C of thc 
dengue virus NSI protein and by reverse transcription-PeR (RT-PeR) for den-
gue virus RNA (see below). Once the cell line had been cured of the repiicon. it 
was subsequently grown in RPMI containing 10% FBS. without glycyrrhizic acid, 
and checked for the continued absence of replicons as described above. 
Analysis of dengue virus RNA levels and NSI expression. K562 .. KprME-
PAC2A cells were grown in the presence of 0, 10, 100, 1,000, or 10.000 IV of 
IFN-a2a (Roferon-A; Roche )/m1 for 24 h, and then the total cellular RNAs were 
extracted by the use of Trizol (Invitrogen). Extracted RNAs were treated with 
RQI RNase-free DNase (Promega) and reverse transcnbed with Moloney mu· 
rine leukemia virus reverse transcriptase (Promega) using random decamer 
primers. PCRs were performed and analyzed on a Rotorgene instrument (Cor-
bett Research) by the use of custom primers and a fluorescent probe specific for 
dengue virus NSI (forward primer, S'CfGAAGTGTGGCAGTGGGA1T; re-
verse primer, S'CITCAAAGCfAGCITCAGCfATCCA; probe. S'CACAGA 
CAACGTGCACACATGGACAGA). The housekeeping gene glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) was analyzed in the same samples by the 
use of specific primers (forward primer,S' ACAGTCCATGCCA TCACfGCC; 
reverse primer, S'GCCfGCITCACCACCITCITG) and Quantifect SYBR 
green (QIAGEN). In parallel experiments, K562 . .1CprME-PAC2A cells were 
grown in the presence of 100 IV of IFN-a2a/ml, and cell-associated and secreted 
dengue virus NSI proteins were analyzed by immunoblotting and an enzyme· 
linked immunosorbent assay (ELISA), respectively. as previously described (14, 
44). 
EMCV trans rescue assay. K562 cells that did and did not contain dengue virus 
replicons were grown in RPMI containing 10% FBS with 0, 10. and 100 IV of 
IFN-a2a/m1 for 24 h. The cells were washed in RPMI. and IIf' cells were then 
infected with S x lIP PFU of encephalomyocarditis virus (EMCV) in RPMl 
containing 2% FBS for 1 h. The cells were washed and then cultured for a further 
24 h in RPMI plus 10% FBS. The culture supernatants were then harvested, and 
serial dilutions were plated onto confluent A~49 cells in a 96-wcll platc for 1 h 
before replacing the inoculum with RPMI containing 10% FBS. After a further 
24 h, the A~49 cells were fixed and stained with methyl violet. and the optical 
density in each well was read at 570 nm in an automated plate reader (27). 
MxA and PKR gene expression. K562 and K562 . .1CprME-PAC2A cells were 
grown in the presence or absence of 100 IV of IFN-a2alml for 6 and 24 h. RNA 
extraction and reverse transcription were performed as described above. PCRs 
were performed and analyzed on a Rotorgene instrument by the use of SYBR 
green as described above, using primers specific for the MxA gene (forward 
primer. S'AACAACCfGTGCAGCCAGTA; reverse primer. S'AAG~GC~C 
TCCfGAGAGTG) or the protein kinase R (PKR) gene (forward pnmer. 5 T 
CfCfGGCGGTCITCAGAA T; reverse primer, S' ACfCCCfGCITCfGACG 
GTA). The housekeeping gene GAPDH was analyzed in the same samples as 
described above. 
ISG expression profiling by macroarray analysis. K562 and K562 . .1CprME-
PAC2A cells (2 x 107 per reaction) were treated with 100 IV of 1~-a2a/m.1 for 
24 h before extraction of the total cellular RNAs by the use of Tnzol. Ra~I~la­
beled cDNAs were generated from 20 ~g of total RNA by reverse transcnptlon 
with Superscript II (Gibco) in the presence of e2p)d~. Residual RNAs were 
h d lyzed by an alkaline treatment at 7(fC for 20 mlO, and the cON As were y ro h'.h "d" " purified through G-50 columns (Amersharn Pharmacia). Before Jun lZal10n to 
the macroarrays, the labeled cDNAs were mixed with SO I'-g of COT-DNA 
(Gibco) and 10 I'-g of poly(A) DNA (S~gma?, d~natured at ~S"C for S mm, and 
hybridized for 1 h to minimize nonspecific bmdlOg. PreparatIon of t~e macroar-
( t · ISO genes including many that are known to be stimulated by rays represen m . ."
interferon), hybridization ofthe radioactive cDNAs, and scannlOg and analysIs of 
the macroarrays were performed as descnbed previously (33). . . 
Immunoblotting. K562 cells (2.5 '< lIP per reaction) that dId and did not 
contain replicons were stimulated with 100 IV of IFN-a2a or IF~-'Y (R&D 
Systems)/m1 for 30 min. Unstimulated cells were included for compan<;()n. C~lls 
h t d d lysed in 250 III of sodium dodecyl sulfate (SDS) 10adlOg were arves e an r- c; 
buffer (0.0625 M phosphate [PH 7.0). 1Olj( glycerol. 2% S~S. 0.001 7c bromo-
phenol blue) that had been prewarmed to 6O"c. Ten m~croltters of each sample 
d by SDS POlyacrylamide gel electrophoresIS (SDS-PAGE). and the was separate - .""". H 
. then transferred 10 a polyvtnyhdene dlfluonde membrane: ( y-protems were d 
bond-Po Amersham). Mouse monoclonal antibodies to STATI. phosphorylate 
STATI' (Tyr-701) (both Zyrned). or STAT2 (BD Transduction Laboratones). a 
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rahbit polyclonal antibody to pho phorylated STA T2 (Upstate Biotechnolo ) 
goat polyclonal antw?dy to. IFNAR 1 (Ab~am), and a rabbit polyclonaJ ant~od; 
to If AR2 (PBL BIOmedIcal Laboratories) were used as primary antibodies. 
Detection was performed by tbe use of relevant horseradi b peroxidase-co . _ 
gated secondary antibodies (Jackson Immunochemicals) and enhanced cbe:-
luminescence reagent (ECL +; Amersham). 
Fluorescence-acti:ated cell. sorting (FACS) analysis. K562 and K562 . ..l 
CprME-PAC2A (10 . ~r reaction) cells were stained with an anti-IFNAR2 anti-
body in RP~1 co~tammg 2% FBS at ~oc. Detection was performed by use of a 
phycoerythnn-conJugated donkey antI-rabbit secondary antibody (Jackson Im-
munochemicals), and sa~ple were analyzed on a Becton Dickinson FACScan 
instrument. Data analYSIS was performed with WinMDI software. 
Dengue virus inrect~on of K.S6~ cells. K562 cells were incubated with dengue 
virus type 2 (New Gumea C stram) at a mUltiplicity of infection of 4 and then 
grown in RPMI ~ontaining 10% FBS. After 48 h, the cells were air dried on glass 
~lides and .fixed 10 cold met~anol-acet?ne (50:50 [vol/Vol]). The cells were dually 
labeled WIth a mouse anti-dengue VUllS NSI antibody (5H5.4) and a rabbit 
anti-ST~T2 antibody (C2?; S~ta Cruz BiotechnOlOgy). Fluorescein isothiocya-
nate-conjugated goat anU-rabblt and Texas Red-conjugated horse anti-mouse 
antibodies (both from ~ector Labo~atories) were used for detection. Images 
were analyzed under a BIO-Rad Radiance 2100 confocal micro cope. In parallel 
experiment, cells (2 X 106 per reaction) were lysed and analyzed by immuno-
blotting as described above. 
RESULTS 
Dengue virus replicon RNA replication is resistant to 
IFN-a. Previous studies have shown that the antiviral effect of 
~F~-~ on. dengue virus infection in cell cultures is markedly 
mhlblted if the treatment is delayed a few hours after infection 
(5, 6), suggesting that dengue virus can counter the IFN re-
sponse once replication has been established. We tested di-
rectly whether IFN could inhibit established dengue virus 
RNA replication in the form of the dengue virus replicon 
~CprME-PAC2A, which is stably maintained in K562 . .1. 
CprME-PAC2A cells (unpublished data). K562 . .1.CprME-
PAC2A cells were grown in the presence of 0, 10, 100, 1,000, or 
10,000 IU of IFN-a2a/ml for 24 h, and dengue virus replicon 
RNA levels were measured by quantitative RT-PCR. In addi-
tion, the effect of 100 IV of IFN-a/ml on the levels of cell-
a sociated and secreted NSI protein was analyzed by Western 
blotting and ELISA, respectively. Figure 2 shows that IFN-a 
had no significant effect on dengue virus replicon RNA levels 
or NSI expression. These data confirm previous evidence sug-
gesting that established dengue virus RNA replication is resis-
tant to IFN-a (5). 
Antiviral action of IFN-Q is blocked by dengue virus RNA 
r~plication. We next tested whether the presence of dengue 
VlfUS replicons inhibits the general antiviral action of IFN in 
cells. K562 cells that did and did not contain replicons were 
first treated with IFN-a2a and then infected with an IFN-
. ensitive virus, EMCV. The basis of this technique is that the 
mhibition of the antiviral action of IFN by dengue virus repli-
Cons results in a rescue of EMCV replication, which is detected 
~n a modified plaque assay on A549 cells. Figure 3 shows that 
III the absence of lFN-a2a, EMCV replication was equal in 
cells that did and did not contain replicons. As expected, a 
pretreatment of K562 cells with either 10 or 100 IV of IFN-
Q2a/ml dramatically inhibited the replication of EMCV. In 
Contra t, pretreatments of K562 . .1.CprME-PAC2A cells with 
the arne concentrations of IFN-a2a had no effect on EMCV 
repl!cation (Fig. 3). In order to prove that dengue virus RNA 
replication inhibited the IFN response, we repeated the 
EMCV rescue assay, using K562 . .1.CprME-PAC2A cells that 
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FIG. 3. Antiviral effect of IFN-a is blocked in dengue virus repli-
con-containing cells. K562 cells (solid lines) and K562.L1CprME-
PAC2A cells (broken lines) were treated with 0 (e), 10 (D), or 100 (0) 
ru of IFN-a2a/ml for 24 h. The cells were then infected with EMCV, 
and after a further 24 h, the supernatants were harvested and serially 
diluted on confluent A549 cells. After 24 h, the A549 celJs were fixed 
and stained with methyl violet. The amount of staining was quantified 
by measuring the optical density (OD) of each well at 570 nrn. More 
EMCV replication resulted in increased cell death and lower optical 
density readings. 
in K562 cells. In contrast, the IFN induction of MxA and PKR 
gene transcription was dramatically inhibited in K562.L1 
CprME-PAC2A cells (Fig. 4). Having shown that the induc-
tion of two genes, MxA and PKR, was inhibited in replicon-
containing celis, we examined the global pattern of lPN-induc-
ible gene transcription in cells that did and did not contain 
replicons by using a custom macroarray. We found that the 
IFN response was profoundly suppressed in K562.L1CprME-
PAC2A cells compared with K562 cells. Table 1 lists the ISGs 
that were most up-regulated (more than fourfold) in K562 
cells in response to IFN and shows comparative data for 
K562.llCprME-PAC2A cells. These data indicate that IFN-a-
induced gene expression is inhibited in cells containing dengue 
virus replicons, though not absolutely, and suggest that IFN-a 
ignal transduction is inhibited. 
Dengue virus RNA replication inhibits early events in IFN-a 
signaling by down-regulating steady-state STAT2 levels. In 
order to determine whether early events in IFN signal trans-
duction were inhibited in replicon-containing cells, we per-
formed a Western blot analysis of STAT! phosphorylation in 
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FIG. 6. Dengue virus RNA replication does not affect IFNAR pro-
tein level. (A) Cell lysates from K562 and K562.LlCprME-PAC2A 
cell were separated by SDS-PAGE and then analyzed by immuno-
blottmg with specific antibodies for IFNARI and IFNAR2, as indi-
cated. (8) K562 and K562.D.CprME-PAC2A cells were stained with 
pccifie anti-~AR2 antibodies and lhen analyzed by flow cytomelry. 
Cells stained wlth ~e sec~n?ary antibody alone (gray-filled plot) were 
mcluded as a negatIve stammg control. 
cell in response to IFN-a, but the response was restored to 
normal in cured K562 cells. In contrast, STATI-P levels were 
not reduced in K562.dCprME-PAC2A cells in response to 
IFN-'Y, w~ch signals through a distinct but overlapping path-
way (9); ill fact, we observed a consistent increase in STATI 
phosphorylation in response to IFN--y in K562.dCprME-
PAC2A cells compared with K562 cells (Fig. 5A). In order to 
ensure that these observations were not limited to the specific 
cell type used, we repeated these experiments with THP-l cells 
that stably expressed IiCprME-PAC2A, with similar results 
(Fig. SB). These data imply that early components of the 
IFN-a but not the IFN--y signal transduction pathway are tar-
gets for dengue virus inhibition. 
We next performed a Western blot analysis of STA 1'2 phos-
ph~rylation, which is a key step in IFN-a but not IFN--y sig-
nalmg (9). Figure S shows that the steady-state levels of STAT2 
were very markedly reduced in both K562 and THP-l cells 
containing dengue virus replicons compared with the parental 
cells. The levels of STATI-P in response to IFN-a were also 
greatly reduced in both replicon-containing cell lines. Cured 
~62 celJs reverted to the phenotype of parental K562 cells, 
WIth similar steady-state levels of STAT2 and STAT2-P in 
re ponse to IFN-a (Fig. SA). In order to confirm that cells 
containing dengue virus replicons did not have a generally 
reduced expression of proteins involved in the first part of the 
IFN-a signal transduction pathway, we examined the levels of 
IFNARI and IFNAR2. Total IFNARI and IFNAR2 protein 
levels were assessed by Western blotting and were similar in K562 
and K562.dCprME-PAC2A cells (Fig. 6A). The cell surface ex-
~re~ion of 1FNAR2 was measured by flow cytometry and was 
lll1iJar in K562 celJs that did and did not contain replicons (Fig. 
6B); reagents to examine the cell surface expression of IFNARI 
by FACS analysis were not available. Similar levels of IFNARI 
and lFNAR2 were also found in ruP-l cells that did and did not 
Contain replicons (data not shown). Taken together, these data 
s~o.w that the presence of dengue virus replicons specifically in-
hibits early events in IFN-a but not IFN--y signal transduction by 
redUcing STA 1'2 levels. 
Dengue virus infection reduces STAT2 levels. In order to 
determine whether STAT2 expression is also reduced in den-
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fected with dengue virus, we analyzed TA 1'2 level at 4 h 
postinfection by immunoblotting. At thi tlIDe pint, appro .j-
mately 30 to 50% of cell that had been infected tained 
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proteins NS2A, NS4A, and NS4B have the capacity to inhibit 
the nuclear translocation of STAT1-P in response to IFN-f3 
(25). We show here for the first time that dengue virus RNA 
replication not only reduces ST AT1-P levels in response to 
IFN-a but also results in a marked reduction in STAT2-P 
levels as a consequence of reduced steady-state levels of 
STATI. We first made this observation with dengue virus rep-
licon-containing cells and subsequently with cells infected with 
dengue virus. Since STAT2-P recruits STAT1 for phosphory-
lation in response to IFN-a (22), generating STATl/STAT2 
heterodimers, all of our data can be explained if dengue virus 
specifically down-regulates ST A T2 levels in order to counter 
the IFN response. In keeping with this hypothesis, dengue 
virus RNA replication did not reduce STAT1 phosphorylation 
in response to IFN-,,(, which is independent of STAT2 (22). In 
fact, dengue virus rep Ii con RNA replication increased rather 
than decreased STAT1 phosphorylation in response to IFN-,,(, 
consistent with previous data showing increased STAT1 phos-
phorylation (30) and IFN-,,(-mediated gene transcription (1) in 
the context of reduced STA T2 levels. The mechanism under-
lying this effect and its biological significance are as yet un-
known. 
We concluded that dengue virus specifically inhibits IFN-a/f3 
signaling by down-regulating the expression of STAT2. Mu-
noz-Jordan and colleagues reported conflicting data showing 
an inhibition of both IFN-a/f3- and IFN-,,(-mediated STAT1 
phosphorylation by dengue virus NS4B and dengue virus in-
fection in LLCMK2 (monkey kidney) cells, and they suggested 
that common players involved in both signaling pathways 
(which do not include STA T2) were likely targets for IFN 
antagonism by dengue virus (25). The differences in our find-
ings may reflect interspecies differences in IFN antagonism. 
Although the cell tropism of dengue virus in humans is not 
definitively known, the predominant targets are probably cells 
of hematopoietic origin, particularly dendritic cells, mono-
cytes, and macrophages, as well as hepatocytes (2, 40, 41). For 
this study, we used human cell lines (K562 and THP-1) related 
to cells targeted by dengue virus in vivo, and our data provide 
the basis for further work to confirm the relevance of our 
observations to human dengue virus infection. 
Despite the fact that IFN-o. signaling was not completely 
blocked in dengue virus replicon-containing cells, supraphysi-
ological concentrations of IFN-o.2a had no significant effect on 
dengue virus replicon RNA replication or protein production. 
It is possible that dengue virus utilizes more than one mecha-
nism to counter the IFN response, as suggested for other 
viruses, including another flavivirus, hepatitis C virus (8, 28, 37, 
38). Alternatively, the inhibition of IFN signaling by reducing 
ST A T2 levels may be sufficient for dengue virus replication to 
proceed faster than can be inhibited by the reduced antiviral 
IFN response. Future work will elucidate whether STAT21ev-
els are reduced as a consequence of a down-regulation of 
STAT2 gene transcription or protein synthesis or an enhanced 
degradation of the STAT2 protein. Further data are also 
needed to determine if the capacity to reduce STA T2 levels is 
conserved among all dengue virus strains (including field iso-
lates) and in any other members of the Flaviviridae family. 
~~ent data suggest that Japanese encephalitis virus also in-
hibits IFN-a signal transduction but utilizes a different mech-
anism that results in reduced levels of phosphorylated Tyk2 
"-........, 
A 
(and hence STATZ-P) without altering the expression of STATI 
(23). Two important human pathogens in the Paramyxm'iridae 
family of enveloped, negative-strand RNA viruses, Respiratol)' 
syncytial virus and Human parainfluenza drus type 2. have been 
shown to subvert antiviral IFN responses by reducing ST A TI 
levels (26, 30). This effect is likely mediated through protea-
some-mediated degradation of STATI. However, other para-
myxoviruses do not reduce steady-state ST A T2 levels and in-
stead have evolved a variety of different strategies to block 
IFN-a/f3 signaling (10, 19,32,43), which is a broadly effective 
strategy for countering the IFN response. 
Future work is needed to define the precise interaction be-
tween components of the IFN signal transduction pathway and 
specific dengue virus proteins. Replicon-containing human cell 
lines are powerful tools for these studies because preliminary 
evidence suggests that several dengue virus nonstructural pro-
teins may act together to produce strong, species-specific in-
hibition of IFN (25). We were careful to ensure that our 
observations did not reflect the selection of an IFN-defective 
subpopulation of cells during the generation of our stable 
replicon-containing cell lines. Several lines of evidence mit-
igate against this conclusion and suggest that our results 
accurately reflect an important host-pathogen interaction 
that subverts the IFN response: replicon-expressing cells were 
propagated from a total population of transfected cells rather 
than from individual cell clones; our observations were the 
same for two cell types, K562 and THP-l; and K562 cells that 
had previously expressed replicons and had been cured with 
glycyrrhizic acid reverted to the phenotype of parental K562 
cells. Most importantly, the key observation made with our 
replicon model, namely, the reduction in STAT2 levels, led us 
to the same finding with cells infected with dengue virus. Col-
lectively, the data suggest that the down-regulation of ST AT2 
expression is an important mechanism by which dengue virus 
subverts innate antiviral defenses mediated by IFN. 
Understanding the molecular basis of the race between den-
gue virus replication and the IFN response early in infection 
would represent a critical advance, as the efficiency wilh which 
dengue virus evades the IFN response in humans is probably 
an important factor in early viral replication, and hence, dis-
ease pathogenesis. Further data will elucidate whether differ-
ences in IFN antagonism contribute to the differences in 
pathogenicity observed among dengue virus strains (31). Un-
derstanding the molecular mechanisms that dengue virus uti-
lizes to subvert innate immune responses mediated by IFN may 
also inform strategies for rational attenuation in order to gen-
erate safer and more cost -effective dengue vaccine candidates. 
ACKNOWLEDGMENTS 
M.J. is a Wellcome Advanced Fellow. Work in G.R.F."s labora-
tory is funded by the EC. Work in J.S.'s laboratory is funded by the 
Deutsche Forschungsgemeinschafi. 
We thank Paul Young for anti-NSI antibodies, Pablo de Felipe for 
the plasmid pPDF14b (which contains ~e PAC2~ cassette), Mari~)O 
Macey for assistance with F ACS analYSIs. and TIm Cowen and TIm 
Robson for assistance with confocal microscopy. 
REFERENCES 
1. Aodrejeva, J., D. F. Young, S. Goodbouro. B.nd R ~ Randall. 2()J2 Dc:gra. 
dation of STATl and STATI by the V protems of suman Vlru..; 5 and human 
parainfluenza virus type 2. respectively: consequences for,virus re~h~t~on In 
the presence of a1phalbeta and gamma mterferons. J. VITO!. 76:_1)~_167. 
o 
o 
~ 
0" 
Q) 
a. (I) 
a. 
-. 
a 
3 
~: 
i» (I) 
3 
(:) 
13 
Q) 
-C 
::J 
~' 
iii 
~ 
o Q. 
(j) 
10 
(l) 
r 
o 
::J 
a. 
o 
::J 
o 
::J 
'TI (I) 
0" 
2 
Q) 
-< 
9' 
N 
o 
o 
OJ 
~-
5420 JONES ET AL. 
2 Couvelard. A., P. Marianneau, C. Bedel, M. T. Drouet, F. Vacbon, D. Benin, 
. d V. Deubel. 1999. Report of a fatal case of dengue infection with hepa-~tis: demonstration of dengue antigens in hepatocytes and liver apoptosis. 
Hum. Pathol. 30:1106-1110. 
3. Crance, J. M., N. Scaramozzino, A.. J.ouan, ~~d D. Garin. 2003. ~nterfe~on, 
nbavirin, 6-azauridine and ~~cyrrhizin: antIVIral compounds active agamst 
pathogenic flaviviruses. AntiVIral Res. 58:7>-79. 
4. Damel!,J. E.,Jr .. I. M. Kerr,and G. R. Stark. 1994. Jak-STATpathwa~ and 
transcriptional activation in response to IFNs and other extracellular Signal-
ing proteins. Science 264:1415-1421. 
5. Diamond, M. S., and E. Ha~s. 200!. Interferon inhibits den~e virus in-
fection by preventing translatIOn of VITal RNA through a PKR-mdependent 
mechanism. Virology 289:297-311. 
6. Diamond, M. S., T. G. Roberts, D. Edgil, B. Lu, J. Ernst, and E. Harris. 2000. 
Modulation of dengue virus infection in human cells by alpha, beta, and 
gamma interferons. J. Virol. 74:4957-4966. 
7. Falconar, A. K., and P. R. Young. 1991. Production of ~im~r-specific and 
dengue virus group cross-reactive mo~se monoclonal a~tIbodles to the den-
gue 2 virus non-structural glycoprotem NS1. J. Gen. VlTol. 72:961-965. 
8. Foy, E., K. Li, C. Wang, R. Sumpter, Jr .. M. Ikeda, S. M. Lemon, and ~. 
Gale, Jr. 2003. Regulation of interferon regulatory factor-3 by the hepatitis 
C virus serine protease. Science 300:1145-1148. . 
9. Goodbouro, S., L. Didcock, and R. E. Randall. 2000. Interferons: cell sig-
nalling, immune modulation, antiviral response and virus countermeasures. 
J. Gen. Virol. 81:2341-2364. 
10. Gotob, B .. K. Takeucbi, T. Komatsu, and J. Yokoo. 2~3. The STATI 
activation process is a crucial target of Sendai virus C protem for the block-
ade of alpha interferon signaling. J. Virol. 77:3360-3370. 
11. Halstead, S. B .. and J. Deen. 2002. The future of dengue vaccines. Lancet 
360:1243-1245. 
12. Honath, C. M., G. R. Stark, L M. Kerr, and J. E. Darnell, Jr. 1996. 
Interactions between STAT and non-STAT proteins in the interferon-stim-
ulated gene factor 3 transcription complex. Mol. Cell. BioI. 16:6957--6964. 
13. Jacobs, B. L., and J. O. Langland. 1996. When two strands are better than 
one: the mediators and modulators of the cellular responses to double-
stranded RNA. Virology 219:339-349. 
14. Jacobs, M. G .. P. J. Robinson, C. Bletcbly, J. M. Mackenzie, and P. R. 
Young. 2000. Dengue virus nonstructural protein 1 is exp~essed in a gly~syl­
phosphatidylinositol-linked form that is capable of Signal transduction. 
FASEB J. 14:1603-1610. 
15. Johnson, A. J .. and J. T. Roehrig. 1999. New mouse model for dengue virus 
vaccine testing. J. Virol. 73:783-786. 
16. Khromykb, A. A., M. T. Kenney, and E. G. Westaway. 1998. trans-Comple-
mentation of tlavivirus RNA polymerase gene NS5 by using Kunjin virus 
replicon-expressing BHK cells. J. Virol. 72:7270-7279. 
17. Kbromykb, A. A., P. L. Sedlak, K. J. Guyatt, R. A. Hall, and E. G. Westawa!. 
1999. Efficient trans-complementation of the flavivirus Kunjin NS5 protem 
but not of the NSI protein requires its coexpression with other components 
of the viral replicase. J. Virol. 73:10272-10280. 
18. Khromykb, A. A., and E. G. Westaway. 1997. Subgenomic replicons of the 
flavivirus Kunjin: construction and applications. J. Virol. 71:1497-1505. 
19. Kubota, T., N. Yokosawa, S. Yokota, and N. Fujii. 2001. C terminal Cys-rich 
region of mumps virus structural V protein correlates with block of inter-
feron alpha and gamma signal transduction pathway through decrease of 
STAT I-alpha. Biochem. Biophys. Res. Commun. 283:255-259. . 
20. Kuhen, K. L., and C. E. Samuel. 1999. Mechanism of interferon action: 
functional characterization of positive and negative regulatory domains th~t 
modulate transcriptional activation of the human RNA-dependent protem 
kinase Pkr promoter. Virology 254:182-195. 
21. Kurane,l., B. L. Innis, S. Nimmannitya, A. Nisalak, A. Meager, and F. A. 
Ennis. 1993. High levels of interferon alpha in the sera of children with 
dengue virus infection. Am. J. Trop. Med. Hyg. 48:222-229. 
22. Leung, S., S. A. Quresbi, L M. Kerr, J. E. Darnell, Jr., and G. R. Stark. 1995. 
Role of STAT2 in the alpha interferon signaling pathway. Mol. Cell. BioI. 
15:1312-1317. 
23. Un, R. J .. C. L. Liao, E. Un, and Y. L. Lin. 2004. Blocking of the alpha 
interferon-induced JAK-STAT signaling pathway by Japanese encephalitis 
virus infection. J. Virol. 78:9285-9294. 
24. Uu, W. J.. P. L. Sedlak, N. Kondratieva, and A. A. Kbromykb. 2002. 
Complementation analysis of the tlavivirus Kunjin NS3 and NS5 proteins 
defines the minimal regions essential for formation of a replication complex 
and shows a requirement of NS3 in cis for virus assembly. J. Virol. 76:10766-
10175. 
25. Munoz·Jordan, J. L., G. G. Sancbez-Burgos, M. Laurent-Rolle, and A. Gar-
cia·Sastre. 2003. Inhibition of interferon signaling by dengue virus. Proc. 
Natl. Acad. Sci. USA 100:14333-14338. 
1. VIROL. 
26. Parisien, J. p .. J. F. Lao, J. J. Rodriguez, B. M. Sullivan, A. Mosc:ona.. G. D. 
Parks, R. A. Lamb, and C. M. Horvalb. 2001. The V protein of human 
parainfluenza virus 2 antagonizes type I interferon responses hy destahllinng 
signal transducer and activator of transcription 2. Virology 283:230-239. 
27. Paterson, M .. C. D. Laxton, H. C. Thomas, A. M. Ackrill, and G. R. Foster. 
1999. Hepatitis C virus NS5A protein inhibits interferon antivircil activity. but 
the effects do not correlate with clinical response. Gastroenterology 117: 
1187-1197. 
28. Pflugbeber, J .. B. Fredericksen, R. Sumpter, Jr .. C. Wang, F. Ware. D. L. 
Sodora, and M. Gale, Jr. 2002. Regulation of PKR and IRF-l during hep-
atitis C virus RNA replication. Proc. Natl. Acad. Sci. USA 99:4650-4655. 
29. PIyor, M. J., J. M. Carr, B. Hocking, A. D. Davidson, P. u.. and P. J. Wright. 
2001. Replication of dengue virus type 2 in human monocyte-derived mac-
rophages: comparisons of isolates and recombinant viruses with substitutions 
at amino acid 390 in the envelope glycoprotein. Am. J. Trop. Med. Hyg. 
65:427-434. 
30. Ramaswamy, M .. L. Shi, M. M. Monick, G. W. Hunninghake, and D. C. 
Look. 2004. Specific inhibition of type I interferon signal transduction by 
respiratory syncytial virus. Am. J. Respir. CeJl Mol. BioI. 30:893-900. 
31. Rico-Hesse, R., L. M. Harrison, R. A. Salas, D. Tovar, A. Nisalak, C. Ramos, 
J. Boshell, M. T. de Mesa, R. M. Nogueira, and A. T. da Rosa. 1997. Origins 
of dengue type 2 viruses associated with increased pathogenicity in the 
Americas. Virology 230:244-251. 
32. Rodriguez, J. J .. C. D. Cruz, and C. M. Horvath. 2004. Identification of the 
nuclear export signal and STAT-binding domains of the Nipah virus V 
protein reveals mechanisms underlying interferon evasion. J. Virol. 78:5358--
5367. 
33. Scblaak, J. F., C. M. Bilkens, A. P. Costa-Pereira, B. Strobl, F. Aberger, 
A. M. Frischauf, and I. M. Kerr. 2002. Cell-type and donor-specific tran-
scriptional responses to interferon-alpha. Use of customized gene arrays. 
J. BioI. Chem. 277:49428-49437. 
34. Sbresta, S., J. L. Kyle, B. M. Snider, M. Basavapatna, P. R. Beatty, and E. 
Barris. 2004. Interferon-dependent immunity is essential for resistance to 
primary dengue virus infection in mice, whereas T- and B-cell-dependent 
immunity are less critical. J. Virol. 78:2701-2710. 
35. Stark., G. R., I. M. Kerr, B. R. Williams, R. H. Silverman, an~ R. D. 
Schreiber. 1998. How ceJls respond to interferons. Annu. Rev. Blochem. 
67:227-264. 
36. Sudiro, T. M., J. Zivny, B. Ishiko, S. Green, D. W. Vaugbn, S. Kalayana~j, 
A. Nisalak, J. E. Norman, F. A. Ennis, and A. L. Rothman. 2001. AnalysIS of 
plasma viral RNA levels during acute dengue virus inf~ction ~ing quanti-
tative competitor reverse transcription-polymerase cham reactIon. J. Med. 
Virol. 63:29-34. 
37. Tagucbi, T .. M. Nagano-Fujii, M. Akutsu, H. Kadoya, ~. ?bgimoto, .S. 
Ishido, and H. Hotta. 2004. Hepatitis C virus NS5A protem mteracts. With 
2',5'-0Iigoadenylate synthetase and inhibits antiviral activity of I~ 10 an 
IFN sensitivity-determining region-independent manner. J. Gen. Vlrol. 85: 
959-969. 
38. Taylor, D. R., S. T. Shi, P. R. Romano, G. ~. B~ber, and M. M. Lai. 1999. 
Inhibition of the interferon-inducible protem kinase PKR by HCV E2 pro-
tein. Science 285:107-110. 
39. Vaughn, D. W., S. Green, S. Kalayanarooj, B. L. Innis, S. Nimmannitya, .S. 
Suntayakorn, T. P. Endy, B. Raengsakulracb, A. L. Rothman, F. A. EnRls, 
and A. Nisalak. 2000. Dengue viremia titer, antibody response pattern, and 
virus serotype correlate with disease severity. J. Infect. Dis. 181:2-9. . 
40. Wang, W. K., T. L. Sung, Y. C. Tsai, ~. ~. ~o, S •. M. Cbang, and C. C. King. 
2002. Detection of dengue virus replIcatIon 10 penpheral blood mono~u~lear 
cells from dengue virus type 2-infected patients by a reverse transcnpuon-
real-time PCR assay. J. Clin. Microbiol. 40:4472-4478. 
41. Wu, S. J., G. Grouard-Vogel, W. Sun, J. R. Mascola, E. Brachtel, R. Putva-
tana, M. K. Louder, L. Filgueira, M. A. Marovicb, H. K. Wong, A. Blauvelt, 
G. S. Murphy, M. L. Robb, B. L. Innes, D. L. Bin, C. G. Hayes, and S: S. 
Frankel. 2000. Human skin Langerhans cells are targets of dengue Virus 
infection. Nat. Med. 6:816-820. 
42. Young, D. F .. L. Andrejeva, A. Livingstone, S. Good~um, R.. A. ~~b, P'I:-
Collins, R. M. Elliott, and R. E. Randall. 2003. Virus reph~tlon m .,engI-
neered human cells that do not respond to interferons. J. VITol. 77:~174--
2181. 
43. Young, D. F., L. Didcock, S. Goodboum, a~d R. E. ~ndall. 2000. Paramyxo-
viridae use distinct virus-specific mechanISms to circumvent the mterferon 
response. Virology 269:383-390. . 
44. Young, P. R., P. A. Hilditcb, C. Bletcbly, and W. Hallor:ao. 2000. An antigen 
capture enzyme-linked immunosorben~ assay revea.1s high leve.1s of ~he d~n­
gue virus protein NSI in the sera of infected patients. J. am. Mlcroblol. 
38:1053-1057. 
c 
~ (5 
Gl 
C 
t1I 
C 
a 
3 
~ 
Dl 
(II 
3 
o 
ca 
~ 
C 
:::l 
<: (Ii 
..., 
CIi 
~ 
(" 
g 
it 
u::: 
a 
r g 
C g 
g 
., 
a 
S 
r::: 
!! 
'< 
c; 
" c c 
o 
